fluorouracil has been researched along with Mucositis in 240 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Mucositis: An INFLAMMATION of the MUCOSA with burning or tingling sensation. It is characterized by atrophy of the squamous EPITHELIUM, vascular damage, inflammatory infiltration, and ulceration. It usually occurs at the mucous lining of the MOUTH, the GASTROINTESTINAL TRACT or the airway due to chemical irritations, CHEMOTHERAPY, or radiation therapy (RADIOTHERAPY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "to evaluate the effect of oral cryotherapy compared to physiological serum on the development of oral mucositis in outpatient cancer patients using the 5-fluorouracil antineoplastic agent." | 9.34 | Effect of cryotherapy in preventing mucositis associated with the use of 5-fluorouracil. ( Aguiar, MIF; Alves, NP; Lopes, TSS; Oliveira, PP; Rodrigues, AB; Silva, RA; Vitorino, WO, 2020) |
| "Gastrointestinal mucositis is a common and dose-limiting side effect characterized by ulcerative lesions in the mucosa of the digestive tract in patients receiving anticancer drugs such as 5-fluorouracil (5-FU), a potent antineoplastic drug." | 9.22 | Possible cytoprotective mechanisms of oxytocin against 5-fluorouracil-induced gastrointestinal mucositis. ( Abacioglu, N; Chukwunyere, U; Mercan, M; Sehirli, AO, 2022) |
| "Adverse events associated with 5-fluorouracil (5FU) based adjuvant therapy in colorectal cancer (CRC) patients may predict survival." | 9.19 | Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity? ( André, T; Bono, P; de Gramont, A; Hermunen, K; Österlund, P; Poussa, T; Quinaux, E; Soveri, LM, 2014) |
| "This study evaluated the maximum tolerated dose (MTD) and the dose limiting toxicity (DLT) of erlotinib when combined to irinotecan and capecitabine in pre-treated metastatic colorectal cancer patients." | 9.14 | Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients. ( Bajetta, E; Bajetta, R; Buzzoni, R; Di Bartolomeo, M; Dotti, KF; Ferrario, E; Galassi, M; Gevorgyan, A; Mariani, L; Venturino, P, 2009) |
| "Capecitabine is effective against metastatic breast cancer (MBC)." | 9.14 | Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer. ( Aramendía, JM; Arbea, L; Aristu, J; De la Cruz, S; Espinós, J; Fernández-Hidalgo, O; Martínez-Monge, R; Moreno, M; Nieto, Y; Pina, L; Regueira, FM; Santisteban, M; Sola, J; Zornoza, G, 2010) |
| " Oral glutamine supplements (OGS) may have a role in the prevention of chemotherapy-induced mucositis/stomatitis." | 9.12 | The effect of oral glutamine on 5-fluorouracil/leucovorin-induced mucositis/stomatitis assessed by intestinal permeability test. ( Choi, K; Jeon, WK; Kim, JW; Lee, SS; Lim, SY; Oh, SJ; Oh, TY, 2007) |
| "Intestinal mucositis and diarrhea are common manifestations of anticancer regimens that include irinotecan, 5-fluorouracil (5-FU), and other cytotoxic drugs." | 8.93 | Irinotecan- and 5-fluorouracil-induced intestinal mucositis: insights into pathogenesis and therapeutic perspectives. ( Cunha, FQ; Leite, CA; Lima-Júnior, RC; Mota, JM; Ribeiro, RA; Souza, MH; Wanderley, CW; Wong, DV, 2016) |
| "An electronic search was undertaken to identify randomized controlled trials comparing raltitrexed-based regimen to 5-fluorouracil-based regimen in patients with advanced colorectal cancer." | 8.90 | Raltitrexed-based chemotherapy for advanced colorectal cancer. ( Hong, W; Huang, Q; Liu, Y; Sun, X; Wu, J; Wu, W, 2014) |
| "The aim of this study was to evaluate systematically the efficacy and safety of oral uracil-tegafur (UFT) plus leucovorin (LV) compared with infusional fluorouracil (5-FU) plus LV for advanced colorectal cancer." | 8.87 | Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials. ( Bin, Q; Cao, Y; Gao, F; Li, J; Liao, C, 2011) |
| "5-Fluorouracil (5-FU) is a common anti-tumor drug, but there is no effective treatment for its side effect, intestinal mucositis." | 8.31 | Short-Chain Fatty Acids Attenuate 5-Fluorouracil-Induced THP-1 Cell Inflammation through Inhibiting NF-κB/NLRP3 Signaling via Glycerolphospholipid and Sphingolipid Metabolism. ( Gong, W; Wang, C; Wang, D; Wu, L; Xi, Y; Yang, C; Zhang, Y, 2023) |
| "This study aims to evaluate the effect of berberine-based carbon quantum dots (Ber-CDs) on improving 5-fluorouracil (5-FU)-induced intestinal mucositis in C57BL/6 mice, and explored the mechanisms behind this effect." | 8.31 | Berberine-Based Carbon Quantum Dots Improve Intestinal Barrier Injury and Alleviate Oxidative Stress in C57BL/6 Mice with 5-Fluorouracil-Induced Intestinal Mucositis by Enhancing Gut-Derived Short-Chain Fatty Acids Contents. ( He, J; Li, H; Sun, C; Tan, J; Wang, D; Wu, L; Xi, Y; Yan, M, 2023) |
| "Mucositis is among the most common side effects of 5-Fluorouracil (5-FU) and other cancer therapeutic drugs." | 8.31 | Thymoquinone protects against 5-Fluorouracil-induced mucositis by NF-κβ and HIF-1 mechanisms in mice. ( Hosseini, SM; Kazemi, S; Lotfi, M; Madani, F; Moghadamnia, AA; Shirafkan, F, 2023) |
| "Intestinal mucositis (IM) is a common side effect of several anticancer medications, including 5-fluorouracil (5-FU), and can lead to treatment disruptions and compromised outcomes." | 8.31 | Mucoprotective effect of ellagic acid in 5 fluorouracil-induced intestinal mucositis model. ( Al-Hoshary, DM; Zalzala, MH, 2023) |
| "5-fluorouracil (5-FU) is an antineoplastic drug used to treat colorectal cancer, but it causes, among other adverse effects, diarrhea and mucositis, as well as enteric neuropathy, as shown in experimental animals." | 8.31 | Effect of the Cannabinoid Agonist WIN 55,212-2 on Neuropathic and Visceral Pain Induced by a Non-Diarrheagenic Dose of the Antitumoral Drug 5-Fluorouracil in the Rat. ( Abalo, R; Girón, R; López-Gómez, L; Martín-Fontelles, MI; Nurgali, K; Uranga, JA; Vera, G, 2023) |
| " polysaccharides (PCCL) on 5-fluorouracil-(5-FU)-induced intestinal mucositis (IM) in mice." | 8.12 | Protective effect of polysaccharides isolated from the seeds of Cuscuta chinensis Lam. on 5-fluorouracil-induced intestinal mucositis in mice. ( Chen, Z; Ji, Y; Lu, H; Luo, R; Tan, W; Tian, C; You, Y; Zhao, X; Zhou, L; Zhou, W; Zhou, X, 2022) |
| " The chemotherapy drug 5-fluorouracil (5FU) can cause intestinal mucositis." | 8.12 | Taurine Treatment Alleviates Intestinal Mucositis Induced by 5-Fluorouracil in Mice. ( Liu, C; Liu, S; Wang, J; Wang, L; Wei, L; Yan, L; Zheng, L; Zheng, W, 2022) |
| " We evaluated the effect of WMP on CIM by observing the general conditions of the mice (body weight, food intake, spleen weight, diarrhea score, and hematoxylin and eosin stained tissues)." | 8.12 | Wumei pills attenuates 5-fluorouracil-induced intestinal mucositis through Toll-like receptor 4/myeloid differentiation factor 88/nuclear factor-κB pathway and microbiota regulation. ( Chen, BY; Liu, F; Liu, HX; Lu, DX; Lu, Y; Sun, ZG; Wu, H; Yan, J, 2022) |
| "In order to provide evidence for clinical application, the therapeutic effect and mechanism of Huangqi Bazhen decoction on chemotherapeutic intestinal mucositis induced by capecitabine in mice are investigated." | 8.12 | Study on Huangqi Bazhen Decoction on Relieving Chemotherapy Intestinal Mucositis in Capecitabine Gavage Mice. ( Chen, B; Liu, C; Lu, K; Shi, T, 2022) |
| "Mucositis is one of the most strenuous side effects caused by chemotherapy drugs, such as 5-fluorouracil (5-FU), during the treatment of several types of cancers." | 8.12 | Antarctic Strain of Rhodotorula mucilaginosa UFMGCB 18,377 Attenuates Mucositis Induced by 5-Fluorouracil in Mice. ( Campos, MRA; Cardoso, VN; Coutinho, JOPA; de Menezes, GCA; Fernandes, SOA; Ferreira, E; Martins, FS; Nicoli, JR; Quintanilha, MF; Rosa, CA; Rosa, LH; Tiago, FCP; Vital, KD, 2022) |
| "Intestinal mucositis is one of chemotherapeutics' most common adverse effects, such as 5-fluorouracil (5-FU)." | 8.02 | The protective effects of quercetin nano-emulsion on intestinal mucositis induced by 5-fluorouracil in mice. ( Barary, M; Ebrahimpour, A; Hosseini, SM; Hosseinzadeh, R; Kazemi, S; Lotfi, M; Moghadamnia, AA; Shirafkan, F; Sio, TT, 2021) |
| "Intestinal mucositis (IM) is a common side effect of 5-fluorouracil (5-FU)-based chemotherapy, which negatively impacts therapeutic outcomes and delays subsequent cycles of chemotherapy resulting in dose reductions and treatment discontinuation." | 8.02 | Losartan improves intestinal mucositis induced by 5-fluorouracil in mice. ( Barra, PB; da Silva Martins Rebouças, C; de Araújo, AA; de Carvalho Leitão, RF; de Castro Brito, GA; de Medeiros, CACX; de Sales Mota, PCM; Figueiredo, JG; Guerra, GCB; Marques, VB; Oliveira, MMB; Ribeiro, SB, 2021) |
| " Reactive oxygen species (ROS) have been reported to be involved in the induction of intestinal mucositis and diarrhea, which are common side effects of treatment with fluoropyrimidine 5-fluorouracil (5-FU)." | 8.02 | Oral administration of cystine and theanine attenuates 5-fluorouracil-induced intestinal mucositis and diarrhea by suppressing both glutathione level decrease and ROS production in the small intestine of mucositis mouse model. ( Kurihara, S; Nishikawa, S; Yoneda, J, 2021) |
| "5-Fluorouracil (5-FU) is an anticancer agent that induces intestinal mucositis, which causes diarrhea and dehydration." | 8.02 | NOD-Like Receptor Family Pyrin Domain-Containing 3 Inflammasome Activation Exacerbates 5-Fluorouracil-Induced Small Intestinal Mucositis via Interleukin-1β Activation. ( Fujiwara, Y; Higashimori, A; Hosomi, S; Kamata, N; Kosaka, S; Matsumoto, Y; Nadatani, Y; Nagami, Y; Nakata, A; Otani, K; Taira, K; Tanaka, F; Tanigawa, T; Watanabe, T, 2021) |
| "The present study investigated how mild moxibustion treatment affects the intestinal microbiome and expression of NLRP3-related immune factors in a rat model of intestinal mucositis (IM) induced with 5-fluorouracil (5-Fu)." | 8.02 | Effects of mild moxibustion on intestinal microbiome and NLRP3 inflammasome in rats with 5-fluorouracil-induced intestinal mucositis. ( Ji, Q; Jia, R; Li, BR; Li, Q; Liu, H; Shao, SY; Sui, H; Sun, J; Wang, Y; Yuan, L; Zhang, BM; Zhang, Y; Zhou, LH, 2021) |
| "Mucositis is one of the most adverse effects of 5-fluorouracil (5-FU) and had no standard drug for treatment." | 8.02 | Oral Administration of Melatonin or Succinyl Melatonin Niosome Gel Benefits 5-FU-Induced Small Intestinal Mucositis Treatment in Mice. ( Boonsiri, P; Chio-Srichan, S; Daduang, J; Lee, YC; Leelayuwat, C; Mahakunakorn, P; Priprem, A; Puthongking, P; Settasatian, C; Tippayawat, P; Uthaiwat, P, 2021) |
| "Intestinal mucositis is a commonly encountered toxic side effect in patients undergoing 5-fluorouracil (5-FU)-based chemotherapy." | 8.02 | Amelioration of 5-fluorouracil-induced intestinal mucositis by Streptococcus thermophilus ST4 in a mouse model. ( Chen, WJ; Chu, HF; Shen, SR; Shen, TL; Wang, YR; Wu, SH, 2021) |
| "5-Fluorouracil (5-FU), a chemotherapeutic drug, has severe deteriorating effects on the intestine, leading to mucositis." | 8.02 | Evaluating the mucoprotective effects of glycyrrhizic acid-loaded polymeric nanoparticles in a murine model of 5-fluorouracil-induced intestinal mucositis via suppression of inflammatory mediators and oxidative stress. ( Ain, QU; Ali, H; Ali, J; Atiq, A; Khan, S; Zeeshan, M, 2021) |
| "oil in treating 5-fluorouracil (5-FU)-induced intestinal mucositis have not yet been reported." | 7.96 | Patchouli oil ameliorates 5-fluorouracil-induced intestinal mucositis in rats via protecting intestinal barrier and regulating water transport. ( Ai, G; Chen, L; Gan, Y; Huang, Q; Huang, X; Li, M; Liu, Y; Luo, H; Su, Z; Wu, J; Wu, X; Xu, N, 2020) |
| "Intestinal mucositis is the most common side effect of 5-fluorouracil (5-Fu) treatment in cancer patients." | 7.96 | Protective effect of Andrographolide on 5-Fu induced intestinal mucositis by regulating p38 MAPK signaling pathway. ( Li, M; Liu, D; Xiang, DC; Xu, YJ; Yang, JY; Zhang, CL; Zhang, S; Zhu, C, 2020) |
| "We used 90 mice of the CF-1 strain in which oral mucositis was induced using a protocol with 5-fluorouracil (5-FU) chemotherapy." | 7.96 | Cannabidiol on 5-FU-induced oral mucositis in mice. ( Borghetti, RL; Cherubini, K; Cuba, LF; de Figueiredo, MAZ; Guimarães, FS; Salum, FG, 2020) |
| "5-Fluorouracil (5-FU)-induced intestinal mucositis (IM) is one of the most common oncological problem." | 7.91 | Mucoprotective effects of Saikosaponin-A in 5-fluorouracil-induced intestinal mucositis in mice model. ( Ali, H; Ali, J; Islam, SU; Khan, AU; Khan, S; Kim, YS; Shah, FA, 2019) |
| "5-Fluorouracil (5-FU) is an anticancer agent whose main side effects include intestinal mucositis associated with intestinal motility alterations maybe due to an effect on the enteric nervous system (ENS), but the underlying mechanism remains unclear." | 7.91 | 5-Fluorouracil Induces Enteric Neuron Death and Glial Activation During Intestinal Mucositis via a S100B-RAGE-NFκB-Dependent Pathway. ( Bolick, DT; Bon-Frauches, AC; Brito, GAC; Castelucci, P; Costa, DVS; Freitas, GB; Guerrant, RL; Leitão, RFC; Lima-Júnior, RCP; Martins, CS; Moura-Neto, V; Silva, AMHP; Warren, CA, 2019) |
| "Mice body weight, food consumption, faeces consistency and the presence of blood in faeces were assessed daily during experimental mucositis induced by 5-fluorouracil (5FU)." | 7.91 | Treatment with selenium-enriched Saccharomyces cerevisiae UFMG A-905 partially ameliorates mucositis induced by 5-fluorouracil in mice. ( Almeida-Leite, CM; Alvarez-Leite, JI; Cardoso, VN; Generoso, SV; Leocádio, PCL; Martins, FS; Monteiro, CF; Nicoli, JR; Pessione, E; Porto, BAA; Santos, DA; Santos, JRA; Souza, ÉLS, 2019) |
| " The aim of this study was to test whether oral administration of a synbiotic (Simbioflora®) preparation containing Lactobacillus paracasei, Lactobacillus rhamnosus, Lactobacillus acidophilus and Bifidobacterium lactis plus fructooligosaccharide could help control mucosal inflammation in experimental mucositis induced by 5-fluorouracil (5-FU)." | 7.88 | Oral administration of Simbioflora® (synbiotic) attenuates intestinal damage in a mouse model of 5-fluorouracil-induced mucositis. ( Almeida-Leite, CM; Cardoso, VN; Costa, GMF; Faria, AMC; Generoso, SV; Maioli, TU; Martins, FS; Martins, VD; Rodrigues, NM; Souza, ELS; Trindade, LM, 2018) |
| "The compound 5-fluorouracil (5-FU) is the first choice chemotherapeutic agent for the treatment of colorectal cancer (CRC), but intestinal mucositis is a primary limiting factor in anticancer therapy." | 7.88 | Carboxymethyl pachyman (CMP) reduces intestinal mucositis and regulates the intestinal microflora in 5-fluorouracil-treated CT26 tumour-bearing mice. ( Cao, L; Gao, L; Wang, C; Wang, L; Yang, S, 2018) |
| " 5-Fluorouracil (5-FU) is a first-line chemotherapy for CRC, but chemoresistance and gastrointestinal mucositis limit its efficacy." | 7.88 | Ellagitannins from Pomegranate Ameliorates 5-Fluorouracil-Induced Intestinal Mucositis in Rats while Enhancing Its Chemotoxicity against HT-29 Colorectal Cancer Cells through Intrinsic Apoptosis Induction. ( Chen, XX; Feng, YB; Lam, KK; Lee, CK; Leung, GP; Li, ST; Shi, J; Sze, SC; Tang, SC; Xu, K; Yang, ZJ; Zhang, KY; Zhang, ZJ, 2018) |
| "simvastatin has pleiotropic anti-inflammatory and immunomodulatory effects potentially usefull to prevent chemotherapy-induced gastrointestinal mucositis." | 7.88 | Effects of simvastatin on 5-fluorouracil-induced gastrointestinal mucositis in rats. ( Araújo Filho, I; Azevedo, ÍM; Lima, ML; Medeiros, ADC; Moreira, MD, 2018) |
| "The chemotherapeutic agent 5-fluorouracil (5-FU) causes intestinal mucositis with severe diarrhoea, but the pathogenesis is not fully understood." | 7.85 | Apoptosis, Dysbiosis and Expression of Inflammatory Cytokines are Sequential Events in the Development of 5-Fluorouracil-Induced Intestinal Mucositis in Mice. ( Amagase, K; Hamouda, N; Higuchi, K; Kato, S; Matsumoto, K; Oikawa, Y; Ozaki, T; Sano, T; Shimakawa, M, 2017) |
| "The objective of the present study was to evaluate the effect of mulberry leaf extract (ME) fermented with Lactobacillus acidophilus A4 (A4) on intestinal mucositis induced by 5-fluorouracil (5-FU) in a rat model." | 7.85 | Mulberry leaf extract fermented with Lactobacillus acidophilus A4 ameliorates 5-fluorouracil-induced intestinal mucositis in rats. ( Kim, Y; Lee, JM; Lee, JY; Lee, KW; Oh, NS, 2017) |
| " 5-Fluorouracil (5-FU), widely used for cancer chemotherapy, is known to frequently induce intestinal mucositis accompanied by severe diarrhoea." | 7.85 | Probiotic Bifidobacterium bifidum G9-1 attenuates 5-fluorouracil-induced intestinal mucositis in mice via suppression of dysbiosis-related secondary inflammatory responses. ( Amagase, K; Hamouda, N; Kano, Y; Kato, S; Matsumoto, K; Oikawa, Y; Shimakawa, M; Tanaka, Y, 2017) |
| "5-Fluorouracil (5-FU) has broadly been applied to treat colorectal cancer as one of the most effective chemotherapeutic agents." | 7.85 | Oral Administration of Polaprezinc Attenuates Fluorouracil-induced Intestinal Mucositis in a Mouse Model. ( Li, M; Liang, X; Liu, Z; Teng, N; Wang, X; Xie, W; Yang, Z; Zhang, Z, 2017) |
| "Disturbed homeostasis of gut microbiota has been suggested to be closely associated with 5-fluorouracil (5-Fu) induced mucositis." | 7.85 | Alteration of Gut Microbiota and Inflammatory Cytokine/Chemokine Profiles in 5-Fluorouracil Induced Intestinal Mucositis. ( Huang, F; Li, HL; Lu, L; Qin, LY; Qiu, SP; Shi, HL; Wang, P; Wang, XS; Wu, H; Wu, XJ; Zhang, BB, 2017) |
| "This study investigated the prophylactic effects of orally administered surface-deacetylated chitin nanofibers (SDACNFs) and chitosan against 5-fluorouracil (5-FU)-induced intestinal mucositis, which is a common side effect of 5-FU chemotherapy." | 7.85 | Oral Administration of Surface-Deacetylated Chitin Nanofibers and Chitosan Inhibit 5-Fluorouracil-Induced Intestinal Mucositis in Mice. ( Azuma, K; Ifuku, S; Imagawa, T; Ito, N; Izawa, H; Koizumi, R; Morimoto, M; Ochi, K; Okamoto, Y; Osaki, T; Saimoto, H; Tsuka, T, 2017) |
| "Here we assessed the impact of L-citrulline (CIT) on a murine model of 5-fluorouracil (5FU)-induced mucositis." | 7.83 | Pretreatment With L-Citrulline Positively Affects the Mucosal Architecture and Permeability of the Small Intestine in a Murine Mucositis Model. ( Alvarez-Leite, JI; Antunes, MM; Cara, DC; Cardoso, VN; Correia, MI; Generoso, Sde V; Leocádio, PC; Leonel, AJ; Menezes, GB; Teixeira, LG, 2016) |
| "5-Fluorouracil is one of the most commonly used anticancer drugs for the treatment of various types of cancer but has potential adverse effects such as intestinal mucositis, renal, hepatic, and reproductive organ toxicity." | 7.83 | Taurine ameliorates 5-flourouracil-induced intestinal mucositis, hepatorenal and reproductive organ damage in Wistar rats: A biochemical and histological study. ( Al-Asmari, AK; Al-Shahrani, HM; Al-Zahrani, AM; Ali Al Amri, M; Khan, AQ, 2016) |
| "Intestinal mucositis is a serious toxic side effect of 5-fluorouracil (5-FU) treatment." | 7.83 | Protective effect of Bu-Zhong-Yi-Qi decoction, the water extract of Chinese traditional herbal medicine, on 5-fluorouracil-induced intestinal mucositis in mice. ( Gou, H; Gu, LY; Shang, BZ; Wang, C; Xiong, Y, 2016) |
| "Wei-Chang-An pill (WCA pill), a traditional Chinese pharmaceutical preparation, possessed potential anti-inflammatory advantages and noteworthy gastrointestinal regulations in digestive diseases, which might represent a promising candidate for the treatment of intestinal mucositis (IM) induced by 5-fluorouracil (5-FU)." | 7.83 | Protective effect and potential mechanisms of Wei-Chang-An pill on high-dose 5-fluorouracil-induced intestinal mucositis in mice. ( Chen, Y; Gao, W; Jin, Z; Wang, L; Zhang, J; Zheng, H, 2016) |
| "This study assessed the protective potential of rifaximin in 5-fluorouracil (5-FU) induced intestinal mucositis in the Wistar rats'." | 7.83 | Rifaximin modulates 5-fluorouracil-induced gastrointestinal mucositis in rats. ( Bedecean, I; Berce, C; Catoi, C; Ciobanu, L; Mîrleneanu, R; Parau, A; Tantau, M; Taulescu, M; Valean, S, 2016) |
| "5-Fluorouracil (5-FU)-induced intestinal mucositis is one of the most common morbidities in chemotherapy and involves the reactive oxygen species (ROS) system, apoptosis, and inflammatory cytokines." | 7.81 | Rebamipide attenuates 5-Fluorouracil-induced small intestinal mucositis in a mouse model. ( Han, SH; Kim, HJ; Kim, JH; Lee, JH; Moon, W; Park, J; Park, SJ; Song, GA, 2015) |
| " The objective of this study was to determine whether a diet with the addition of n-3 FA helps control the inflammation observed in 5-fluorouracil (5-FU) induced mucositis." | 7.81 | Dietary supplementation with omega-3 fatty acid attenuates 5-fluorouracil induced mucositis in mice. ( Cardoso, VN; Carneiro, CM; Faria, AM; Ferreira, AV; Generoso, Sde V; Maioli, TU; Paiva, NC; Rodrigues, NM; Trindade, LM, 2015) |
| " This gene codifies for the target enzyme of 5-fluorouracil (5-FU), the basic treatment in colorectal cancer." | 7.81 | Long Survival and Severe Toxicity Under 5-Fluorouracil-Based Therapy in a Patient With Colorectal Cancer Who Harbors a Germline Codon-Stop Mutation in TYMS. ( Balboa-Beltrán, E; Barros, F; Carracedo, A; Duran, G; Lamas, MJ, 2015) |
| "Our results bring support to the hUP1 inhibitor strategy as a novel possibility of prevention and treatment of mucositis during the 5-FU chemotherapy, based on the approach of uridine accumulation in plasma and tissues." | 7.80 | Human uridine phosphorylase-1 inhibitors: a new approach to ameliorate 5-fluorouracil-induced intestinal mucositis. ( Basso, LA; Campos, MM; Lopes, TG; Machado, P; Petersen, GO; Renck, D; Santos, AA; Santos, DS, 2014) |
| "Although 5-fluorouracil (5-FU) is a widely used as chemotherapy agent, severe mucositis develops in approximately 80% of patients." | 7.79 | Increased expression of 5-HT3 and NK 1 receptors in 5-fluorouracil-induced mucositis in mouse jejunum. ( Arakawa, K; Horie, S; Kato, S; Matsumoto, K; Nakajima, T; Narita, M; Sagara, A; Sakai, H; Tashima, K, 2013) |
| "Chemotherapeutic agents, including 5-fluorouracil (5-FU), frequently cause intestinal mucositis resulting in severe diarrhoea and morphological mucosal damage." | 7.79 | 5-HT₃ receptor antagonists ameliorate 5-fluorouracil-induced intestinal mucositis by suppression of apoptosis in murine intestinal crypt cells. ( Amagase, K; Horie, S; Iimori, M; Kato, S; Kitahara, Y; Matsumoto, K; Takeuchi, K; Utsumi, D; Yamanaka, N; Yasuda, M, 2013) |
| " In the present study, we investigated the role of NOX1 in the pathogenesis of intestinal mucositis induced by the cancer chemotherapeutic agent 5-fluorouracil (5-FU) in mice." | 7.78 | Potential role of the NADPH oxidase NOX1 in the pathogenesis of 5-fluorouracil-induced intestinal mucositis in mice. ( Amagase, K; Iimori, M; Iwata, K; Kato, S; Kitahara, Y; Matsuno, K; Takeuchi, K; Utsumi, D; Yabe-Nishimura, C; Yamanaka, N; Yasuda, M, 2012) |
| "This study demonstrates that CR3294 acts on key molecular targets to reduce the signs of mucositis and the occurrence of diarrhea in mice exposed to the chemotherapy drug 5-fluorouracil." | 7.76 | Efficacy of CR3294, a new benzamidine derivative, in the prevention of 5-fluorouracil-induced gastrointestinal mucositis and diarrhea in mice. ( Bonazzi, A; Booth, C; Caselli, G; Garofalo, P; Letari, O; Makovec, F; Rovati, LC, 2010) |
| " Body weight loss results, diarrhea scores, and villi measurements showed that minocycline attenuated the severity of intestinal mucositis induced by 5-fluorouracil (5-FU)." | 7.75 | Minocycline attenuates 5-fluorouracil-induced small intestinal mucositis in mouse model. ( Chao, YC; Chu, HC; Ho, WH; Hou, HS; Huang, TY; Liao, CL; Lin, YL, 2009) |
| "In this study, we investigated the effects of an Eriobotrya japonica seed extract (ESE) on mucositis using a 5-fluorouracil (5-FU)-induced mucositis hamster model." | 7.74 | Effect of Eriobotrya japonica seed extract on 5-fluorouracil-induced mucositis in hamsters. ( Guangchen, S; Hamada, A; Kusunose, M; Kyotani, S; Miyamura, M; Nishioka, Y; Onogawa, M; Takuma, D; Yokota, J; Yoshioka, S, 2008) |
| "To evaluate gastrointestinal motility during 5-fluorouracil (5-FU)-induced intestinal mucositis." | 7.74 | Gastrointestinal dysmotility in 5-fluorouracil-induced intestinal mucositis outlasts inflammatory process resolution. ( Assreuy, AM; Brito, GA; Gomes, AS; Mota, JM; Oliveira, RB; Ribeiro, RA; Santos, AA; Soares, PM; Souza, MH, 2008) |
| "Lafutidine could offer the possibility of more effective prevention of CT-induced mucositis through the activation of GI mucus cells." | 7.74 | Effects of acid antisecretory drugs on mucus barrier of the rat against 5-fluorouracil-induced gastrointestinal mucositis. ( Goso, Y; Ichikawa, T; Ikezawa, T; Ishihara, K; Iwai, T; Nakano, M; Saegusa, Y; Saigenji, K; Shikama, N, 2008) |
| "Chemotherapy-induced oral mucositis (COM) is a common adverse effect of cancer chemotherapy." | 5.91 | Preparation and pharmaceutical properties of Hangeshashinto oral ointment and its safety and efficacy in Syrian hamsters with 5-fluorouracil-induced oral mucositis. ( Hira, D; Imai, S; Ito, M; Itohara, K; Kagawa, M; Matsubara, K; Nakagawa, S; Nakagawa, T; Ogihara, T; Terada, T; Yamanaka, R; Yonezawa, A, 2023) |
| "The current idea of how oral mucositis (OM) develops is primarily based on hypotheses and the early events which precede clinically established OM remain to be demonstrated." | 5.91 | Moderate temperature reduction is sufficient for prevention of 5-fluorouracil-induced oral mucositis: an experimental in vivo study in rats. ( Aydogdu, Ö; Dankis, M; Jontell, M; Walladbegi, J; Winder, M, 2023) |
| "Mucositis is defined as inflammatory and ulcerative lesions along of the gastrointestinal tract that leads to the imbalance of the intestinal microbiota." | 5.91 | Association of Fructo-oligosaccharides and Arginine Improves Severity of Mucositis and Modulate the Intestinal Microbiota. ( Andrade, MER; Cardoso, VN; Cassali, GD; Cavalcante, GG; da Silva, TF; de Carvalho Azevedo, VA; de Oliveira Carvalho, RD; de Oliveira, JS; Dos Reis, DC; Fernandes, SOA; Generoso, SV; Leite, JIA; Leocádio, PCL; Trindade, LM, 2023) |
| "Mucositis was induced through a single injection with 2 mg/kg idarubicin (with saline as control), followed by daily treatments of anakinra (100 mg/kg/day), dexamethasone (10 mg/kg/day) or both for 3 days." | 5.91 | Anakinra and dexamethasone treatment of idarubicin-induced mucositis and diarrhoea in rats. ( Dahlgren, D; Heindryckx, F; Kullenberg, F; Lennernäs, H; Peters, K; Sjöblom, M, 2023) |
| "Intestinal mucositis is a commonly reported side effect in oncology patients undergoing chemotherapy and radiotherapy." | 5.91 | Synergistic synbiotic containing fructooligosaccharides and Lactobacillus delbrueckii CIDCA 133 alleviates chemotherapy-induced intestinal mucositis in mice. ( Américo, MF; Azevedo, V; Barroso, FAL; Batista, VL; Belo, GA; Birbrair, A; Campos, GM; Cardoso, VN; Coelho-Rocha, ND; da Silva, TF; de Jesus, LCL; Dos Santos Freitas, A; Drumond, MM; Fernandes, SOA; Ferreira, E; Laguna, JG; Mancha-Agresti, P; Martins, FS; Tavares, LM; Vital, KD, 2023) |
| "5-Fluorouracil (5-FU) is a front-line cytotoxic therapy." | 5.72 | Thymol ameliorates 5-fluorouracil-induced intestinal mucositis: Evidence of down-regulatory effect on TGF-β/MAPK pathways through NF-κB. ( Al-Amin, MA; Al-Khrashi, LA; Badr, AM; Mahran, YF, 2022) |
| "5-Fluorouracil (5-FU) is a chemotherapy drug used to treat tumors." | 5.72 | Akkermansia muciniphila and its outer membrane protein Amuc_1100 prophylactically attenuate 5-fluorouracil-induced intestinal mucositis. ( Chen, S; Qian, K; Zhang, G; Zhang, M, 2022) |
| "Intestinal mucositis is a common side effect of chemotherapy and radiotherapy." | 5.62 | TBHQ attenuates ferroptosis against 5-fluorouracil-induced intestinal epithelial cell injury and intestinal mucositis via activation of Nrf2. ( Deng, S; Li, J; Li, L; Wu, D; Xu, Y, 2021) |
| "Mucositis was induced by intraperitoneal injection (300 mg/kg) of 5-fluorouracil (5-FU)." | 5.62 | Prophylactic and therapeutic supplementation using fructo-oligosaccharide improves the intestinal homeostasis after mucositis induced by 5- fluorouracil. ( Alvarez-Leite, JI; Andrade, MER; Cardoso, VN; Carvalho, PLA; Cassali, GD; Dos Reis, DC; Dos Santos Martins, F; Fernandes, SOA; Generoso, SV; Gouveia Peluzio, MDC; Leocádio, PCL; Souza E Melo, ÉLS; Trindade, LM, 2021) |
| "5-Fluorouracil (5-FU) is a chemotherapy agent that is widely used in clinical oncologic practice." | 5.62 | Anti-inflammatory effects of Radix Aucklandiae herbal preparation ameliorate intestinal mucositis induced by 5-fluorouracil in mice. ( Chang, CW; Chen, YJ; Hsieh, CH; Liu, CY; Liu, JH; Tsai, TH, 2021) |
| "Patchouli alcohol (PA) is an active compound extracted from Pogostemon cablin, and has potent gastrointestinal protective effect." | 5.56 | Patchouli alcohol attenuates 5-fluorouracil-induced intestinal mucositis via TLR2/MyD88/NF-kB pathway and regulation of microbiota. ( Chen, L; Gan, Y; Li, M; Liang, J; Lin, Z; Liu, Y; Luo, H; Su, Z; Wu, J; Wu, Q; Wu, X; Xu, N; Zhuo, J, 2020) |
| "Zinc sulfate has a beneficial role, decreasing the severity of gut mucosal injuries induced by 5-FU in Wistar rats." | 5.56 | Beneficial effect of oral administration of zinc sulfate on 5-fluorouracil-induced gastrointestinal mucositis in rats. ( Berce, C; Ciobanu, L; Meșter, A; Onica, S; Tanțău, M; Taulescu, M; Tefas, C; Toma, C, 2020) |
| "Mucositis was induced in mice by administration of 5-FU (50 mg/kg, i." | 5.51 | Diadzein ameliorates 5-fluorouracil-induced intestinal mucositis by suppressing oxidative stress and inflammatory mediators in rodents. ( Al-Sharari, SD; Ali, J; Atiq, A; Khan, A; Khan, S; Kim, YS; Naveed, M; Shal, B; Zeeshan, S, 2019) |
| "Mucositis was induced by intraperitoneal injection of 300 mg/kg 5-FU." | 5.48 | Conjugated linoleic acid prevents damage caused by intestinal mucositis induced by 5-fluorouracil in an experimental model. ( Alvarez Leite, JI; Antunes Fernandes, SO; Cardoso, VN; Cassali, GD; da Gama, MAS; de Barros, PAV; de Sales E Souza, ÉL; de Vasconcelos Generoso, S; Dos Reis, DC; Dos Santos Martins, F; Lacerda Leocádio, PC; Mendes Miranda, SE; Rabelo Andrade, ME, 2018) |
| "Mucositis was induced by daily injections of 5-fluororacil (5-FU) after which mice were either given L." | 5.48 | Protective effect of the riboflavin-overproducing strain Lactobacillus plantarum CRL2130 on intestinal mucositis in mice. ( de Moreno de LeBlanc, A; LeBlanc, JG; Levit, R; Savoy de Giori, G, 2018) |
| " On the 7th day, the mice were euthanized, and intestinal samples were collected for histopathology and morphometric analysis, as well as for the determination of myeloperoxidase activity and cytokine dosage (TNF-α and IL-6)." | 5.43 | A new animal model of intestinal mucositis induced by the combination of irinotecan and 5-fluorouracil in mice. ( Almeida, PR; Assis-Júnior, EM; Brito, GA; Lima-Júnior, RC; Melo, AT; Pereira, VB; Ribeiro, RA; Wong, DV, 2016) |
| "Intestinal mucositis is a common toxic side effect in cancer patients receiving high-dose chemotherapy." | 5.42 | Bifidobacterium infantis has a beneficial effect on 5-fluorouracil-induced intestinal mucositis in rats. ( Chong, P; Feng, WD; Shi, HP; Xue, CL; Yang, T; Yu, HL; Yu, M; Yuan, KT, 2015) |
| "Mucositis is a side effect of chemotherapy treatment that affects approximately 40% of patients." | 5.42 | L-arginine pretreatment reduces intestinal mucositis as induced by 5-FU in mice. ( Alvarez-Leite, JI; Antunes, MM; Cardoso, VN; Correia, MI; Generoso, SV; Leocádio, PC; Leonel, AJ; Machado, DC; Teixeira, LG, 2015) |
| "Mouse body weight was monitored daily." | 5.42 | Alanyl-glutamine attenuates 5-fluorouracil-induced intestinal mucositis in apolipoprotein E-deficient mice. ( Alves, LA; Aquino, CC; Araújo, CV; Bertolini, LR; Brito, GA; Costa, TB; Figueiredo, IL; Lazzarotto, CR; Lima, AA; Oriá, RB; Ribeiro, RA, 2015) |
| "5-Fluorouracil (5-FU) is a commonly used drug for the treatment of malignant cancers." | 5.38 | 5-Fluorouracil induced intestinal mucositis via nuclear factor-κB activation by transcriptomic analysis and in vivo bioluminescence imaging. ( Chang, CT; Ho, TY; Hsiang, CY; Huang, HC; Huang, YF; Li, CC; Liang, JA; Lin, H; Lo, HY; Wu, SL, 2012) |
| "Intestinal mucositis is one of the major troublesome side effects of anticancer chemotherapy leading to poor patient compliance." | 5.38 | Apolipoprotein E COG 133 mimetic peptide improves 5-fluorouracil-induced intestinal mucositis. ( Araújo, CV; Azevedo, OG; Costa, TB; Guerrant, RL; Lima, AÂ; Lima, RC; Lucena, HB; Oliveira, BC; Oliveira, RA; Oriá, RB; Ribeiro, RA; Vitek, MP; Warren, CA; Wong, DV; Zaja-Milatovic, S, 2012) |
| "Mucositis affects about 40 % of patients undergoing chemotherapy." | 5.38 | Oral supplementation of butyrate reduces mucositis and intestinal permeability associated with 5-Fluorouracil administration. ( Alvarez-Leite, JI; Cara, DC; Cardoso, VN; Correia, MI; Ferreira, TM; Leonel, AJ; Melo, MA; Santos, RR, 2012) |
| "Gastrointestinal mucositis is a common side effect of cancer chemotherapy." | 5.37 | Role of platelet-activating factor in the pathogenesis of 5-fluorouracil-induced intestinal mucositis in mice. ( Brito, GA; Cunha, FQ; Justino, PF; Lima-Junior, RC; Mota, JM; Ribeiro, RA; Soares, PM; Souza, MH, 2011) |
| "5-Fluorouracil (5-FU) is a commonly used chemotherapy agent in clinical oncology practice." | 5.35 | Gastrointestinal microflora and mucins may play a critical role in the development of 5-Fluorouracil-induced gastrointestinal mucositis. ( Bowen, JM; Gibson, RJ; Hamilton, J; Keefe, DM; Logan, RM; Stringer, AM; Yeoh, AS, 2009) |
| "Intestinal mucositis is a common and debilitating side-effect of chemotherapy, associated with severe small intestinal inflammation." | 5.35 | Lyprinol only partially improves indicators of small intestinal integrity in a rat model of 5-fluorouracil-induced mucositis. ( Butler, RN; Geier, MS; Howarth, GS; Smith, CL; Tooley, KL; Torres, DM, 2008) |
| "to evaluate the effect of oral cryotherapy compared to physiological serum on the development of oral mucositis in outpatient cancer patients using the 5-fluorouracil antineoplastic agent." | 5.34 | Effect of cryotherapy in preventing mucositis associated with the use of 5-fluorouracil. ( Aguiar, MIF; Alves, NP; Lopes, TSS; Oliveira, PP; Rodrigues, AB; Silva, RA; Vitorino, WO, 2020) |
| " Three of six patients in cohort 2B-1 experienced grade 3 mucositis, and further study of the combination of everolimus, mFOLFOX6 and panitumumab was aborted." | 5.19 | A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors. ( Bernard, S; Davies, JM; Dees, EC; Goldberg, RM; Ivanova, A; Keller, K; McRee, AJ; O'Neil, BH; Sanoff, HG, 2014) |
| "Adverse events associated with 5-fluorouracil (5FU) based adjuvant therapy in colorectal cancer (CRC) patients may predict survival." | 5.19 | Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity? ( André, T; Bono, P; de Gramont, A; Hermunen, K; Österlund, P; Poussa, T; Quinaux, E; Soveri, LM, 2014) |
| "This study evaluated the maximum tolerated dose (MTD) and the dose limiting toxicity (DLT) of erlotinib when combined to irinotecan and capecitabine in pre-treated metastatic colorectal cancer patients." | 5.14 | Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients. ( Bajetta, E; Bajetta, R; Buzzoni, R; Di Bartolomeo, M; Dotti, KF; Ferrario, E; Galassi, M; Gevorgyan, A; Mariani, L; Venturino, P, 2009) |
| "Capecitabine is effective against metastatic breast cancer (MBC)." | 5.14 | Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer. ( Aramendía, JM; Arbea, L; Aristu, J; De la Cruz, S; Espinós, J; Fernández-Hidalgo, O; Martínez-Monge, R; Moreno, M; Nieto, Y; Pina, L; Regueira, FM; Santisteban, M; Sola, J; Zornoza, G, 2010) |
| "To assess the predictive value of polymorphisms in dihydropyrimidine dehydrogenase (DPYD ), thymidylate synthase (TYMS ), and methylene tetrahydrofolate reductase (MTHFR ) and of nongenetic factors for severe leukopenia, diarrhea, and mucositis related to fluorouracil (FU) treatment." | 5.13 | Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. ( Blievernicht, J; Bokemeyer, C; Dippon, J; Eichelbaum, M; Fischer, J; Hofmann, U; Kerb, R; Klein, K; Marx, C; Schaeffeler, E; Schwab, M; Zanger, UM, 2008) |
| " Oral glutamine supplements (OGS) may have a role in the prevention of chemotherapy-induced mucositis/stomatitis." | 5.12 | The effect of oral glutamine on 5-fluorouracil/leucovorin-induced mucositis/stomatitis assessed by intestinal permeability test. ( Choi, K; Jeon, WK; Kim, JW; Lee, SS; Lim, SY; Oh, SJ; Oh, TY, 2007) |
| "Pegylated liposomal doxorubicin-based combination chemotherapy with capecitabine or gemcitabine was not effective as salvage therapy in advanced hepatocellular carcinoma." | 5.11 | Pegylated liposomal doxorubicin-based combination chemotherapy as salvage treatment in patients with advanced hepatocellular carcinoma. ( Bai, LY; Chen, PM; Poh, SB, 2005) |
| "Intestinal mucositis and diarrhea are common manifestations of anticancer regimens that include irinotecan, 5-fluorouracil (5-FU), and other cytotoxic drugs." | 4.93 | Irinotecan- and 5-fluorouracil-induced intestinal mucositis: insights into pathogenesis and therapeutic perspectives. ( Cunha, FQ; Leite, CA; Lima-Júnior, RC; Mota, JM; Ribeiro, RA; Souza, MH; Wanderley, CW; Wong, DV, 2016) |
| " This review focuses on the development and establishment of the Dark Agouti rat mammary adenocarcinoma model by the Mucositis Research Group of the University of Adelaide over the past 20 years to characterize the mechanisms underlying methotrexate-, 5-fluorouracil-, and irinotecan-induced mucositis." | 4.91 | Dark Agouti rat model of chemotherapy-induced mucositis: establishment and current state of the art. ( Bateman, E; Keefe, D; Mayo, B; Stringer, A; Thorpe, D; Vanhoecke, B; Vanlancker, E, 2015) |
| "An electronic search was undertaken to identify randomized controlled trials comparing raltitrexed-based regimen to 5-fluorouracil-based regimen in patients with advanced colorectal cancer." | 4.90 | Raltitrexed-based chemotherapy for advanced colorectal cancer. ( Hong, W; Huang, Q; Liu, Y; Sun, X; Wu, J; Wu, W, 2014) |
| "The aim of this study was to evaluate systematically the efficacy and safety of oral uracil-tegafur (UFT) plus leucovorin (LV) compared with infusional fluorouracil (5-FU) plus LV for advanced colorectal cancer." | 4.87 | Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials. ( Bin, Q; Cao, Y; Gao, F; Li, J; Liao, C, 2011) |
| "We reviewed published studies reporting phase II and III clinical trials of dose-dense regimens for breast cancer and NHL, TAC (docetaxel, adriamycin, cyclophosphamide) chemotherapy for breast cancer, and infusional 5-fluorouracil-based regimens for colorectal cancer." | 4.83 | Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. ( Avritscher, EB; Bekele, BN; Cooksley, CD; Elting, LS; Jones, JA; Michelet, M, 2006) |
| "Intestinal mucositis is characterized by inflammation and ulceration of the mucosa that affects the gastrointestinal tract and is associated with administering some drugs, such as 5- Fluorouracil (5-FU), conventional chemotherapy used in clinics for cancer therapy." | 4.31 | Protective Effect of ( Araújo, DD; da Silva Souza, B; de Andrade, GL; de Freitas, CDT; de Oliveira, JS, 2023) |
| " In vivo analyses were conducted to investigate the anti-inflammatory effects of the strains on a mouse model of 5-Fluorouracil-induced mucositis." | 4.31 | Evaluation of Probiotic Properties of Novel Brazilian Lactiplantibacillus plantarum Strains. ( Azevedo, VAC; Barh, D; Barroso, FAL; Coelho-Rocha, ND; da Silva, TF; de Jesus, LCL; de Oliveira Carvalho, RD; Dos Santos Martins, F; Ferreira, E; Gonçalves, JE, 2023) |
| "5-Fluorouracil (5-FU) is a common anti-tumor drug, but there is no effective treatment for its side effect, intestinal mucositis." | 4.31 | Short-Chain Fatty Acids Attenuate 5-Fluorouracil-Induced THP-1 Cell Inflammation through Inhibiting NF-κB/NLRP3 Signaling via Glycerolphospholipid and Sphingolipid Metabolism. ( Gong, W; Wang, C; Wang, D; Wu, L; Xi, Y; Yang, C; Zhang, Y, 2023) |
| "This study aims to evaluate the effect of berberine-based carbon quantum dots (Ber-CDs) on improving 5-fluorouracil (5-FU)-induced intestinal mucositis in C57BL/6 mice, and explored the mechanisms behind this effect." | 4.31 | Berberine-Based Carbon Quantum Dots Improve Intestinal Barrier Injury and Alleviate Oxidative Stress in C57BL/6 Mice with 5-Fluorouracil-Induced Intestinal Mucositis by Enhancing Gut-Derived Short-Chain Fatty Acids Contents. ( He, J; Li, H; Sun, C; Tan, J; Wang, D; Wu, L; Xi, Y; Yan, M, 2023) |
| "5-Fluorouracil (5-FU) is a conventional and effective drug for colorectal cancer patients, and it is an important part of combined chemotherapy and adjuvant chemotherapy." | 4.31 | Peficitinib ameliorates 5-fluorouracil-induced intestinal damage by inhibiting aging, inflammatory factors and oxidative stress. ( Chen, C; Dai, Q; He, S; Jia, H; Wang, XB; Xia, J; Zhou, Y, 2023) |
| "5-fluorouracil (5-FU) is an antineoplastic drug used to treat colorectal cancer, but it causes, among other adverse effects, diarrhea and mucositis, as well as enteric neuropathy, as shown in experimental animals." | 4.31 | Effect of the Cannabinoid Agonist WIN 55,212-2 on Neuropathic and Visceral Pain Induced by a Non-Diarrheagenic Dose of the Antitumoral Drug 5-Fluorouracil in the Rat. ( Abalo, R; Girón, R; López-Gómez, L; Martín-Fontelles, MI; Nurgali, K; Uranga, JA; Vera, G, 2023) |
| "5-Fluorouracil (5-FU) is a used chemotherapy drug for cancer, and its main side effect is intestinal mucositis which causes chemotherapy to fail." | 4.12 | Three important short-chain fatty acids (SCFAs) attenuate the inflammatory response induced by 5-FU and maintain the integrity of intestinal mucosal tight junction. ( Chang, S; Jie, M; Liang, W; Long-Kun, D; Man, Y; Min, Z; Shuang-Yu, L; Wen, S; Xin, Q; Yue, X, 2022) |
| " polysaccharides (PCCL) on 5-fluorouracil-(5-FU)-induced intestinal mucositis (IM) in mice." | 4.12 | Protective effect of polysaccharides isolated from the seeds of Cuscuta chinensis Lam. on 5-fluorouracil-induced intestinal mucositis in mice. ( Chen, Z; Ji, Y; Lu, H; Luo, R; Tan, W; Tian, C; You, Y; Zhao, X; Zhou, L; Zhou, W; Zhou, X, 2022) |
| " We evaluated the effect of WMP on CIM by observing the general conditions of the mice (body weight, food intake, spleen weight, diarrhea score, and hematoxylin and eosin stained tissues)." | 4.12 | Wumei pills attenuates 5-fluorouracil-induced intestinal mucositis through Toll-like receptor 4/myeloid differentiation factor 88/nuclear factor-κB pathway and microbiota regulation. ( Chen, BY; Liu, F; Liu, HX; Lu, DX; Lu, Y; Sun, ZG; Wu, H; Yan, J, 2022) |
| "In order to provide evidence for clinical application, the therapeutic effect and mechanism of Huangqi Bazhen decoction on chemotherapeutic intestinal mucositis induced by capecitabine in mice are investigated." | 4.12 | Study on Huangqi Bazhen Decoction on Relieving Chemotherapy Intestinal Mucositis in Capecitabine Gavage Mice. ( Chen, B; Liu, C; Lu, K; Shi, T, 2022) |
| "5-Fluorouracil (5-FU) is one of the most widely used chemotherapeutic agents; however, it often causes intestinal mucositis with severe diarrhea." | 4.12 | Alleviative effects of glutamate against chemotherapeutic agent-induced intestinal mucositis. ( Amagase, K; Fujita, T; Fujiwara, A; Hamouda, N; Iwata, K; Jonan, S; Kato, S, 2022) |
| "The aim of this study was to analyze the effects of three different Photobiomodulation Therapy (PBMT) protocols in the treatment of 5-fluorouracil-induced oral mucositis in hamsters." | 4.02 | Wound healing process with different photobiomodulation therapy protocols to treat 5-FU-induced oral mucositis in hamsters. ( Arana-Chavez, VE; Calarga, CC; Cotomacio, CC; Simões, A; Yshikawa, BK, 2021) |
| "Intestinal mucositis is one of chemotherapeutics' most common adverse effects, such as 5-fluorouracil (5-FU)." | 4.02 | The protective effects of quercetin nano-emulsion on intestinal mucositis induced by 5-fluorouracil in mice. ( Barary, M; Ebrahimpour, A; Hosseini, SM; Hosseinzadeh, R; Kazemi, S; Lotfi, M; Moghadamnia, AA; Shirafkan, F; Sio, TT, 2021) |
| "Intestinal mucositis (IM) is a common side effect of 5-fluorouracil (5-FU)-based chemotherapy, which negatively impacts therapeutic outcomes and delays subsequent cycles of chemotherapy resulting in dose reductions and treatment discontinuation." | 4.02 | Losartan improves intestinal mucositis induced by 5-fluorouracil in mice. ( Barra, PB; da Silva Martins Rebouças, C; de Araújo, AA; de Carvalho Leitão, RF; de Castro Brito, GA; de Medeiros, CACX; de Sales Mota, PCM; Figueiredo, JG; Guerra, GCB; Marques, VB; Oliveira, MMB; Ribeiro, SB, 2021) |
| " Reactive oxygen species (ROS) have been reported to be involved in the induction of intestinal mucositis and diarrhea, which are common side effects of treatment with fluoropyrimidine 5-fluorouracil (5-FU)." | 4.02 | Oral administration of cystine and theanine attenuates 5-fluorouracil-induced intestinal mucositis and diarrhea by suppressing both glutathione level decrease and ROS production in the small intestine of mucositis mouse model. ( Kurihara, S; Nishikawa, S; Yoneda, J, 2021) |
| "To evaluate a mixture of selected lactic acid bacteria (LAB) (a riboflavin-producer, a folate-producer and an immunomodulatory strain) as co-adjuvant for 5-fluorouracil (5-FU) chemotherapy in cell culture and using a 4T1 cell animal model of breast cancer." | 4.02 | Evaluation of vitamin-producing and immunomodulatory lactic acid bacteria as a potential co-adjuvant for cancer therapy in a mouse model. ( de Moreno de LeBlanc, A; LeBlanc, JG; Levit, R; Savoy de Giori, G, 2021) |
| "Mucositis is one of the most adverse effects of 5-fluorouracil (5-FU) and had no standard drug for treatment." | 4.02 | Oral Administration of Melatonin or Succinyl Melatonin Niosome Gel Benefits 5-FU-Induced Small Intestinal Mucositis Treatment in Mice. ( Boonsiri, P; Chio-Srichan, S; Daduang, J; Lee, YC; Leelayuwat, C; Mahakunakorn, P; Priprem, A; Puthongking, P; Settasatian, C; Tippayawat, P; Uthaiwat, P, 2021) |
| "Intestinal mucositis is a commonly encountered toxic side effect in patients undergoing 5-fluorouracil (5-FU)-based chemotherapy." | 4.02 | Amelioration of 5-fluorouracil-induced intestinal mucositis by Streptococcus thermophilus ST4 in a mouse model. ( Chen, WJ; Chu, HF; Shen, SR; Shen, TL; Wang, YR; Wu, SH, 2021) |
| "Although first-line chemotherapy drugs, including 5-fluorouracil (5-FU), remain one of the major choice for cancer treatment, the clinical use is also accompanied with dose-depending toxicities, such as intestinal mucositis (IM), in cancer patients undergoing treatment." | 4.02 | RNA-seq and ( Cai, BY; Lu, Y; Wang, XY; Wang, YJ; Xu, L; Yao, QH; Zhang, B, 2021) |
| " Intestinal mucositis characterized by intense inflammation is the main side effect associated with 5-fluorouracil (5-FU) treatment." | 3.96 | Modulation of 5-fluorouracil activation of toll-like/MyD88/NF-κB/MAPK pathway by Saccharomyces boulardii CNCM I-745 probiotic. ( Barbosa, ALR; Czerucka, D; Franco, AX; Justino, PFC; Monteiro, CES; Pontier-Bres, R; Soares, PMG; Souza, MHLP, 2020) |
| "oil in treating 5-fluorouracil (5-FU)-induced intestinal mucositis have not yet been reported." | 3.96 | Patchouli oil ameliorates 5-fluorouracil-induced intestinal mucositis in rats via protecting intestinal barrier and regulating water transport. ( Ai, G; Chen, L; Gan, Y; Huang, Q; Huang, X; Li, M; Liu, Y; Luo, H; Su, Z; Wu, J; Wu, X; Xu, N, 2020) |
| "Intestinal mucositis is the most common side effect of 5-fluorouracil (5-Fu) treatment in cancer patients." | 3.96 | Protective effect of Andrographolide on 5-Fu induced intestinal mucositis by regulating p38 MAPK signaling pathway. ( Li, M; Liu, D; Xiang, DC; Xu, YJ; Yang, JY; Zhang, CL; Zhang, S; Zhu, C, 2020) |
| "We used 90 mice of the CF-1 strain in which oral mucositis was induced using a protocol with 5-fluorouracil (5-FU) chemotherapy." | 3.96 | Cannabidiol on 5-FU-induced oral mucositis in mice. ( Borghetti, RL; Cherubini, K; Cuba, LF; de Figueiredo, MAZ; Guimarães, FS; Salum, FG, 2020) |
| "5-Fluorouracil (5-FU)-induced intestinal mucositis (IM) is one of the most common oncological problem." | 3.91 | Mucoprotective effects of Saikosaponin-A in 5-fluorouracil-induced intestinal mucositis in mice model. ( Ali, H; Ali, J; Islam, SU; Khan, AU; Khan, S; Kim, YS; Shah, FA, 2019) |
| "Mice body weight, food consumption, faeces consistency and the presence of blood in faeces were assessed daily during experimental mucositis induced by 5-fluorouracil (5FU)." | 3.91 | Treatment with selenium-enriched Saccharomyces cerevisiae UFMG A-905 partially ameliorates mucositis induced by 5-fluorouracil in mice. ( Almeida-Leite, CM; Alvarez-Leite, JI; Cardoso, VN; Generoso, SV; Leocádio, PCL; Martins, FS; Monteiro, CF; Nicoli, JR; Pessione, E; Porto, BAA; Santos, DA; Santos, JRA; Souza, ÉLS, 2019) |
| " The aim of this study was to test whether oral administration of a synbiotic (Simbioflora®) preparation containing Lactobacillus paracasei, Lactobacillus rhamnosus, Lactobacillus acidophilus and Bifidobacterium lactis plus fructooligosaccharide could help control mucosal inflammation in experimental mucositis induced by 5-fluorouracil (5-FU)." | 3.88 | Oral administration of Simbioflora® (synbiotic) attenuates intestinal damage in a mouse model of 5-fluorouracil-induced mucositis. ( Almeida-Leite, CM; Cardoso, VN; Costa, GMF; Faria, AMC; Generoso, SV; Maioli, TU; Martins, FS; Martins, VD; Rodrigues, NM; Souza, ELS; Trindade, LM, 2018) |
| "The compound 5-fluorouracil (5-FU) is the first choice chemotherapeutic agent for the treatment of colorectal cancer (CRC), but intestinal mucositis is a primary limiting factor in anticancer therapy." | 3.88 | Carboxymethyl pachyman (CMP) reduces intestinal mucositis and regulates the intestinal microflora in 5-fluorouracil-treated CT26 tumour-bearing mice. ( Cao, L; Gao, L; Wang, C; Wang, L; Yang, S, 2018) |
| "Ablation of L-cells led to impaired GLP-2 secretion; increased loss of body weight; lower small intestinal weight; lower crypt depth, villus height and mucosal area; and increased the mucositis severity score in mice given 5-fluorouracil." | 3.88 | Endogenous glucagon-like peptide- 1 and 2 are essential for regeneration after acute intestinal injury in mice. ( Balk-Møller, E; Hartmann, B; Holst, JJ; Hytting-Andreasen, R; Kissow, H; Pedersen, J; Windeløv, JA, 2018) |
| "Mucositis is an inflammatory condition of the gut, caused by an adverse effect of chemotherapy drugs, such as 5-fluorouracil (5-FU)." | 3.88 | Gut microbiome modulation during treatment of mucositis with the dairy bacterium Lactococcus lactis and recombinant strain secreting human antimicrobial PAP. ( Aguiar, E; Azevedo, V; Bermudez, L; Carvalho, R; Chatel, JM; Dorella, F; Fernandes, G; Figueiredo, H; Goes-Neto, A; Langella, P; Pereira, FL; Vaz, A, 2018) |
| "simvastatin has pleiotropic anti-inflammatory and immunomodulatory effects potentially usefull to prevent chemotherapy-induced gastrointestinal mucositis." | 3.88 | Effects of simvastatin on 5-fluorouracil-induced gastrointestinal mucositis in rats. ( Araújo Filho, I; Azevedo, ÍM; Lima, ML; Medeiros, ADC; Moreira, MD, 2018) |
| "The chemotherapeutic agent 5-fluorouracil (5-FU) causes intestinal mucositis with severe diarrhoea, but the pathogenesis is not fully understood." | 3.85 | Apoptosis, Dysbiosis and Expression of Inflammatory Cytokines are Sequential Events in the Development of 5-Fluorouracil-Induced Intestinal Mucositis in Mice. ( Amagase, K; Hamouda, N; Higuchi, K; Kato, S; Matsumoto, K; Oikawa, Y; Ozaki, T; Sano, T; Shimakawa, M, 2017) |
| "The objective of the present study was to evaluate the effect of mulberry leaf extract (ME) fermented with Lactobacillus acidophilus A4 (A4) on intestinal mucositis induced by 5-fluorouracil (5-FU) in a rat model." | 3.85 | Mulberry leaf extract fermented with Lactobacillus acidophilus A4 ameliorates 5-fluorouracil-induced intestinal mucositis in rats. ( Kim, Y; Lee, JM; Lee, JY; Lee, KW; Oh, NS, 2017) |
| " 5-Fluorouracil (5-FU), widely used for cancer chemotherapy, is known to frequently induce intestinal mucositis accompanied by severe diarrhoea." | 3.85 | Probiotic Bifidobacterium bifidum G9-1 attenuates 5-fluorouracil-induced intestinal mucositis in mice via suppression of dysbiosis-related secondary inflammatory responses. ( Amagase, K; Hamouda, N; Kano, Y; Kato, S; Matsumoto, K; Oikawa, Y; Shimakawa, M; Tanaka, Y, 2017) |
| "5-Fluorouracil (5-FU) has broadly been applied to treat colorectal cancer as one of the most effective chemotherapeutic agents." | 3.85 | Oral Administration of Polaprezinc Attenuates Fluorouracil-induced Intestinal Mucositis in a Mouse Model. ( Li, M; Liang, X; Liu, Z; Teng, N; Wang, X; Xie, W; Yang, Z; Zhang, Z, 2017) |
| "This study aimed to elucidate the effect of 5-fluorouracil (5-FU) on the histological aspects of the major salivary glands, salivary flow and saliva composition using an established oral mucositis model in hamsters." | 3.85 | 5-Fluorouracil induces inflammation and oxidative stress in the major salivary glands affecting salivary flow and saliva composition. ( Bomfin, LE; Braga, CM; Brito, GAC; Costa, DVS; Foschetti, DA; Leitão, RFC; Martins, CS; Oliveira, TA; Santos, AAQA, 2017) |
| "Disturbed homeostasis of gut microbiota has been suggested to be closely associated with 5-fluorouracil (5-Fu) induced mucositis." | 3.85 | Alteration of Gut Microbiota and Inflammatory Cytokine/Chemokine Profiles in 5-Fluorouracil Induced Intestinal Mucositis. ( Huang, F; Li, HL; Lu, L; Qin, LY; Qiu, SP; Shi, HL; Wang, P; Wang, XS; Wu, H; Wu, XJ; Zhang, BB, 2017) |
| "This study investigated the prophylactic effects of orally administered surface-deacetylated chitin nanofibers (SDACNFs) and chitosan against 5-fluorouracil (5-FU)-induced intestinal mucositis, which is a common side effect of 5-FU chemotherapy." | 3.85 | Oral Administration of Surface-Deacetylated Chitin Nanofibers and Chitosan Inhibit 5-Fluorouracil-Induced Intestinal Mucositis in Mice. ( Azuma, K; Ifuku, S; Imagawa, T; Ito, N; Izawa, H; Koizumi, R; Morimoto, M; Ochi, K; Okamoto, Y; Osaki, T; Saimoto, H; Tsuka, T, 2017) |
| "Here we assessed the impact of L-citrulline (CIT) on a murine model of 5-fluorouracil (5FU)-induced mucositis." | 3.83 | Pretreatment With L-Citrulline Positively Affects the Mucosal Architecture and Permeability of the Small Intestine in a Murine Mucositis Model. ( Alvarez-Leite, JI; Antunes, MM; Cara, DC; Cardoso, VN; Correia, MI; Generoso, Sde V; Leocádio, PC; Leonel, AJ; Menezes, GB; Teixeira, LG, 2016) |
| "5-Fluorouracil is one of the most commonly used anticancer drugs for the treatment of various types of cancer but has potential adverse effects such as intestinal mucositis, renal, hepatic, and reproductive organ toxicity." | 3.83 | Taurine ameliorates 5-flourouracil-induced intestinal mucositis, hepatorenal and reproductive organ damage in Wistar rats: A biochemical and histological study. ( Al-Asmari, AK; Al-Shahrani, HM; Al-Zahrani, AM; Ali Al Amri, M; Khan, AQ, 2016) |
| "Wei-Chang-An pill (WCA pill), a traditional Chinese pharmaceutical preparation, possessed potential anti-inflammatory advantages and noteworthy gastrointestinal regulations in digestive diseases, which might represent a promising candidate for the treatment of intestinal mucositis (IM) induced by 5-fluorouracil (5-FU)." | 3.83 | Protective effect and potential mechanisms of Wei-Chang-An pill on high-dose 5-fluorouracil-induced intestinal mucositis in mice. ( Chen, Y; Gao, W; Jin, Z; Wang, L; Zhang, J; Zheng, H, 2016) |
| "This study assessed the protective potential of rifaximin in 5-fluorouracil (5-FU) induced intestinal mucositis in the Wistar rats'." | 3.83 | Rifaximin modulates 5-fluorouracil-induced gastrointestinal mucositis in rats. ( Bedecean, I; Berce, C; Catoi, C; Ciobanu, L; Mîrleneanu, R; Parau, A; Tantau, M; Taulescu, M; Valean, S, 2016) |
| " Chemotherapy-induced mouse model of intestinal mucositis was prepared by a single injection of the chemotherapeutic agent 5-fluorouracil (5-FU)." | 3.81 | The chemokine CXCL9 exacerbates chemotherapy-induced acute intestinal damage through inhibition of mucosal restitution. ( Han, L; Han, W; Liu, H; Lu, H; Moldenhauer, A; Qian, L; Shen, J; Sun, T; Wang, J; Weng, S; Wu, M; Yu, Y; Zhu, J; Zhu, S, 2015) |
| "5-Fluorouracil (5-FU)-induced intestinal mucositis is one of the most common morbidities in chemotherapy and involves the reactive oxygen species (ROS) system, apoptosis, and inflammatory cytokines." | 3.81 | Rebamipide attenuates 5-Fluorouracil-induced small intestinal mucositis in a mouse model. ( Han, SH; Kim, HJ; Kim, JH; Lee, JH; Moon, W; Park, J; Park, SJ; Song, GA, 2015) |
| " The objective of this study was to determine whether a diet with the addition of n-3 FA helps control the inflammation observed in 5-fluorouracil (5-FU) induced mucositis." | 3.81 | Dietary supplementation with omega-3 fatty acid attenuates 5-fluorouracil induced mucositis in mice. ( Cardoso, VN; Carneiro, CM; Faria, AM; Ferreira, AV; Generoso, Sde V; Maioli, TU; Paiva, NC; Rodrigues, NM; Trindade, LM, 2015) |
| " This gene codifies for the target enzyme of 5-fluorouracil (5-FU), the basic treatment in colorectal cancer." | 3.81 | Long Survival and Severe Toxicity Under 5-Fluorouracil-Based Therapy in a Patient With Colorectal Cancer Who Harbors a Germline Codon-Stop Mutation in TYMS. ( Balboa-Beltrán, E; Barros, F; Carracedo, A; Duran, G; Lamas, MJ, 2015) |
| "The aim of the present study was to compare the effectiveness of four different laser wavelengths (660, 810, 980, and 1,064 nm) used for low-level laser therapy (LLLT) on the healing of mucositis in an animal model of wound healing by investigating the expression of platelet-derived growth factor (PDGF), transforming growth factor beta (TGF-β), and blood-derived fibroblast growth factor (bFGF)." | 3.80 | Effects of laser irradiation at different wavelengths (660, 810, 980, and 1,064 nm) on mucositis in an animal model of wound healing. ( Aras, MH; Cengiz, B; Demir, T; Gutknecht, N; Oztuzcu, S; Usumez, A, 2014) |
| "Female Dark Agouti rats were gavaged with grape seed extract (400-1000 mg/kg) or water (day 3-11) and were injected intraperitoneally with 5-Fluorouracil (150 mg/kg) or saline (control) on day 9 to induce mucositis." | 3.80 | Grape seed extract dose-responsively decreases disease severity in a rat model of mucositis; concomitantly enhancing chemotherapeutic effectiveness in colon cancer cells. ( Bastian, SE; Cheah, KY; Howarth, GS, 2014) |
| " We tested whether SGLT-1 engagement might protect the intestinal mucosa from doxorubicin (DXR)- and 5-fluorouracil (5-FU)-induced injury in animal models mimicking acute or chronic mucositis." | 3.80 | Sodium glucose cotransporter 1 ligand BLF501 as a novel tool for management of gastrointestinal mucositis. ( Balsari, A; Cardani, D; D'Orazio, G; Koepsell, H; La Ferla, B; Marcucci, F; Nicotra, F; Olivero, D; Rumio, C; Sardi, C; Sommariva, M; Tagliabue, E, 2014) |
| "Chemotherapy-induced intestinal mucositis (CIM) is a major dose-limiting side effect, resulting from the nonspecific cytoablative actions of chemoagents, including 5-fluorouracil (5-FU) and irinotecan (CPT-11)." | 3.80 | IL-1Ra selectively protects intestinal crypt epithelial cells, but not tumor cells, from chemotoxicity via p53-mediated upregulation of p21(WAF1) and p27(KIP1.). ( Chan, GL; Gao, J; Han, W; Qian, L; Wang, X; Wu, M; Yu, Y; Zhang, Y; Zhu, S, 2014) |
| " boulardii was not able to prevent the effects of experimental mucositis induced by 5- Fluorouracil." | 3.80 | Pretreatment with Saccharomyces boulardii does not prevent the experimental mucositis in Swiss mice. ( Cardoso, VN; Carneiro, CM; de Melo Silva, B; de Vasconcelos Generoso, S; Dias, MN; Dos Santos Martins, F; Fernandes, SO; Maioli, TU; Paiva, NC, 2014) |
| "Chemotherapy-induced mucositis (CIM) is a major does limiting side-effect of chemoagents such as 5-fluorouracil (5-FU)." | 3.80 | Activation of p38-MAPK by CXCL4/CXCR3 axis contributes to p53-dependent intestinal apoptosis initiated by 5-fluorouracil. ( Gao, J; Han, W; Qian, L; Wang, X; Wu, M; Ye, H; Yu, Y; Zhang, Y; Zhu, S, 2014) |
| "Our results bring support to the hUP1 inhibitor strategy as a novel possibility of prevention and treatment of mucositis during the 5-FU chemotherapy, based on the approach of uridine accumulation in plasma and tissues." | 3.80 | Human uridine phosphorylase-1 inhibitors: a new approach to ameliorate 5-fluorouracil-induced intestinal mucositis. ( Basso, LA; Campos, MM; Lopes, TG; Machado, P; Petersen, GO; Renck, D; Santos, AA; Santos, DS, 2014) |
| "Although 5-fluorouracil (5-FU) is a widely used as chemotherapy agent, severe mucositis develops in approximately 80% of patients." | 3.79 | Increased expression of 5-HT3 and NK 1 receptors in 5-fluorouracil-induced mucositis in mouse jejunum. ( Arakawa, K; Horie, S; Kato, S; Matsumoto, K; Nakajima, T; Narita, M; Sagara, A; Sakai, H; Tashima, K, 2013) |
| "Chemotherapeutic agents, including 5-fluorouracil (5-FU), frequently cause intestinal mucositis resulting in severe diarrhoea and morphological mucosal damage." | 3.79 | 5-HT₃ receptor antagonists ameliorate 5-fluorouracil-induced intestinal mucositis by suppression of apoptosis in murine intestinal crypt cells. ( Amagase, K; Horie, S; Iimori, M; Kato, S; Kitahara, Y; Matsumoto, K; Takeuchi, K; Utsumi, D; Yamanaka, N; Yasuda, M, 2013) |
| "Mice were injected with 5-fluorouracil (5-FU) or saline to induce mucositis and were then treated with GLP-1, GLP-2, GLP-2 (3-33), exendin (9-39) or vehicle." | 3.79 | Glucagon-like peptide-1 as a treatment for chemotherapy-induced mucositis. ( Hartmann, B; Holst, JJ; Kissow, H; Poulsen, SS, 2013) |
| "5-Fluorouracil (5-FU) induces intestinal mucositis, which is characterized by epithelial ulcerations in the mucosa and clinical manifestations, such as pain and dyspeptic symptoms." | 3.79 | Inflammatory intestinal damage induced by 5-fluorouracil requires IL-4. ( Cunha, FQ; Franco, AX; Justino, PF; Mota, JM; Ribeiro, RA; Soares, PM; Souza, EP; Souza, MH, 2013) |
| " In the present study, we investigated the role of NOX1 in the pathogenesis of intestinal mucositis induced by the cancer chemotherapeutic agent 5-fluorouracil (5-FU) in mice." | 3.78 | Potential role of the NADPH oxidase NOX1 in the pathogenesis of 5-fluorouracil-induced intestinal mucositis in mice. ( Amagase, K; Iimori, M; Iwata, K; Kato, S; Kitahara, Y; Matsuno, K; Takeuchi, K; Utsumi, D; Yabe-Nishimura, C; Yamanaka, N; Yasuda, M, 2012) |
| "The patients with local advanced and metastatic colorectal cancer, receiving fluorouracil-based chemotherapy, and with an average plasma concentration of fluorouracil between 25 - 35 mg/L have a better prognosis, and lower incidence of adverse reactions such as bone marrow suppression, mucositis and diarrhea." | 3.78 | [Role of pharmacokinetic monitoring of serum fluorouracil concentration in patients with local advanced and metastatic colorectal cancer and further improving efficacy of fluorouracil-based chemotherapy]. ( Cai, X; Gu, HL; Hu, J; Song, WF; Wang, LW; Xue, P; Yang, HY, 2012) |
| " They had osteosarcoma in methotrexate group (n=7), gastrointestinal malignancies in 5FU group (n=9) and breast cancer in the capecitabine group (n=2)." | 3.78 | Relationship between antimetabolite toxicity and pharmacogenetics in Turkish cancer patients. ( Akbulut, H; Demirkazik, A; Dincol, D; Dogan, M; Icli, F; Karabulut, HG; Tukun, A; Utkan, G; Yalcin, B, 2012) |
| "This study demonstrates that CR3294 acts on key molecular targets to reduce the signs of mucositis and the occurrence of diarrhea in mice exposed to the chemotherapy drug 5-fluorouracil." | 3.76 | Efficacy of CR3294, a new benzamidine derivative, in the prevention of 5-fluorouracil-induced gastrointestinal mucositis and diarrhea in mice. ( Bonazzi, A; Booth, C; Caselli, G; Garofalo, P; Letari, O; Makovec, F; Rovati, LC, 2010) |
| "One hundred fifty-six patients with locally advanced or metastatic esophageal adenocarcinoma received neoadjuvant chemotherapy with cisplatin, 5-fluorouracil, and leucovorin followed by resection." | 3.76 | Interleukin-10 and -12 predict chemotherapy-associated toxicity in esophageal adenocarcinoma. ( Friess, H; Holzmann, B; Knoefel, WT; Peiper, M; Schauer, MC; Theisen, J, 2010) |
| " Body weight loss results, diarrhea scores, and villi measurements showed that minocycline attenuated the severity of intestinal mucositis induced by 5-fluorouracil (5-FU)." | 3.75 | Minocycline attenuates 5-fluorouracil-induced small intestinal mucositis in mouse model. ( Chao, YC; Chu, HC; Ho, WH; Hou, HS; Huang, TY; Liao, CL; Lin, YL, 2009) |
| "To evaluate gastrointestinal motility during 5-fluorouracil (5-FU)-induced intestinal mucositis." | 3.74 | Gastrointestinal dysmotility in 5-fluorouracil-induced intestinal mucositis outlasts inflammatory process resolution. ( Assreuy, AM; Brito, GA; Gomes, AS; Mota, JM; Oliveira, RB; Ribeiro, RA; Santos, AA; Soares, PM; Souza, MH, 2008) |
| "Lafutidine could offer the possibility of more effective prevention of CT-induced mucositis through the activation of GI mucus cells." | 3.74 | Effects of acid antisecretory drugs on mucus barrier of the rat against 5-fluorouracil-induced gastrointestinal mucositis. ( Goso, Y; Ichikawa, T; Ikezawa, T; Ishihara, K; Iwai, T; Nakano, M; Saegusa, Y; Saigenji, K; Shikama, N, 2008) |
| "Mucositis is a common and most debilitating complication associated with the cytotoxicity of chemotherapy." | 2.82 | Experimental Chemotherapy-Induced Mucositis: A Scoping Review Guiding the Design of Suitable Preclinical Models. ( Cirillo, N; Huang, J; Hwang, AYM; Iskandar, M; Jia, Y; Kim, B; Mohammed, AI, 2022) |
| "Mucositis was the most common dose-limiting toxicity." | 2.80 | A phase 1 clinical trial of sequential pralatrexate followed by a 48-hour infusion of 5-fluorouracil given every other week in adult patients with solid tumors. ( Evande, RE; Grem, JL; Kos, ME; Meza, JL; Schwarz, JK, 2015) |
| "We performed a prospective phase II trial to investigate the safety and efficacy of radiotherapy combined with capecitabine in patients suffering from a recurrence of a squamous cell carcinoma of the head and neck (SCCHN) within a previously irradiated field." | 2.77 | Re-irradiation combined with capecitabine in locally recurrent squamous cell carcinoma of the head and neck. A prospective phase II trial. ( Kornek, G; Lemaire, C; Radonjic, D; Selzer, E; Vormittag, L, 2012) |
| "In locally advanced head and neck cancer, concurrent chemoradiotherapy (CRT) with combined 5-fluorouracil (5-FU) and cisplatin has increased acute toxicities as well as survival." | 2.75 | Weekly 5-fluorouracil plus cisplatin for concurrent chemoradiotherapy in patients with locally advanced head and neck cancer. ( Cho, BC; Choi, EC; Choi, HJ; Kim, GE; Kim, JH; Lee, CG; Lee, YJ; Sohn, JH, 2010) |
| "Patients with resectable advanced squamous cell carcinoma of the larynx (tumor stage T3-T4) or hypopharynx (T2-T4), with regional lymph nodes in the neck staged as N0-N2 and with no metastasis, were randomly assigned to treatment in the sequential (or control) or the alternating (or experimental) arm." | 2.74 | Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. ( Bardet, E; Barzan, L; Bernier, J; Bogaerts, J; Chevalier, D; de Raucourt, D; Geoffrois, L; Horiot, JC; Hupperets, P; Lacombe, D; Leemans, CR; Lefebvre, JL; Licitra, L; Lunghi, F; Rolland, F; Stupp, R; Tesselaar, M; Vermorken, JB, 2009) |
| "This concurrent chemoradiotherapy with PFML was safe and well tolerated." | 2.73 | Analysis of efficacy and toxicity of chemotherapy with cisplatin, 5-fluorouracil, methotrexate and leucovorin (PFML) and radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck. ( Katori, H; Taguchi, T; Tsukuda, M, 2007) |
| "Celecoxib was administered as 400 mg, twice daily starting on day 2 of cycle 1." | 2.73 | Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil. ( Cao, S; Creaven, PJ; Durrani, FA; Iyer, RV; Javle, MM; Lawrence, DD; Noel, DC; Pendyala, L; Rustum, YM; Smith, PF, 2007) |
| "Grade III mucositis was more frequently observed in test group than in control group (75." | 2.73 | [Concurrent chemoradiotherapy followed by adjuvant chemotherapy for stage III-IVa nasopharyngeal carcinoma]. ( Fu, ZF; Hu, QY; Liu, P; Wang, L, 2007) |
| "Complete surgical resection of gastric cancer is potentially curative, but long-term survival is poor." | 2.73 | Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. ( Antimi, M; Antonuzzo, L; Arcangeli, A; Banducci, S; Bellini, V; Biagioni, F; Bianchini, D; Bilancia, D; Bisagni, G; Biscottini, B; Boni, C; Bracci, R; Bravi, S; Bruno, L; Cabassi, A; Camera, S; Camisa, R; Canaletti, R; Carboni, M; Carlini, P; Carroccio, R; Cascinu, S; Catalano, G; Catalano, V; Cavalli, C; Cesari, M; Cognetti, F; Contu, A; Corgna, E; Cortesi, E; Croce, E; Dalla Mola, A; De Filippis, S; De Stefanis, M; Di Costanzo, F; Dinota, A; Enzo, MR; Farris, A; Figoli, F; Floriani, I; Foa, P; Fornarini, G; Francavilla, F; Frignano, M; Gasperoni, S; Gilli, G; Giunta, A; Grigniani, F; Ionta, MT; Italia, M; Labianca, R; Lastraioli, E; Leoni, M; Lungarotti, F; Luppi, G; Manzione, L; Masoni, L; Massidda, B; Mela, M; Messerini, L; Monzio Compagnoni, B; Muscogiuri, A; Natalini, G; Nelli, F; Nicolosi, A; Oldani, S; Olgiati, A; Olivetti, A; Orselli, G; Pandolfi, U; Papiani, G; Pazzola, A; Piga, A; Pisani Leretti, A; Porrozzi, S; Recchia, F; Romiti, A; Rondini, E; Rossetti, R; Rovei, R; Saggese, M; Sarobba, MG; Scipioni, L; Strafiuso, G; Tomao, S; Tonato, M; Torri, V; Trignano, M; Zironi, S, 2008) |
| "Acute mucositis is a dose-limiting toxicity of concurrent chemoradiotherapy regimens for locally advanced head and neck cancer." | 2.73 | Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. ( Berger, D; Brizel, DM; Brizel, HE; Chen, MG; Glück, S; Mendenhall, W; Meredith, RF; Murphy, BA; Pandya, KJ; Rosenthal, DI, 2008) |
| " The most frequent common adverse events were nausea, Grades 1 - 2 in 13 patients (81." | 2.72 | Chronomodulated chemotherapy with oxaliplatin, 5-FU and sodium folinate in metastatic gastrointestinal cancer patients: original analysis of non-hematological toxicity and patient characteristics in a pilot investigation. ( Farker, K; Hippius, M; Höffken, K; Hoffmann, A; Merkel, U; Wedding, U, 2006) |
| " Gastrointestinal mucositis is a common and debilitating side-effect of anticancer therapy contributing to dose reductions, delays and cessation of treatment, greatly impacting clinical outcomes." | 2.66 | Impact of chemotherapy-induced enteric nervous system toxicity on gastrointestinal mucositis. ( Al Thaalibi, M; McQuade, RM; Nurgali, K, 2020) |
| "Chemotherapy-induced diarrhea (CID) is a common and often severe side effect experienced by colorectal cancer (CRC) patients during their treatment." | 2.50 | Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation. ( Doherty, GA; Lee, CS; Ryan, EJ, 2014) |
| "Chemotherapy-induced oral mucositis (COM) is a common adverse effect of cancer chemotherapy." | 1.91 | Preparation and pharmaceutical properties of Hangeshashinto oral ointment and its safety and efficacy in Syrian hamsters with 5-fluorouracil-induced oral mucositis. ( Hira, D; Imai, S; Ito, M; Itohara, K; Kagawa, M; Matsubara, K; Nakagawa, S; Nakagawa, T; Ogihara, T; Terada, T; Yamanaka, R; Yonezawa, A, 2023) |
| "The current idea of how oral mucositis (OM) develops is primarily based on hypotheses and the early events which precede clinically established OM remain to be demonstrated." | 1.91 | Moderate temperature reduction is sufficient for prevention of 5-fluorouracil-induced oral mucositis: an experimental in vivo study in rats. ( Aydogdu, Ö; Dankis, M; Jontell, M; Walladbegi, J; Winder, M, 2023) |
| "Mucositis is defined as inflammatory and ulcerative lesions along of the gastrointestinal tract that leads to the imbalance of the intestinal microbiota." | 1.91 | Association of Fructo-oligosaccharides and Arginine Improves Severity of Mucositis and Modulate the Intestinal Microbiota. ( Andrade, MER; Cardoso, VN; Cassali, GD; Cavalcante, GG; da Silva, TF; de Carvalho Azevedo, VA; de Oliveira Carvalho, RD; de Oliveira, JS; Dos Reis, DC; Fernandes, SOA; Generoso, SV; Leite, JIA; Leocádio, PCL; Trindade, LM, 2023) |
| "Oral and intestinal mucositis are debilitating inflammatory diseases observed in cancer patients undergoing chemo-radiotherapy." | 1.91 | Characterization of a novel dual murine model of chemotherapy-induced oral and intestinal mucositis. ( Celentano, A; Cirillo, N; Low, JT; McCullough, MJ; Mohammed, AI; O' Reilly, LA; Paolini, R, 2023) |
| "Mucositis was induced through a single injection with 2 mg/kg idarubicin (with saline as control), followed by daily treatments of anakinra (100 mg/kg/day), dexamethasone (10 mg/kg/day) or both for 3 days." | 1.91 | Anakinra and dexamethasone treatment of idarubicin-induced mucositis and diarrhoea in rats. ( Dahlgren, D; Heindryckx, F; Kullenberg, F; Lennernäs, H; Peters, K; Sjöblom, M, 2023) |
| "To evaluate the association of age with treatment-related adverse events and survival in patients with mCRC and explore the potential underlying factors." | 1.91 | Association of Age With Treatment-Related Adverse Events and Survival in Patients With Metastatic Colorectal Cancer. ( Delgado, MG; Gomez, MF; Hubbard, JM; Ji, R; Kim, RD; Knepper, TC; Laber, DA; Meng, L; Permuth, JB; Thapa, R; Wang, X; Xie, H, 2023) |
| "Intestinal mucositis is a commonly reported side effect in oncology patients undergoing chemotherapy and radiotherapy." | 1.91 | Synergistic synbiotic containing fructooligosaccharides and Lactobacillus delbrueckii CIDCA 133 alleviates chemotherapy-induced intestinal mucositis in mice. ( Américo, MF; Azevedo, V; Barroso, FAL; Batista, VL; Belo, GA; Birbrair, A; Campos, GM; Cardoso, VN; Coelho-Rocha, ND; da Silva, TF; de Jesus, LCL; Dos Santos Freitas, A; Drumond, MM; Fernandes, SOA; Ferreira, E; Laguna, JG; Mancha-Agresti, P; Martins, FS; Tavares, LM; Vital, KD, 2023) |
| "5-Fluorouracil (5-FU) is a front-line cytotoxic therapy." | 1.72 | Thymol ameliorates 5-fluorouracil-induced intestinal mucositis: Evidence of down-regulatory effect on TGF-β/MAPK pathways through NF-κB. ( Al-Amin, MA; Al-Khrashi, LA; Badr, AM; Mahran, YF, 2022) |
| " We therefore suggest that future studies should focus on elucidating the complex interplay between chemotherapy in combination with luminal irritants on the intestinal permeability of other probes." | 1.72 | Chemotherapeutics Combined with Luminal Irritants: Effects on Small-Intestinal Mannitol Permeability and Villus Length in Rats. ( Cano-Cebrián, MJ; Dahlgren, D; Kullenberg, F; Lennernäs, H; Olander, T; Peters, K; Sjöblom, M, 2022) |
| "Intestinal mucositis is a common side effect of chemotherapy and radiotherapy." | 1.62 | TBHQ attenuates ferroptosis against 5-fluorouracil-induced intestinal epithelial cell injury and intestinal mucositis via activation of Nrf2. ( Deng, S; Li, J; Li, L; Wu, D; Xu, Y, 2021) |
| "Mucositis was induced by intraperitoneal injection (300 mg/kg) of 5-fluorouracil (5-FU)." | 1.62 | Prophylactic and therapeutic supplementation using fructo-oligosaccharide improves the intestinal homeostasis after mucositis induced by 5- fluorouracil. ( Alvarez-Leite, JI; Andrade, MER; Cardoso, VN; Carvalho, PLA; Cassali, GD; Dos Reis, DC; Dos Santos Martins, F; Fernandes, SOA; Generoso, SV; Gouveia Peluzio, MDC; Leocádio, PCL; Souza E Melo, ÉLS; Trindade, LM, 2021) |
| "5-Fluorouracil (5-FU) is a chemotherapy agent that is widely used in clinical oncologic practice." | 1.62 | Anti-inflammatory effects of Radix Aucklandiae herbal preparation ameliorate intestinal mucositis induced by 5-fluorouracil in mice. ( Chang, CW; Chen, YJ; Hsieh, CH; Liu, CY; Liu, JH; Tsai, TH, 2021) |
| "Patchouli alcohol (PA) is an active compound extracted from Pogostemon cablin, and has potent gastrointestinal protective effect." | 1.56 | Patchouli alcohol attenuates 5-fluorouracil-induced intestinal mucositis via TLR2/MyD88/NF-kB pathway and regulation of microbiota. ( Chen, L; Gan, Y; Li, M; Liang, J; Lin, Z; Liu, Y; Luo, H; Su, Z; Wu, J; Wu, Q; Wu, X; Xu, N; Zhuo, J, 2020) |
| "Dihydrotanshinone I (DHTS) is a liposoluble extract of Salvia miltiorrhiza Bunge with many bioactivities." | 1.56 | Dihydrotanshinone attenuates chemotherapy-induced intestinal mucositis and alters fecal microbiota in mice. ( Du, GH; Wang, L; Wang, R; Wang, SM; Wei, GY, 2020) |
| "Oral mucositis is a common inflammatory complication among patients with cancer." | 1.56 | Effect of Topical 2% Eucalyptus Extract on 5-FU-Induced Oral Mucositis in Male Golden Hamsters. ( Andisheh-Tadbir, A; Badie, A; Habibagahi, R; Haghnegahdar, S; Koohi-Hosseinabadi, O; Tanideh, N, 2020) |
| "Zinc sulfate has a beneficial role, decreasing the severity of gut mucosal injuries induced by 5-FU in Wistar rats." | 1.56 | Beneficial effect of oral administration of zinc sulfate on 5-fluorouracil-induced gastrointestinal mucositis in rats. ( Berce, C; Ciobanu, L; Meșter, A; Onica, S; Tanțău, M; Taulescu, M; Tefas, C; Toma, C, 2020) |
| "Mucositis was induced by intraperitoneal injection of 5-FU (400 mg/kg)." | 1.51 | Dipeptidyl-peptidase-4 (DPP-4) inhibitor ameliorates 5-flurouracil induced intestinal mucositis. ( Choi, HS; Chun, HJ; Jeen, YT; Keum, B; Kim, CD; Kim, ES; Kim, SH; Lee, HS; Lee, JM; Seo, YS; Um, SH; Yoo, IK, 2019) |
| "Altogether, 11 components were identified or tentatively characterized in dosed plasma." | 1.51 | The protective effects of Aquilariae Lignum Resinatum extract on 5-Fuorouracil-induced intestinal mucositis in mice. ( Gao, J; Gao, W; Jin, Z; Man, S; Zhang, J; Zheng, H, 2019) |
| "Mucositis was induced in mice by administration of 5-FU (50 mg/kg, i." | 1.51 | Diadzein ameliorates 5-fluorouracil-induced intestinal mucositis by suppressing oxidative stress and inflammatory mediators in rodents. ( Al-Sharari, SD; Ali, J; Atiq, A; Khan, A; Khan, S; Kim, YS; Naveed, M; Shal, B; Zeeshan, S, 2019) |
| "Specific-pathogen-free (SPF) and germ-free Swiss Webster mice in the experimental groups were dosed with 5-fluorouracil (5-FU) to induce OM." | 1.51 | Role of oral flora in chemotherapy-induced oral mucositis in vivo. ( Ferreira, J; Gupta, N; Hong, CHL; Quah, SY; Tan, KS; Yeo, JF, 2019) |
| " At least one grade 1 adverse event (AE) was observed in 69." | 1.48 | A correlation study of fluorouracil pharmacodynamics with clinical efficacy and toxicity. ( Esin, E; Telli, TA; Yalcin, S; Yuce, D, 2018) |
| "Oral mucositis is a common adverse effect of chemotherapy that limits the required dose of chemotherapeutic agents." | 1.48 | Rebamipide suppresses 5-fluorouracil-induced cell death via the activation of Akt/mTOR pathway and regulates the expression of Bcl-2 family proteins. ( Asano, RT; Fujimoto, SI; Imano, M; Itoh, T; Matsuda, T; Nishida, S; Satou, T; Takeda, T; Tsubaki, M, 2018) |
| "Oral mucositis is still one of the most painful side effects of chemotherapeutic treatment and a mounting body of evidence suggests a key role for the oral microbiome in mucositis development." | 1.48 | Oral microbiota reduce wound healing capacity of epithelial monolayers, irrespective of the presence of 5-fluorouracil. ( Beterams, A; Bourgeois, J; De Moerloose, B; De Vos, WH; Sieprath, T; Van de Wiele, T; Vanhoecke, B; Vanlancker, E, 2018) |
| "Mucositis was induced by intraperitoneal injection of 300 mg/kg 5-FU." | 1.48 | Conjugated linoleic acid prevents damage caused by intestinal mucositis induced by 5-fluorouracil in an experimental model. ( Alvarez Leite, JI; Antunes Fernandes, SO; Cardoso, VN; Cassali, GD; da Gama, MAS; de Barros, PAV; de Sales E Souza, ÉL; de Vasconcelos Generoso, S; Dos Reis, DC; Dos Santos Martins, F; Lacerda Leocádio, PC; Mendes Miranda, SE; Rabelo Andrade, ME, 2018) |
| "Mucositis was induced by daily injections of 5-fluororacil (5-FU) after which mice were either given L." | 1.48 | Protective effect of the riboflavin-overproducing strain Lactobacillus plantarum CRL2130 on intestinal mucositis in mice. ( de Moreno de LeBlanc, A; LeBlanc, JG; Levit, R; Savoy de Giori, G, 2018) |
| " Although some progress has been made in understanding the intestinal toxicity of 5-FU, confusion remains about animal models of 5-FU-induced intestinal injury, especially the dosage of 5-FU." | 1.48 | Assessment of dose-response relationship of 5-fluorouracil to murine intestinal injury. ( Liu, D; Liu, Y; Ren, X; Xiang, D; Yang, J; Zhang, C; Zhang, S, 2018) |
| "Mucositis is the most common side effect due to chemotherapy or radiotherapy." | 1.46 | Effect of Conjugated Linoleic Acid-enriched Butter After 24 hours of Intestinal Mucositis Induction. ( Andrade, ME; Barros, PA; Cardoso, VN; da Gama, MA; de Sales E Souza, ÉL; Fernandes, SO; Generoso, SV; Lopes, FC; Martins, FD; Miranda, SE, 2017) |
| "5-FU-induced mucositis affects 80% of patients undergoing oncological treatment causing mucosal gut dysfunctions and great discomfort." | 1.46 | Secretion of biologically active pancreatitis-associated protein I (PAP) by genetically modified dairy Lactococcus lactis NZ9000 in the prevention of intestinal mucositis. ( Azevedo, V; Bermúdez-Humarán, LG; Breyner, N; Carmona, D; Carvalho, RD; Chatel, JM; da Gloria Souza, D; de Azevedo, MS; de Faria, AM; Figueiredo, HC; Langella, P; Lemos, L; Maioli, TU; Menezes-Garcia, Z; Rodrigues, NM, 2017) |
| "Intestinal mucositis is a frequent side-effect of chemotherapy treatment." | 1.43 | Effects of acute chemotherapy-induced mucositis on spontaneous behaviour and the grimace scale in laboratory rats. ( Howarth, GS; Leach, MC; Lymn, KA; Preston, FL; Whittaker, AL, 2016) |
| " On the 7th day, the mice were euthanized, and intestinal samples were collected for histopathology and morphometric analysis, as well as for the determination of myeloperoxidase activity and cytokine dosage (TNF-α and IL-6)." | 1.43 | A new animal model of intestinal mucositis induced by the combination of irinotecan and 5-fluorouracil in mice. ( Almeida, PR; Assis-Júnior, EM; Brito, GA; Lima-Júnior, RC; Melo, AT; Pereira, VB; Ribeiro, RA; Wong, DV, 2016) |
| " Emu Oil combined with Lyprinol™ partially reduced acute small intestinal inflammation." | 1.43 | Emu Oil Combined with Lyprinol™ Reduces Small Intestinal Damage in a Rat Model of Chemotherapy-Induced Mucositis. ( Bajic, JE; Cheah, KY; Eden, GL; Howarth, GS; Lampton, LS; Lymn, KA; Mashtoub, S, 2016) |
| "Mucositis is a common side effect of cancer therapies that causes painful, erythematous lesions to develop in the gastrointestinal tract." | 1.43 | Potential Benefits of Oral Cryotherapy for Chemotherapy-Induced Mucositis. ( Wodzinski, A, 2016) |
| "Mucositis is a common and serious side-effect experienced by cancer patients during treatment with chemotherapeutic agents." | 1.42 | The assessment of general well-being using spontaneous burrowing behaviour in a short-term model of chemotherapy-induced mucositis in the rat. ( Howarth, GS; Lymn, KA; Nicholson, A; Whittaker, AL, 2015) |
| "Intestinal mucositis is a common toxic side effect in cancer patients receiving high-dose chemotherapy." | 1.42 | Bifidobacterium infantis has a beneficial effect on 5-fluorouracil-induced intestinal mucositis in rats. ( Chong, P; Feng, WD; Shi, HP; Xue, CL; Yang, T; Yu, HL; Yu, M; Yuan, KT, 2015) |
| "Mucositis is a side effect of chemotherapy treatment that affects approximately 40% of patients." | 1.42 | L-arginine pretreatment reduces intestinal mucositis as induced by 5-FU in mice. ( Alvarez-Leite, JI; Antunes, MM; Cardoso, VN; Correia, MI; Generoso, SV; Leocádio, PC; Leonel, AJ; Machado, DC; Teixeira, LG, 2015) |
| "Mouse body weight was monitored daily." | 1.42 | Alanyl-glutamine attenuates 5-fluorouracil-induced intestinal mucositis in apolipoprotein E-deficient mice. ( Alves, LA; Aquino, CC; Araújo, CV; Bertolini, LR; Brito, GA; Costa, TB; Figueiredo, IL; Lazzarotto, CR; Lima, AA; Oriá, RB; Ribeiro, RA, 2015) |
| "Intestinal mucositis is a frequently encountered side effect in oncology patients undergoing chemotherapy." | 1.42 | Amelioration of Chemotherapy-Induced Intestinal Mucositis by Orally Administered Probiotics in a Mouse Model. ( Chan, WT; Chang, SW; Cheng, ML; Chiang Chiau, JS; Jiang, CB; Lee, HC; Liu, CY; Yeung, CY, 2015) |
| " Severe toxic reactions to 5-FU have been associated with decreased levels of dihydropyrimidine dehydrogenase (DPD) enzyme activity." | 1.40 | A DPYD variant (Y186C) specific to individuals of African descent in a patient with life-threatening 5-FU toxic effects: potential for an individualized medicine approach. ( Diasio, RB; Lee, AM; McConnell, K; Offer, SM; Relias, V; Saif, MW, 2014) |
| " Grade 3/4 adverse events were: neutropenia (54." | 1.39 | Safety and efficacy of modified FOLFOX6 plus high-dose bevacizumab in second-line or later treatment of patients with metastatic colorectal cancer. ( Maruyama, S; Takii, Y, 2013) |
| "5-Fluorouracil (5-FU) is a commonly used drug for the treatment of malignant cancers." | 1.38 | 5-Fluorouracil induced intestinal mucositis via nuclear factor-κB activation by transcriptomic analysis and in vivo bioluminescence imaging. ( Chang, CT; Ho, TY; Hsiang, CY; Huang, HC; Huang, YF; Li, CC; Liang, JA; Lin, H; Lo, HY; Wu, SL, 2012) |
| "Intestinal mucositis is one of the major troublesome side effects of anticancer chemotherapy leading to poor patient compliance." | 1.38 | Apolipoprotein E COG 133 mimetic peptide improves 5-fluorouracil-induced intestinal mucositis. ( Araújo, CV; Azevedo, OG; Costa, TB; Guerrant, RL; Lima, AÂ; Lima, RC; Lucena, HB; Oliveira, BC; Oliveira, RA; Oriá, RB; Ribeiro, RA; Vitek, MP; Warren, CA; Wong, DV; Zaja-Milatovic, S, 2012) |
| "Gastrointestinal mucositis is an unwanted and often dose-limiting side effect to most cancer treatments." | 1.38 | Exogenous glucagon-like peptide-2 (GLP-2) prevents chemotherapy-induced mucositis in rat small intestine. ( Hartmann, B; Holst, JJ; Kissow, H; Poulsen, SS; Thim, L; Timm, M; Viby, NE, 2012) |
| "Gastrointestinal mucositis is a common side effect of cancer chemotherapy." | 1.37 | Role of platelet-activating factor in the pathogenesis of 5-fluorouracil-induced intestinal mucositis in mice. ( Brito, GA; Cunha, FQ; Justino, PF; Lima-Junior, RC; Mota, JM; Ribeiro, RA; Soares, PM; Souza, MH, 2011) |
| "5-fluorouracil (5-FU) is a common cytotoxic agent used to treat solid tumors." | 1.37 | CXCL9 attenuated chemotherapy-induced intestinal mucositis by inhibiting proliferation and reducing apoptosis. ( Cheng, Z; Di, J; Du, Y; Han, X; Jin, Z; Pan, Y; Wang, Y; Wang, Z; Wu, Z; Zhang, H; Zhang, P; Zheng, Q, 2011) |
| "Mucositis was the major acute toxicity, but this was well tolerated in most subjects." | 1.36 | Weekly low-dose docetaxel-based chemoradiotherapy for locally advanced oropharyngeal or hypopharyngeal carcinoma: a retrospective, single-institution study. ( Fujii, M; Fukada, J; Kawaguchi, O; Kubo, A; Kunieda, E; Ohashi, T; Shigematsu, N; Shiotani, A; Takeda, A; Tomita, T, 2010) |
| "5-Fluorouracil (5-FU) is a commonly used chemotherapy agent in clinical oncology practice." | 1.35 | Gastrointestinal microflora and mucins may play a critical role in the development of 5-Fluorouracil-induced gastrointestinal mucositis. ( Bowen, JM; Gibson, RJ; Hamilton, J; Keefe, DM; Logan, RM; Stringer, AM; Yeoh, AS, 2009) |
| "Mucositis is a common side-effect of high-dose chemotherapy regimens." | 1.35 | Grape seed extract protects IEC-6 cells from chemotherapy-induced cytotoxicity and improves parameters of small intestinal mucositis in rats with experimentally-induced mucositis. ( Bastian, SE; Butler, RN; Cheah, KY; Howarth, GS; Payne, C; Whitford, EJ; Wright, TH; Yazbeck, R, 2009) |
| "Chemoradiation for head and neck cancer may produce severe glucose metabolism alteration during treatment." | 1.35 | Altered glucose metabolism during chemoradiation for head and neck cancer. ( Borok, TL; Dutta, S; Jo, BH; Karlsson, U; Lee, H; Martinez, T; Nguyen, LM; Nguyen, N; Nguyen, NP; Sallah, S; Vinh-Hung, V; Vos, P, 2009) |
| "Intestinal mucositis is a common and debilitating side-effect of chemotherapy, associated with severe small intestinal inflammation." | 1.35 | Lyprinol only partially improves indicators of small intestinal integrity in a rat model of 5-fluorouracil-induced mucositis. ( Butler, RN; Geier, MS; Howarth, GS; Smith, CL; Tooley, KL; Torres, DM, 2008) |
| " This study was to explore relationship of DPD to serum concentration of 5-FU in colorectal cancer patients treated with FOLFOX6 regimen, and their correlation to treatment response and adverse events." | 1.33 | [Relationship of serum level of dihydropyrimidine dehydrogenase and serum concentration of 5-fluorouracil to treatment response and adverse events in colorectal cancer patients]. ( Dong, QM; He, YJ; Li, S; Li, YY; Xia, ZJ; Zhang, L; Zhou, ZM; Zhou, ZW, 2005) |
| "Grade IV mucositis was triggered by the initial use of standard-dose anthracycline chemotherapy, and involved not only the mouth but also the genital and anal mucosa, as well as other severe non-mucosal toxicities." | 1.33 | Panmucositis and chemosensitisation associated with betel quid chewing during dose-dense adjuvant breast cancer chemotherapy. ( Cheung, PS; Epstein, RJ; Leung, TW, 2006) |
| " This study was to explore the relationship between activity of DPD and concentration of 5-FU, and their correlation to adverse events among advanced gastric cancer patients treated with the same regimen containing 5-FU continuous infusion." | 1.33 | [Correlative analysis between serum dihydropyrimidine dehydrogenase, activity, concentration of 5-fluorouracil and adverse events in the treatment of advanced gastric cancer patients]. ( Cao, Y; Dong, QM; Jiang, WQ; Li, H; Li, S; Peng, RJ; Shi, YX; Yuan, ZY; Zhou, ZM, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 38 (15.83) | 29.6817 |
| 2010's | 128 (53.33) | 24.3611 |
| 2020's | 74 (30.83) | 2.80 |
| Authors | Studies |
|---|---|
| Cotomacio, CC | 1 |
| Calarga, CC | 1 |
| Yshikawa, BK | 1 |
| Arana-Chavez, VE | 1 |
| Simões, A | 1 |
| Wei, L | 2 |
| Wen, XS | 1 |
| Xian, CJ | 1 |
| Zhao, G | 1 |
| Williams, J | 1 |
| Washington, MK | 1 |
| Yang, Y | 1 |
| Long, J | 1 |
| Townsend, SD | 1 |
| Yan, F | 1 |
| Al-Khrashi, LA | 1 |
| Badr, AM | 1 |
| Al-Amin, MA | 1 |
| Mahran, YF | 1 |
| Chen, G | 1 |
| Zeng, H | 2 |
| Li, X | 1 |
| Liu, J | 1 |
| Li, Z | 1 |
| Xu, R | 1 |
| Ma, Y | 1 |
| Liu, C | 3 |
| Xue, B | 1 |
| Deng, S | 1 |
| Wu, D | 1 |
| Li, L | 1 |
| Li, J | 4 |
| Xu, Y | 1 |
| Lotfi, M | 2 |
| Kazemi, S | 2 |
| Shirafkan, F | 2 |
| Hosseinzadeh, R | 1 |
| Ebrahimpour, A | 1 |
| Barary, M | 1 |
| Sio, TT | 1 |
| Hosseini, SM | 2 |
| Moghadamnia, AA | 2 |
| Oliveira, MMB | 3 |
| de Araújo, AA | 2 |
| Ribeiro, SB | 3 |
| de Sales Mota, PCM | 1 |
| Marques, VB | 1 |
| da Silva Martins Rebouças, C | 1 |
| Figueiredo, JG | 1 |
| Barra, PB | 1 |
| de Castro Brito, GA | 2 |
| de Carvalho Leitão, RF | 1 |
| Guerra, GCB | 2 |
| de Medeiros, CACX | 2 |
| Yoneda, J | 1 |
| Nishikawa, S | 1 |
| Kurihara, S | 1 |
| Cano-Cebrián, MJ | 1 |
| Dahlgren, D | 3 |
| Kullenberg, F | 3 |
| Peters, K | 3 |
| Olander, T | 1 |
| Sjöblom, M | 3 |
| Lennernäs, H | 3 |
| De Francia, S | 2 |
| Berchialla, P | 1 |
| Armando, T | 1 |
| Storto, S | 1 |
| Allegra, S | 1 |
| Sciannameo, V | 1 |
| Soave, G | 1 |
| Sprio, AE | 1 |
| Racca, S | 1 |
| Caiaffa, MR | 1 |
| Ciuffreda, L | 1 |
| Mussa, MV | 1 |
| Chen, KJ | 2 |
| Huang, YL | 1 |
| Kuo, LM | 2 |
| Chen, YT | 1 |
| Hung, CF | 1 |
| Hsieh, PW | 2 |
| Yue, X | 1 |
| Wen, S | 1 |
| Long-Kun, D | 1 |
| Man, Y | 1 |
| Chang, S | 1 |
| Min, Z | 1 |
| Shuang-Yu, L | 1 |
| Xin, Q | 1 |
| Jie, M | 1 |
| Liang, W | 1 |
| Chukwunyere, U | 1 |
| Mercan, M | 1 |
| Sehirli, AO | 1 |
| Abacioglu, N | 1 |
| Ji, Y | 1 |
| Zhou, W | 1 |
| Tan, W | 1 |
| Chen, Z | 1 |
| Lu, H | 4 |
| You, Y | 1 |
| Tian, C | 1 |
| Zhou, X | 1 |
| Zhou, L | 1 |
| Luo, R | 1 |
| Zhao, X | 1 |
| Chen, S | 1 |
| Qian, K | 1 |
| Zhang, G | 1 |
| Zhang, M | 1 |
| Yu, QQ | 1 |
| Zhang, H | 2 |
| Guo, Y | 1 |
| Han, B | 1 |
| Jiang, P | 1 |
| Aksoy, N | 1 |
| Sen, E | 1 |
| Sukmasari, S | 1 |
| Özakpınar, ÖB | 1 |
| Arıcıoğlu, F | 1 |
| Yücel, YY | 1 |
| Dumlu, MR | 1 |
| Doolaanea, AA | 1 |
| AbdulRahman, MN | 1 |
| Olgac, V | 1 |
| Bozkan, P | 1 |
| Ozen, B | 1 |
| Wang, J | 3 |
| Wang, L | 6 |
| Zheng, W | 1 |
| Liu, S | 1 |
| Yan, L | 1 |
| Zheng, L | 1 |
| de Andrade, GL | 1 |
| da Silva Souza, B | 1 |
| Araújo, DD | 1 |
| de Freitas, CDT | 1 |
| de Oliveira, JS | 2 |
| Santana, AB | 1 |
| Souto, BS | 1 |
| Santos, NCM | 1 |
| Pereira, JA | 1 |
| Tagliati, CA | 1 |
| Novaes, RD | 1 |
| Corsetti, PP | 1 |
| de Almeida, LA | 1 |
| Ogihara, T | 1 |
| Kagawa, M | 1 |
| Yamanaka, R | 1 |
| Imai, S | 1 |
| Itohara, K | 1 |
| Hira, D | 1 |
| Nakagawa, S | 1 |
| Yonezawa, A | 1 |
| Ito, M | 1 |
| Nakagawa, T | 1 |
| Terada, T | 1 |
| Matsubara, K | 1 |
| Coelho-Rocha, ND | 2 |
| de Jesus, LCL | 2 |
| Barroso, FAL | 2 |
| da Silva, TF | 3 |
| Ferreira, E | 3 |
| Gonçalves, JE | 1 |
| Dos Santos Martins, F | 4 |
| de Oliveira Carvalho, RD | 2 |
| Barh, D | 1 |
| Azevedo, VAC | 1 |
| Rosenqvist, E | 1 |
| Hellström, PM | 1 |
| Nygren, P | 1 |
| Lu, DX | 1 |
| Liu, F | 1 |
| Wu, H | 2 |
| Liu, HX | 1 |
| Chen, BY | 1 |
| Yan, J | 2 |
| Lu, Y | 2 |
| Sun, ZG | 1 |
| Shi, T | 1 |
| Chen, B | 1 |
| Lu, K | 1 |
| Barbosa, SJA | 2 |
| Lima, MLS | 1 |
| de Araújo Júnior, RF | 1 |
| de Sousa Junior, FC | 1 |
| Martins, AA | 2 |
| Paiva, DFF | 1 |
| Andrade, RVS | 1 |
| Rebouças, CSM | 1 |
| Brito, GAC | 3 |
| Leitâo, RFC | 3 |
| Walladbegi, J | 3 |
| Dankis, M | 3 |
| Aydogdu, Ö | 3 |
| Jontell, M | 3 |
| Winder, M | 3 |
| Huang, J | 2 |
| Hwang, AYM | 2 |
| Jia, Y | 2 |
| Kim, B | 2 |
| Iskandar, M | 2 |
| Mohammed, AI | 3 |
| Cirillo, N | 3 |
| Andrade, MER | 2 |
| Trindade, LM | 4 |
| Leocádio, PCL | 3 |
| Leite, JIA | 1 |
| Dos Reis, DC | 3 |
| Cassali, GD | 3 |
| de Carvalho Azevedo, VA | 1 |
| Cavalcante, GG | 1 |
| Fernandes, SOA | 4 |
| Generoso, SV | 6 |
| Cardoso, VN | 13 |
| Zhang, Y | 7 |
| Xi, Y | 2 |
| Yang, C | 1 |
| Gong, W | 1 |
| Wang, C | 3 |
| Wu, L | 2 |
| Wang, D | 2 |
| Jonan, S | 1 |
| Hamouda, N | 3 |
| Fujiwara, A | 1 |
| Iwata, K | 2 |
| Fujita, T | 1 |
| Kato, S | 8 |
| Amagase, K | 7 |
| Celentano, A | 1 |
| Paolini, R | 1 |
| Low, JT | 1 |
| McCullough, MJ | 1 |
| O' Reilly, LA | 1 |
| Heindryckx, F | 1 |
| Yan, M | 1 |
| Sun, C | 1 |
| Tan, J | 1 |
| He, J | 1 |
| Li, H | 2 |
| Jakubauskas, M | 1 |
| Jakubauskiene, L | 1 |
| Leber, B | 1 |
| Horvath, A | 1 |
| Strupas, K | 1 |
| Stiegler, P | 1 |
| Schemmer, P | 1 |
| Wzorek França Dos Santos, I | 1 |
| Sauruk da Silva, K | 1 |
| Regis Bueno, L | 1 |
| Suzane Schneider, V | 1 |
| Silva Schiebel, C | 1 |
| Mulinari Turin de Oliveira, N | 1 |
| Cristine Malaquias da Silva, L | 1 |
| Soares Fernandes, E | 1 |
| Biondaro Gois, M | 1 |
| Mach Cortes Cordeiro, L | 1 |
| Maria-Ferreira, D | 1 |
| Madani, F | 1 |
| Meng, L | 1 |
| Thapa, R | 1 |
| Delgado, MG | 1 |
| Gomez, MF | 1 |
| Ji, R | 1 |
| Knepper, TC | 1 |
| Hubbard, JM | 1 |
| Wang, X | 5 |
| Permuth, JB | 1 |
| Kim, RD | 1 |
| Laber, DA | 1 |
| Xie, H | 1 |
| Tavares, LM | 1 |
| Batista, VL | 1 |
| Dos Santos Freitas, A | 1 |
| Campos, GM | 1 |
| Américo, MF | 1 |
| Belo, GA | 1 |
| Drumond, MM | 1 |
| Mancha-Agresti, P | 1 |
| Vital, KD | 2 |
| Birbrair, A | 1 |
| Martins, FS | 4 |
| Laguna, JG | 1 |
| Azevedo, V | 3 |
| Al-Hoshary, DM | 1 |
| Zalzala, MH | 1 |
| He, S | 1 |
| Xia, J | 1 |
| Jia, H | 1 |
| Dai, Q | 1 |
| Chen, C | 1 |
| Zhou, Y | 1 |
| Wang, XB | 1 |
| Liu, D | 3 |
| Tang, F | 1 |
| Zhang, L | 2 |
| Zhang, JN | 1 |
| Zhao, XL | 1 |
| Xu, LY | 1 |
| Peng, C | 1 |
| Ao, H | 1 |
| Vera, G | 2 |
| López-Gómez, L | 1 |
| Girón, R | 2 |
| Martín-Fontelles, MI | 2 |
| Nurgali, K | 2 |
| Abalo, R | 2 |
| Uranga, JA | 2 |
| Silva, ASD | 1 |
| Medeiros, CACX | 1 |
| Ferreira, LS | 1 |
| Pinheiro, FASD | 1 |
| Sousa Junior, FC | 1 |
| Araújo Júnior, RF | 1 |
| Garcia, VB | 1 |
| Araújo, AA | 1 |
| Justino, PFC | 1 |
| Franco, AX | 3 |
| Pontier-Bres, R | 1 |
| Monteiro, CES | 1 |
| Barbosa, ALR | 1 |
| Souza, MHLP | 1 |
| Czerucka, D | 1 |
| Soares, PMG | 1 |
| Yazbeck, R | 8 |
| Lindsay, RJ | 2 |
| Geier, MS | 7 |
| Butler, RN | 11 |
| Howarth, GS | 18 |
| Ali, J | 3 |
| Khan, AU | 1 |
| Shah, FA | 1 |
| Ali, H | 2 |
| Islam, SU | 1 |
| Kim, YS | 2 |
| Khan, S | 3 |
| Lee, JM | 3 |
| Yoo, IK | 1 |
| Kim, SH | 2 |
| Choi, HS | 1 |
| Kim, ES | 2 |
| Keum, B | 1 |
| Seo, YS | 1 |
| Jeen, YT | 1 |
| Chun, HJ | 1 |
| Lee, HS | 1 |
| Um, SH | 1 |
| Kim, CD | 1 |
| Yeung, CY | 3 |
| Chiang Chiau, JS | 3 |
| Cheng, ML | 3 |
| Chan, WT | 3 |
| Chang, SW | 3 |
| Chang, YH | 1 |
| Jiang, CB | 3 |
| Lee, HC | 3 |
| Nakata, A | 1 |
| Nadatani, Y | 1 |
| Watanabe, T | 1 |
| Matsumoto, Y | 1 |
| Kosaka, S | 1 |
| Higashimori, A | 1 |
| Otani, K | 1 |
| Hosomi, S | 1 |
| Tanaka, F | 1 |
| Kamata, N | 1 |
| Taira, K | 1 |
| Nagami, Y | 1 |
| Tanigawa, T | 1 |
| Fujiwara, Y | 1 |
| Gan, Y | 2 |
| Ai, G | 1 |
| Wu, J | 3 |
| Luo, H | 2 |
| Chen, L | 2 |
| Huang, Q | 2 |
| Wu, X | 2 |
| Xu, N | 2 |
| Li, M | 5 |
| Su, Z | 2 |
| Liu, Y | 4 |
| Huang, X | 1 |
| Liang, J | 1 |
| Zhuo, J | 1 |
| Wu, Q | 1 |
| Lin, Z | 1 |
| Xiang, DC | 1 |
| Yang, JY | 1 |
| Xu, YJ | 1 |
| Zhang, S | 4 |
| Zhu, C | 1 |
| Zhang, CL | 1 |
| Magalhães, TAFM | 1 |
| Souza, MO | 1 |
| Gomes, SV | 1 |
| Mendes E Silva, R | 1 |
| Martins, FDS | 1 |
| Freitas, RN | 1 |
| Amaral, JFD | 1 |
| Cuba, LF | 1 |
| Salum, FG | 1 |
| Guimarães, FS | 1 |
| Cherubini, K | 1 |
| Borghetti, RL | 1 |
| de Figueiredo, MAZ | 1 |
| Wang, R | 1 |
| Wei, GY | 1 |
| Wang, SM | 1 |
| Du, GH | 1 |
| Fideles, LS | 1 |
| de Miranda, JAL | 1 |
| Martins, CDS | 1 |
| Barbosa, MLL | 1 |
| Pimenta, HB | 1 |
| Pimentel, PVS | 1 |
| Teixeira, CS | 1 |
| Scafuri, MAS | 1 |
| Façanha, SO | 1 |
| Barreto, JEF | 1 |
| Carvalho, PMM | 1 |
| Scafuri, AG | 1 |
| Araújo, JL | 1 |
| Rocha, JA | 1 |
| Vieira, IGP | 1 |
| Ricardo, NMPS | 1 |
| da Silva Campelo, M | 1 |
| Ribeiro, MENP | 1 |
| Cerqueira, GS | 1 |
| Tanideh, N | 1 |
| Badie, A | 1 |
| Habibagahi, R | 1 |
| Koohi-Hosseinabadi, O | 1 |
| Haghnegahdar, S | 1 |
| Andisheh-Tadbir, A | 1 |
| McQuade, RM | 1 |
| Al Thaalibi, M | 1 |
| Rodrigues, AB | 1 |
| Aguiar, MIF | 1 |
| Oliveira, PP | 1 |
| Alves, NP | 1 |
| Silva, RA | 1 |
| Vitorino, WO | 1 |
| Lopes, TSS | 1 |
| Levit, R | 3 |
| Savoy de Giori, G | 3 |
| de Moreno de LeBlanc, A | 3 |
| LeBlanc, JG | 3 |
| Tefas, C | 1 |
| Ciobanu, L | 2 |
| Berce, C | 2 |
| Meșter, A | 1 |
| Onica, S | 1 |
| Toma, C | 1 |
| Tanțău, M | 2 |
| Taulescu, M | 2 |
| Carvalho, PLA | 1 |
| Alvarez-Leite, JI | 5 |
| Souza E Melo, ÉLS | 1 |
| Gouveia Peluzio, MDC | 1 |
| Li, BR | 1 |
| Shao, SY | 1 |
| Yuan, L | 1 |
| Jia, R | 1 |
| Sun, J | 2 |
| Ji, Q | 1 |
| Sui, H | 1 |
| Zhou, LH | 1 |
| Liu, H | 2 |
| Li, Q | 1 |
| Wang, Y | 5 |
| Zhang, BM | 1 |
| Chen, YL | 1 |
| Ueng, SH | 1 |
| Hwang, TL | 1 |
| Gui, MX | 1 |
| Huang, B | 1 |
| Peng, J | 1 |
| Chen, X | 3 |
| Muthu, R | 1 |
| Gao, Y | 2 |
| Wang, RG | 1 |
| Lin, JM | 1 |
| Cai, B | 1 |
| Pan, J | 1 |
| Chen, H | 1 |
| Ye, Z | 1 |
| Yuan, H | 1 |
| Sun, H | 1 |
| Wan, P | 1 |
| Liu, JH | 1 |
| Hsieh, CH | 1 |
| Liu, CY | 2 |
| Chang, CW | 1 |
| Chen, YJ | 2 |
| Tsai, TH | 1 |
| Deng, L | 1 |
| Hu, X | 1 |
| Xiao, M | 1 |
| He, D | 1 |
| Jin, Y | 1 |
| Hu, Y | 2 |
| Zhu, Y | 1 |
| Gong, L | 1 |
| Wang, Z | 4 |
| Xiang, L | 1 |
| Zhu, R | 1 |
| Cheng, Y | 1 |
| Peng, Y | 1 |
| Cao, K | 1 |
| Uthaiwat, P | 1 |
| Priprem, A | 1 |
| Chio-Srichan, S | 1 |
| Settasatian, C | 1 |
| Lee, YC | 2 |
| Mahakunakorn, P | 1 |
| Boonsiri, P | 1 |
| Leelayuwat, C | 1 |
| Tippayawat, P | 1 |
| Puthongking, P | 1 |
| Daduang, J | 1 |
| Hudita, A | 1 |
| Radu, IC | 1 |
| Galateanu, B | 1 |
| Ginghina, O | 1 |
| Herman, H | 1 |
| Balta, C | 1 |
| Rosu, M | 1 |
| Zaharia, C | 1 |
| Costache, M | 1 |
| Tanasa, E | 1 |
| Velonia, K | 1 |
| Tsatsakis, A | 1 |
| Hermenean, A | 1 |
| Coutinho, JOPA | 1 |
| Quintanilha, MF | 1 |
| Campos, MRA | 1 |
| de Menezes, GCA | 1 |
| Rosa, LH | 1 |
| Rosa, CA | 1 |
| Nicoli, JR | 2 |
| Tiago, FCP | 1 |
| Shen, SR | 1 |
| Chen, WJ | 1 |
| Chu, HF | 1 |
| Wu, SH | 1 |
| Wang, YR | 1 |
| Shen, TL | 1 |
| Wang, XY | 1 |
| Zhang, B | 2 |
| Xu, L | 1 |
| Wang, YJ | 1 |
| Cai, BY | 1 |
| Yao, QH | 1 |
| Song, B | 1 |
| Chen, J | 1 |
| Chen, D | 1 |
| Zeeshan, M | 1 |
| Atiq, A | 2 |
| Ain, QU | 1 |
| Sano, T | 2 |
| Oikawa, Y | 2 |
| Ozaki, T | 1 |
| Shimakawa, M | 2 |
| Matsumoto, K | 5 |
| Higuchi, K | 2 |
| Oh, NS | 1 |
| Lee, JY | 1 |
| Lee, KW | 1 |
| Kim, Y | 1 |
| Utsumi, D | 4 |
| Tominaga, M | 1 |
| Takeuchi, T | 1 |
| Kano, Y | 1 |
| Tanaka, Y | 1 |
| Park, JJ | 1 |
| Hajj, C | 1 |
| Reyngold, M | 1 |
| Shi, W | 1 |
| Zhang, Z | 2 |
| Cuaron, JJ | 1 |
| Crane, CH | 1 |
| O'Reilly, EM | 1 |
| Lowery, MA | 1 |
| Yu, KH | 1 |
| Goodman, KA | 1 |
| Wu, AJ | 1 |
| Liu, Z | 1 |
| Xie, W | 1 |
| Teng, N | 1 |
| Liang, X | 1 |
| Yang, Z | 1 |
| Esin, E | 1 |
| Telli, TA | 1 |
| Yuce, D | 1 |
| Yalcin, S | 1 |
| Mi, H | 1 |
| Dong, Y | 1 |
| Wang, H | 1 |
| Peter, CCK | 1 |
| Gao, P | 1 |
| Fu, H | 1 |
| Bomfin, LE | 1 |
| Braga, CM | 1 |
| Oliveira, TA | 1 |
| Martins, CS | 2 |
| Foschetti, DA | 1 |
| Santos, AAQA | 1 |
| Costa, DVS | 2 |
| Tsubaki, M | 1 |
| Takeda, T | 1 |
| Asano, RT | 1 |
| Matsuda, T | 1 |
| Fujimoto, SI | 1 |
| Itoh, T | 1 |
| Imano, M | 1 |
| Satou, T | 1 |
| Nishida, S | 1 |
| Li, HL | 1 |
| Lu, L | 1 |
| Wang, XS | 1 |
| Qin, LY | 1 |
| Wang, P | 1 |
| Qiu, SP | 1 |
| Huang, F | 1 |
| Zhang, BB | 1 |
| Shi, HL | 1 |
| Wu, XJ | 1 |
| Vanlancker, E | 2 |
| Vanhoecke, B | 2 |
| Sieprath, T | 1 |
| Bourgeois, J | 1 |
| Beterams, A | 1 |
| De Moerloose, B | 1 |
| De Vos, WH | 1 |
| Van de Wiele, T | 1 |
| Martins, VD | 1 |
| Rodrigues, NM | 3 |
| Souza, ELS | 2 |
| Costa, GMF | 1 |
| Almeida-Leite, CM | 2 |
| Faria, AMC | 1 |
| Maioli, TU | 4 |
| Yang, S | 1 |
| Gao, L | 1 |
| Cao, L | 1 |
| George, RP | 1 |
| Barker, TH | 1 |
| Lymn, KA | 8 |
| Bigatton, DA | 1 |
| Whittaker, AL | 4 |
| Hytting-Andreasen, R | 1 |
| Balk-Møller, E | 1 |
| Hartmann, B | 3 |
| Pedersen, J | 1 |
| Windeløv, JA | 1 |
| Holst, JJ | 3 |
| Kissow, H | 3 |
| de Barros, PAV | 1 |
| Rabelo Andrade, ME | 1 |
| de Vasconcelos Generoso, S | 2 |
| Mendes Miranda, SE | 1 |
| Lacerda Leocádio, PC | 1 |
| de Sales E Souza, ÉL | 2 |
| da Gama, MAS | 1 |
| Alvarez Leite, JI | 1 |
| Antunes Fernandes, SO | 1 |
| Chen, XX | 1 |
| Lam, KK | 1 |
| Feng, YB | 1 |
| Xu, K | 1 |
| Sze, SC | 1 |
| Tang, SC | 1 |
| Leung, GP | 1 |
| Lee, CK | 1 |
| Shi, J | 1 |
| Yang, ZJ | 1 |
| Li, ST | 1 |
| Zhang, ZJ | 1 |
| Zhang, KY | 1 |
| Xiang, D | 3 |
| Yang, J | 1 |
| Ren, X | 1 |
| Zhang, C | 1 |
| Huang, L | 1 |
| de Freitas-Blanco, VS | 1 |
| Monteiro, KM | 1 |
| de Oliveira, PR | 1 |
| de Oliveira, ECS | 1 |
| de Oliveira Braga, LE | 1 |
| de Carvalho, JE | 1 |
| Ferreira Rodrigues, RA | 1 |
| Carvalho, R | 1 |
| Vaz, A | 1 |
| Pereira, FL | 1 |
| Dorella, F | 1 |
| Aguiar, E | 1 |
| Chatel, JM | 2 |
| Bermudez, L | 1 |
| Langella, P | 2 |
| Fernandes, G | 1 |
| Figueiredo, H | 1 |
| Goes-Neto, A | 1 |
| Medeiros, ADC | 1 |
| Azevedo, ÍM | 1 |
| Lima, ML | 1 |
| Araújo Filho, I | 1 |
| Moreira, MD | 1 |
| Zheng, H | 2 |
| Gao, J | 7 |
| Man, S | 1 |
| Zhang, J | 4 |
| Jin, Z | 3 |
| Gao, W | 2 |
| Shal, B | 1 |
| Naveed, M | 1 |
| Khan, A | 1 |
| Zeeshan, S | 1 |
| Al-Sharari, SD | 1 |
| Bon-Frauches, AC | 1 |
| Silva, AMHP | 1 |
| Lima-Júnior, RCP | 1 |
| Freitas, GB | 1 |
| Castelucci, P | 1 |
| Bolick, DT | 1 |
| Guerrant, RL | 2 |
| Warren, CA | 2 |
| Moura-Neto, V | 1 |
| Gupta, N | 1 |
| Quah, SY | 1 |
| Yeo, JF | 1 |
| Ferreira, J | 1 |
| Tan, KS | 1 |
| Hong, CHL | 1 |
| Porto, BAA | 1 |
| Monteiro, CF | 1 |
| Santos, DA | 1 |
| Santos, JRA | 1 |
| Pessione, E | 1 |
| Hitomi, S | 1 |
| Ujihara, I | 1 |
| Sago-Ito, M | 1 |
| Nodai, T | 1 |
| Shikayama, T | 1 |
| Inenaga, K | 1 |
| Ono, K | 1 |
| Usumez, A | 1 |
| Cengiz, B | 1 |
| Oztuzcu, S | 1 |
| Demir, T | 1 |
| Aras, MH | 1 |
| Gutknecht, N | 1 |
| Goto, Y | 1 |
| Kodaira, T | 1 |
| Furutani, K | 1 |
| Tachibana, H | 1 |
| Tomita, N | 1 |
| Ito, J | 1 |
| Hanai, N | 1 |
| Ozawa, T | 1 |
| Hirakawa, H | 1 |
| Suzuki, H | 1 |
| Hasegawa, Y | 1 |
| Nakajima, T | 1 |
| Sakai, H | 1 |
| Sagara, A | 1 |
| Arakawa, K | 1 |
| Tashima, K | 1 |
| Narita, M | 1 |
| Horie, S | 2 |
| Takii, Y | 1 |
| Maruyama, S | 1 |
| Mashtoub, S | 4 |
| Tran, CD | 1 |
| Callaghan, B | 1 |
| Furness, JB | 1 |
| Saif, MW | 1 |
| Lee, AM | 1 |
| Offer, SM | 1 |
| McConnell, K | 1 |
| Relias, V | 1 |
| Diasio, RB | 2 |
| Wu, W | 1 |
| Hong, W | 1 |
| Sun, X | 1 |
| Cheah, KY | 6 |
| Bastian, SE | 2 |
| Cardani, D | 1 |
| Sardi, C | 1 |
| La Ferla, B | 1 |
| D'Orazio, G | 1 |
| Sommariva, M | 1 |
| Marcucci, F | 1 |
| Olivero, D | 1 |
| Tagliabue, E | 1 |
| Koepsell, H | 1 |
| Nicotra, F | 1 |
| Balsari, A | 1 |
| Rumio, C | 1 |
| Zhu, S | 6 |
| Qian, L | 4 |
| Wu, M | 6 |
| Chan, GL | 1 |
| Yu, Y | 6 |
| Han, W | 6 |
| de Melo Silva, B | 1 |
| Dias, MN | 1 |
| Paiva, NC | 2 |
| Fernandes, SO | 2 |
| Carneiro, CM | 2 |
| Lee, CS | 1 |
| Ryan, EJ | 1 |
| Doherty, GA | 1 |
| Satheeshkumar, PS | 2 |
| Mohan, MP | 2 |
| Ye, H | 2 |
| Zhan, YS | 1 |
| Tan, SW | 1 |
| Mao, W | 1 |
| Jiang, J | 1 |
| Liu, HL | 1 |
| Wu, B | 1 |
| McRee, AJ | 1 |
| Davies, JM | 1 |
| Sanoff, HG | 1 |
| Goldberg, RM | 1 |
| Bernard, S | 1 |
| Dees, EC | 1 |
| Keller, K | 1 |
| Ivanova, A | 1 |
| O'Neil, BH | 1 |
| Karaca, H | 1 |
| Bozkurt, O | 1 |
| Ozaslan, E | 1 |
| Baldane, S | 1 |
| Berk, V | 1 |
| Inanc, M | 1 |
| Duran, AO | 1 |
| Dikilitas, M | 1 |
| Er, O | 1 |
| Ozkan, M | 1 |
| Taieb, J | 1 |
| Tabernero, J | 1 |
| Mini, E | 1 |
| Subtil, F | 1 |
| Folprecht, G | 1 |
| Van Laethem, JL | 1 |
| Thaler, J | 1 |
| Bridgewater, J | 1 |
| Petersen, LN | 1 |
| Blons, H | 1 |
| Collette, L | 1 |
| Van Cutsem, E | 1 |
| Rougier, P | 1 |
| Salazar, R | 1 |
| Bedenne, L | 1 |
| Emile, JF | 1 |
| Laurent-Puig, P | 1 |
| Lepage, C | 1 |
| Guan, W | 1 |
| Renck, D | 1 |
| Santos, AA | 2 |
| Machado, P | 1 |
| Petersen, GO | 1 |
| Lopes, TG | 1 |
| Santos, DS | 1 |
| Campos, MM | 1 |
| Basso, LA | 1 |
| Nicholson, A | 1 |
| Soveri, LM | 1 |
| Hermunen, K | 1 |
| de Gramont, A | 1 |
| Poussa, T | 1 |
| Quinaux, E | 1 |
| Bono, P | 1 |
| André, T | 1 |
| Österlund, P | 1 |
| Yuan, KT | 1 |
| Yu, HL | 1 |
| Feng, WD | 1 |
| Chong, P | 1 |
| Yang, T | 1 |
| Xue, CL | 1 |
| Yu, M | 1 |
| Shi, HP | 1 |
| Shen, J | 1 |
| Weng, S | 1 |
| Han, L | 1 |
| Sun, T | 1 |
| Zhu, J | 1 |
| Moldenhauer, A | 1 |
| Hayashi, S | 1 |
| Kitahara, Y | 3 |
| Nagasawa, K | 1 |
| Aono, H | 1 |
| Shibata, J | 1 |
| Kadowaki, M | 1 |
| Justino, PF | 3 |
| Melo, LF | 1 |
| Nogueira, AF | 1 |
| Morais, CM | 1 |
| Mendes, WO | 1 |
| Souza, EP | 2 |
| Ribeiro, RA | 8 |
| Souza, MH | 5 |
| Soares, PM | 4 |
| Antunes, MM | 2 |
| Leocádio, PC | 2 |
| Teixeira, LG | 2 |
| Leonel, AJ | 3 |
| Cara, DC | 2 |
| Menezes, GB | 1 |
| Generoso, Sde V | 2 |
| Correia, MI | 3 |
| Al-Asmari, AK | 2 |
| Al-Zahrani, AM | 1 |
| Khan, AQ | 2 |
| Al-Shahrani, HM | 1 |
| Ali Al Amri, M | 1 |
| Kim, HJ | 1 |
| Kim, JH | 3 |
| Moon, W | 1 |
| Park, J | 1 |
| Park, SJ | 1 |
| Song, GA | 1 |
| Han, SH | 1 |
| Lee, JH | 1 |
| Machado, DC | 1 |
| Araújo, CV | 2 |
| Lazzarotto, CR | 1 |
| Aquino, CC | 1 |
| Figueiredo, IL | 1 |
| Costa, TB | 2 |
| Alves, LA | 1 |
| Bertolini, LR | 1 |
| Lima, AA | 2 |
| Brito, GA | 4 |
| Oriá, RB | 2 |
| Bateman, E | 1 |
| Mayo, B | 1 |
| Stringer, A | 1 |
| Thorpe, D | 1 |
| Keefe, D | 1 |
| Kawashima, R | 1 |
| Kawakami, F | 1 |
| Maekawa, T | 1 |
| Yamamoto, H | 2 |
| Koizumi, W | 1 |
| Ichikawa, T | 3 |
| Ferreira, AV | 1 |
| Faria, AM | 1 |
| Leach, MC | 1 |
| Preston, FL | 1 |
| Balboa-Beltrán, E | 1 |
| Duran, G | 1 |
| Lamas, MJ | 1 |
| Carracedo, A | 1 |
| Barros, F | 1 |
| Grem, JL | 1 |
| Kos, ME | 1 |
| Evande, RE | 1 |
| Meza, JL | 1 |
| Schwarz, JK | 1 |
| Feo, B | 1 |
| Martinez-Puig, D | 1 |
| Otter, S | 1 |
| Schick, U | 1 |
| Gulliford, S | 1 |
| Lal, P | 1 |
| Franceschini, D | 1 |
| Newbold, K | 1 |
| Nutting, C | 1 |
| Harrington, K | 1 |
| Bhide, S | 1 |
| Pereira, VB | 1 |
| Melo, AT | 1 |
| Assis-Júnior, EM | 1 |
| Wong, DV | 3 |
| Almeida, PR | 1 |
| Lima-Júnior, RC | 3 |
| Gou, H | 1 |
| Gu, LY | 1 |
| Shang, BZ | 1 |
| Xiong, Y | 1 |
| Chen, Y | 1 |
| Tang, Y | 1 |
| Wu, Y | 1 |
| Huang, Z | 1 |
| Dong, W | 1 |
| Deng, Y | 1 |
| Wang, F | 1 |
| Yuan, J | 1 |
| Wanderley, CW | 1 |
| Mota, JM | 4 |
| Leite, CA | 1 |
| Cunha, FQ | 3 |
| Lampton, LS | 1 |
| Eden, GL | 1 |
| Bajic, JE | 1 |
| Wodzinski, A | 1 |
| Barros, PA | 1 |
| Andrade, ME | 1 |
| da Gama, MA | 1 |
| Lopes, FC | 1 |
| Martins, FD | 1 |
| Miranda, SE | 1 |
| Al-Asmari, SA | 1 |
| Al-Rawi, A | 1 |
| Al-Omani, S | 1 |
| Pérez-García, I | 1 |
| de Andrés, R | 1 |
| López-Pérez, AE | 1 |
| Vaudo, CE | 1 |
| Gil, B | 1 |
| Galuski, K | 1 |
| Zarwan, C | 1 |
| Nugent, FW | 1 |
| Kuchay, RA | 1 |
| Valean, S | 1 |
| Parau, A | 1 |
| Bedecean, I | 1 |
| Mîrleneanu, R | 1 |
| Catoi, C | 1 |
| Koizumi, R | 1 |
| Azuma, K | 1 |
| Izawa, H | 1 |
| Morimoto, M | 1 |
| Ochi, K | 1 |
| Tsuka, T | 1 |
| Imagawa, T | 1 |
| Osaki, T | 1 |
| Ito, N | 1 |
| Okamoto, Y | 1 |
| Saimoto, H | 1 |
| Ifuku, S | 1 |
| Sakaguchi, M | 1 |
| Maebayashi, T | 1 |
| Aizawa, T | 1 |
| Ishibashi, N | 1 |
| Saito, T | 1 |
| Carvalho, RD | 1 |
| Breyner, N | 1 |
| Menezes-Garcia, Z | 1 |
| Lemos, L | 1 |
| da Gloria Souza, D | 1 |
| Carmona, D | 1 |
| de Faria, AM | 1 |
| Bermúdez-Humarán, LG | 1 |
| Figueiredo, HC | 1 |
| de Azevedo, MS | 1 |
| Bajetta, E | 1 |
| Di Bartolomeo, M | 1 |
| Buzzoni, R | 1 |
| Ferrario, E | 1 |
| Dotti, KF | 1 |
| Mariani, L | 1 |
| Bajetta, R | 1 |
| Gevorgyan, A | 1 |
| Venturino, P | 1 |
| Galassi, M | 1 |
| Saegusa, Y | 2 |
| Iwai, T | 2 |
| Goso, Y | 2 |
| Okayasu, I | 1 |
| Ikezawa, T | 2 |
| Shikama, N | 2 |
| Saigenji, K | 2 |
| Ishihara, K | 2 |
| Smith, CL | 3 |
| Torres, DM | 2 |
| Lefebvre, JL | 1 |
| Rolland, F | 1 |
| Tesselaar, M | 1 |
| Bardet, E | 1 |
| Leemans, CR | 1 |
| Geoffrois, L | 1 |
| Hupperets, P | 1 |
| Barzan, L | 1 |
| de Raucourt, D | 1 |
| Chevalier, D | 1 |
| Licitra, L | 1 |
| Lunghi, F | 1 |
| Stupp, R | 1 |
| Lacombe, D | 1 |
| Bogaerts, J | 1 |
| Horiot, JC | 1 |
| Bernier, J | 1 |
| Vermorken, JB | 1 |
| Stringer, AM | 2 |
| Gibson, RJ | 2 |
| Logan, RM | 2 |
| Bowen, JM | 2 |
| Yeoh, AS | 1 |
| Hamilton, J | 1 |
| Keefe, DM | 2 |
| Wright, TH | 4 |
| Whitford, EJ | 4 |
| Feinle-Bisset, C | 1 |
| Pilichiewicz, AN | 1 |
| Payne, C | 1 |
| Cummins, AG | 4 |
| Prisciandaro, LD | 4 |
| Fauser, JK | 2 |
| Lawrence, A | 2 |
| Fukada, J | 1 |
| Shigematsu, N | 1 |
| Takeda, A | 1 |
| Ohashi, T | 1 |
| Tomita, T | 1 |
| Shiotani, A | 1 |
| Kunieda, E | 1 |
| Kawaguchi, O | 1 |
| Fujii, M | 1 |
| Kubo, A | 1 |
| Nieto, Y | 1 |
| Aramendía, JM | 1 |
| Espinós, J | 1 |
| De la Cruz, S | 1 |
| Fernández-Hidalgo, O | 1 |
| Santisteban, M | 1 |
| Arbea, L | 1 |
| Aristu, J | 1 |
| Martínez-Monge, R | 1 |
| Moreno, M | 1 |
| Pina, L | 1 |
| Sola, J | 1 |
| Zornoza, G | 1 |
| Regueira, FM | 1 |
| Lee, YJ | 1 |
| Lee, CG | 1 |
| Cho, BC | 2 |
| Kim, GE | 1 |
| Choi, HJ | 2 |
| Choi, EC | 1 |
| Sohn, JH | 2 |
| Oikawa, H | 1 |
| Nakamura, R | 1 |
| Nakasato, T | 1 |
| Nishimura, K | 1 |
| Sato, H | 1 |
| Ehara, S | 1 |
| Huang, TY | 1 |
| Chu, HC | 1 |
| Lin, YL | 1 |
| Ho, WH | 1 |
| Hou, HS | 1 |
| Chao, YC | 1 |
| Liao, CL | 1 |
| Bae, WK | 1 |
| Hwang, JE | 1 |
| Shim, HJ | 1 |
| Cho, SH | 1 |
| Lee, JK | 1 |
| Lim, SC | 1 |
| Chung, WK | 1 |
| Chung, IJ | 1 |
| Nguyen, NP | 1 |
| Vos, P | 1 |
| Vinh-Hung, V | 1 |
| Borok, TL | 1 |
| Dutta, S | 1 |
| Karlsson, U | 1 |
| Lee, H | 1 |
| Martinez, T | 1 |
| Jo, BH | 1 |
| Nguyen, LM | 1 |
| Nguyen, N | 1 |
| Sallah, S | 1 |
| Letari, O | 1 |
| Booth, C | 1 |
| Bonazzi, A | 1 |
| Garofalo, P | 1 |
| Makovec, F | 1 |
| Rovati, LC | 1 |
| Caselli, G | 1 |
| Bin, Q | 1 |
| Liao, C | 1 |
| Cao, Y | 2 |
| Gao, F | 1 |
| Guo, L | 1 |
| Lin, HX | 1 |
| Xu, M | 1 |
| Chen, QY | 1 |
| Wang, CT | 1 |
| Huang, PY | 1 |
| Sperone, P | 1 |
| Ferrero, A | 1 |
| Daffara, F | 1 |
| Priola, A | 1 |
| Zaggia, B | 1 |
| Volante, M | 1 |
| Santini, D | 1 |
| Vincenzi, B | 1 |
| Badalamenti, G | 1 |
| Intrivici, C | 1 |
| Del Buono, S | 1 |
| Kalomirakis, E | 1 |
| Ratti, R | 1 |
| Angeli, A | 1 |
| Dogliotti, L | 1 |
| Papotti, M | 1 |
| Terzolo, M | 1 |
| Berruti, A | 1 |
| Clavel, S | 1 |
| Fortin, B | 1 |
| Després, P | 1 |
| Donath, D | 1 |
| Soulières, D | 1 |
| Khaouam, N | 1 |
| Charpentier, D | 1 |
| Bélair, M | 1 |
| Guertin, L | 1 |
| Nguyen-Tan, PF | 1 |
| Savva-Bordalo, J | 1 |
| Ramalho-Carvalho, J | 1 |
| Pinheiro, M | 1 |
| Costa, VL | 1 |
| Rodrigues, A | 1 |
| Dias, PC | 1 |
| Veiga, I | 1 |
| Machado, M | 1 |
| Teixeira, MR | 1 |
| Henrique, R | 1 |
| Jerónimo, C | 1 |
| Wu, ZQ | 1 |
| Han, XD | 1 |
| Yuan, KL | 1 |
| Jin, ZM | 1 |
| Di, JZ | 1 |
| Pan, Y | 2 |
| Zhang, P | 2 |
| Huang, XY | 1 |
| Wang, ZG | 1 |
| Zheng, Q | 4 |
| Shiota, A | 1 |
| Hada, T | 1 |
| Baba, T | 1 |
| Sato, M | 1 |
| Yamanaka-Okumura, H | 1 |
| Taketani, Y | 1 |
| Takeda, E | 1 |
| Schauer, MC | 1 |
| Holzmann, B | 1 |
| Peiper, M | 1 |
| Friess, H | 1 |
| Knoefel, WT | 1 |
| Theisen, J | 1 |
| Wu, Z | 3 |
| Han, X | 3 |
| Qin, S | 2 |
| Grossberg, AL | 1 |
| Gaspari, AA | 1 |
| Borges, L | 1 |
| Davidson, GP | 1 |
| Di, J | 1 |
| Du, Y | 1 |
| Cheng, Z | 1 |
| Su, NW | 1 |
| Leu, YS | 1 |
| Lee, JC | 1 |
| Chen, HW | 1 |
| Liu, CJ | 1 |
| Chang, YF | 1 |
| Kim, YJ | 1 |
| Goh, PG | 1 |
| Lee, SY | 1 |
| Moon, HS | 1 |
| Lee, ES | 1 |
| Sung, JK | 1 |
| Lee, BS | 1 |
| Jeong, HY | 1 |
| Vormittag, L | 1 |
| Lemaire, C | 1 |
| Radonjic, D | 1 |
| Kornek, G | 1 |
| Selzer, E | 1 |
| Yasuda, M | 2 |
| Yamanaka, N | 2 |
| Iimori, M | 2 |
| Matsuno, K | 1 |
| Yabe-Nishimura, C | 1 |
| Takeuchi, K | 2 |
| Chang, CT | 1 |
| Ho, TY | 1 |
| Lin, H | 1 |
| Liang, JA | 1 |
| Huang, HC | 1 |
| Li, CC | 1 |
| Lo, HY | 1 |
| Wu, SL | 1 |
| Huang, YF | 1 |
| Hsiang, CY | 1 |
| Cai, X | 1 |
| Xue, P | 1 |
| Song, WF | 1 |
| Hu, J | 1 |
| Gu, HL | 1 |
| Yang, HY | 1 |
| Wang, LW | 1 |
| Azevedo, OG | 1 |
| Oliveira, RA | 1 |
| Oliveira, BC | 1 |
| Zaja-Milatovic, S | 1 |
| Lucena, HB | 1 |
| Lima, RC | 1 |
| Vitek, MP | 1 |
| Chua, AE | 1 |
| Sander, GR | 1 |
| Ferreira, TM | 1 |
| Melo, MA | 1 |
| Santos, RR | 1 |
| Viby, NE | 1 |
| Timm, M | 1 |
| Thim, L | 1 |
| Poulsen, SS | 2 |
| Dogan, M | 1 |
| Karabulut, HG | 1 |
| Tukun, A | 1 |
| Demirkazik, A | 1 |
| Utkan, G | 1 |
| Yalcin, B | 1 |
| Dincol, D | 1 |
| Akbulut, H | 1 |
| Icli, F | 1 |
| Zhong, LP | 1 |
| Zhang, CP | 1 |
| Ren, GX | 1 |
| Guo, W | 1 |
| William, WN | 1 |
| Zhu, HG | 1 |
| Tu, WY | 1 |
| Cai, YL | 1 |
| Wang, LZ | 1 |
| Fan, XD | 1 |
| Wang, ZH | 1 |
| Hu, YJ | 1 |
| Ji, T | 1 |
| Yang, WJ | 1 |
| Ye, WM | 1 |
| He, Y | 1 |
| Wang, YA | 1 |
| Xu, LQ | 1 |
| Wang, BS | 1 |
| Kies, MS | 1 |
| Lee, JJ | 1 |
| Myers, JN | 1 |
| Zhang, ZY | 1 |
| Dong, QM | 2 |
| He, YJ | 1 |
| Li, S | 2 |
| Zhou, ZM | 2 |
| Zhou, ZW | 1 |
| Xia, ZJ | 1 |
| Li, YY | 1 |
| Lee, A | 1 |
| Ezzeldin, H | 1 |
| Fourie, J | 1 |
| Diasio, R | 1 |
| Hitt, R | 1 |
| López-Pousa, A | 1 |
| Martínez-Trufero, J | 1 |
| Escrig, V | 1 |
| Carles, J | 1 |
| Rizo, A | 1 |
| Isla, D | 1 |
| Vega, ME | 1 |
| Martí, JL | 1 |
| Lobo, F | 1 |
| Pastor, P | 1 |
| Valentí, V | 1 |
| Belón, J | 1 |
| Sánchez, MA | 1 |
| Chaib, C | 1 |
| Pallarés, C | 1 |
| Antón, A | 1 |
| Cervantes, A | 1 |
| Paz-Ares, L | 1 |
| Cortés-Funes, H | 1 |
| Poh, SB | 1 |
| Bai, LY | 1 |
| Chen, PM | 1 |
| Santasusana, JM | 1 |
| García López, JL | 1 |
| García, JJ | 1 |
| Carbonero, AI | 1 |
| Plazas, JG | 1 |
| Rovira, PS | 1 |
| Martos, CF | 1 |
| Guzmán, MC | 1 |
| Jericó, JF | 1 |
| Delgado, FJ | 1 |
| Espinosa, JC | 1 |
| Muñoz, ML | 1 |
| Aguilar, EA | 1 |
| Valera, JS | 1 |
| García Ribas, I | 1 |
| Mena, AC | 1 |
| Farker, K | 1 |
| Merkel, U | 1 |
| Wedding, U | 1 |
| Hippius, M | 1 |
| Höffken, K | 1 |
| Hoffmann, A | 1 |
| Kim, CB | 1 |
| Ahn, JB | 1 |
| Epstein, RJ | 1 |
| Leung, TW | 1 |
| Cheung, PS | 1 |
| Jones, JA | 1 |
| Avritscher, EB | 1 |
| Cooksley, CD | 1 |
| Michelet, M | 1 |
| Bekele, BN | 1 |
| Elting, LS | 1 |
| Choi, K | 1 |
| Lee, SS | 1 |
| Oh, SJ | 1 |
| Lim, SY | 2 |
| Jeon, WK | 1 |
| Oh, TY | 1 |
| Kim, JW | 1 |
| Peng, RJ | 1 |
| Shi, YX | 1 |
| Yuan, ZY | 1 |
| Jiang, WQ | 1 |
| Katori, H | 1 |
| Tsukuda, M | 1 |
| Taguchi, T | 1 |
| Allen, AM | 1 |
| Elshaikh, M | 1 |
| Worden, FP | 1 |
| Bradford, CR | 1 |
| Teknos, TN | 1 |
| Chepeha, DB | 1 |
| Tsien, C | 1 |
| Dawson, LA | 1 |
| Urba, S | 1 |
| Wolf, GT | 1 |
| Normolle, D | 1 |
| Eisbruch, A | 1 |
| Javle, MM | 1 |
| Cao, S | 1 |
| Durrani, FA | 1 |
| Pendyala, L | 1 |
| Lawrence, DD | 1 |
| Smith, PF | 1 |
| Creaven, PJ | 1 |
| Noel, DC | 1 |
| Iyer, RV | 1 |
| Rustum, YM | 1 |
| Hu, QY | 1 |
| Liu, P | 1 |
| Fu, ZF | 1 |
| Wisinski, K | 1 |
| Benson, A | 1 |
| Tooley, KL | 1 |
| Takuma, D | 1 |
| Guangchen, S | 1 |
| Yokota, J | 1 |
| Hamada, A | 1 |
| Onogawa, M | 1 |
| Yoshioka, S | 1 |
| Kusunose, M | 1 |
| Miyamura, M | 1 |
| Kyotani, S | 1 |
| Nishioka, Y | 1 |
| Ezzeldin, HH | 1 |
| Schwab, M | 1 |
| Zanger, UM | 1 |
| Marx, C | 1 |
| Schaeffeler, E | 1 |
| Klein, K | 1 |
| Dippon, J | 1 |
| Kerb, R | 1 |
| Blievernicht, J | 1 |
| Fischer, J | 1 |
| Hofmann, U | 1 |
| Bokemeyer, C | 1 |
| Eichelbaum, M | 1 |
| Zalcberg, JR | 1 |
| Rosen, LS | 1 |
| Abdi, E | 1 |
| Davis, ID | 1 |
| Gutheil, J | 1 |
| Schnell, FM | 1 |
| Cesano, A | 1 |
| Gayko, U | 1 |
| Chen, MG | 2 |
| Clarke, S | 1 |
| Gomes, AS | 1 |
| Oliveira, RB | 1 |
| Assreuy, AM | 1 |
| Di Costanzo, F | 2 |
| Gasperoni, S | 1 |
| Manzione, L | 1 |
| Bisagni, G | 1 |
| Labianca, R | 1 |
| Bravi, S | 1 |
| Cortesi, E | 1 |
| Carlini, P | 1 |
| Bracci, R | 1 |
| Tomao, S | 1 |
| Messerini, L | 1 |
| Arcangeli, A | 1 |
| Torri, V | 1 |
| Bilancia, D | 1 |
| Floriani, I | 1 |
| Tonato, M | 1 |
| Dinota, A | 1 |
| Strafiuso, G | 1 |
| Corgna, E | 1 |
| Porrozzi, S | 1 |
| Boni, C | 1 |
| Rondini, E | 1 |
| Giunta, A | 1 |
| Monzio Compagnoni, B | 1 |
| Biagioni, F | 1 |
| Cesari, M | 1 |
| Fornarini, G | 1 |
| Nelli, F | 1 |
| Carboni, M | 1 |
| Cognetti, F | 1 |
| Enzo, MR | 1 |
| Piga, A | 1 |
| Romiti, A | 1 |
| Olivetti, A | 1 |
| Masoni, L | 1 |
| De Stefanis, M | 1 |
| Dalla Mola, A | 1 |
| Camera, S | 1 |
| Recchia, F | 1 |
| De Filippis, S | 1 |
| Scipioni, L | 1 |
| Zironi, S | 1 |
| Luppi, G | 1 |
| Italia, M | 1 |
| Banducci, S | 1 |
| Pisani Leretti, A | 1 |
| Massidda, B | 1 |
| Ionta, MT | 1 |
| Nicolosi, A | 1 |
| Canaletti, R | 1 |
| Biscottini, B | 1 |
| Grigniani, F | 1 |
| Rovei, R | 1 |
| Croce, E | 1 |
| Carroccio, R | 1 |
| Gilli, G | 1 |
| Cavalli, C | 1 |
| Olgiati, A | 1 |
| Pandolfi, U | 1 |
| Rossetti, R | 1 |
| Natalini, G | 1 |
| Foa, P | 1 |
| Oldani, S | 1 |
| Bruno, L | 1 |
| Cascinu, S | 1 |
| Catalano, G | 1 |
| Catalano, V | 1 |
| Lungarotti, F | 1 |
| Farris, A | 1 |
| Sarobba, MG | 1 |
| Trignano, M | 1 |
| Muscogiuri, A | 1 |
| Francavilla, F | 1 |
| Figoli, F | 1 |
| Leoni, M | 1 |
| Papiani, G | 1 |
| Orselli, G | 1 |
| Antimi, M | 1 |
| Bellini, V | 1 |
| Cabassi, A | 1 |
| Contu, A | 1 |
| Pazzola, A | 1 |
| Frignano, M | 1 |
| Lastraioli, E | 1 |
| Saggese, M | 1 |
| Bianchini, D | 1 |
| Antonuzzo, L | 1 |
| Mela, M | 1 |
| Camisa, R | 1 |
| Sonis, ST | 1 |
| Nakano, M | 1 |
| Brizel, DM | 1 |
| Murphy, BA | 1 |
| Rosenthal, DI | 1 |
| Pandya, KJ | 1 |
| Glück, S | 1 |
| Brizel, HE | 1 |
| Meredith, RF | 1 |
| Berger, D | 1 |
| Mendenhall, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effectiveness of Topical Oral Vitamin D Gel in Prevention of Radiation-induced Oral Mucositis[NCT04308161] | Phase 2 | 45 participants (Anticipated) | Interventional | 2019-11-02 | Recruiting | ||
| The Effectiveness of Melatonin in Prevention of Radiation-induced Oral Mucositis[NCT03833570] | Phase 2 | 40 participants (Actual) | Interventional | 2018-01-12 | Completed | ||
| A Sequential Phase I Study Of The Combination Of Everolimus (Rad001) With 5-Fu/Lv (De Gramont), Folfox6, And Folfox6/Panitumumab In Patients With Refractory Solid Malignancies[NCT00610948] | Phase 1 | 74 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Chemotherapy For Unresectable Locally Advanced Colon Cancer: An Open, Multi-centered, Randomize Controlled Phase 3 Trial.[NCT03970694] | Phase 3 | 49 participants (Actual) | Interventional | 2019-05-11 | Terminated (stopped due to Significant differences in conversion rate as well as R0 resection rate between the two groups.) | ||
| Adjuvant Treatment of Fully Resected Stage III Colon Cancer With FOLFOX-4 Versus FOLFOX-4 Plus Cetuximab[NCT00265811] | Phase 3 | 2,559 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| Ancillary Study of miR-31-3p and miR-31-5p Expression Levels in Patients Enrolled in the PETACC-8 Study, and of the Predictive Role of miR-31-3p Expression Level on Clinical Outcomes of Patients Treated With Cetuximab[NCT03362684] | Phase 3 | 1,808 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| Biomarker Validation Study of Linear Quantification of CD3 Positive Cells in Localized Colorectal Carcinomas, Based on the Cohort of Patient Included in PETACC8 International Phase III Trial (NCT00265811)[NCT02364024] | 856 participants (Actual) | Observational | 2005-11-30 | Completed | |||
| A Phase I Clinical Trial of Sequential Pralatrexate Followed by a 48-hour Infusion of 5- Fluorouracil Given Every Other Week in Adult Patients With Solid Tumors[NCT01206465] | Phase 1 | 29 participants (Actual) | Interventional | 2010-09-14 | Completed | ||
| PHASE II STUDY ON LARYNX PRESERVATION COMPARING INDUCTION CHEMOTHERAPY AND RADIOTHERAPY VERSUS ALTERNATING CHEMO-RADIOTHERAPY IN RESECTABLE HYPOPHARYNX AND LARYNX CANCERS[NCT00002839] | Phase 3 | 564 participants (Anticipated) | Interventional | 1996-07-31 | Completed | ||
| Prospective Randomized Trial Comparing Induction Chemotherapy Plus Concurrent Chemoradiotherapy With Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma[NCT01245959] | Phase 3 | 476 participants (Anticipated) | Interventional | 2011-01-31 | Active, not recruiting | ||
| A Prospective, Single-arm, Phase II Study of Adelbelimab Combined With Carboplatin and Nab-paclitaxel in Neoadjuvant Therapy for Patients With Resectable Locally Advanced Squamous Cell Carcinoma of the Head and Neck[NCT06016413] | Phase 2 | 30 participants (Anticipated) | Interventional | 2023-09-01 | Not yet recruiting | ||
| Study of TPF (Docetaxel, Cisplatin, 5-fluorouracil) Induction Chemotherapy Followed by Surgery and Radiotherapy in Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma[NCT01542931] | Phase 2/Phase 3 | 256 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Trial to Determine the CR Rate at the Primary Tumor Site After 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head & Neck Carcinoma Treated With Definitive Concurrent Cisplatin & Radiation Therapy[NCT00736944] | Phase 2 | 30 participants (Actual) | Interventional | 2008-12-19 | Completed | ||
| Prospective Registration of Head and Neck Cancer Patients for Clinical Data and Tissue Collection[NCT02546895] | 2,000 participants (Anticipated) | Observational | 2015-09-30 | Recruiting | |||
| Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC): an Open-label, Single-center, Phase 2, Single-arm Trial (CaboPen)[NCT03943602] | Phase 2 | 37 participants (Anticipated) | Interventional | 2019-08-01 | Recruiting | ||
| A Randomized Study of a New Medical Device for Oral Mucositis (MDOM Trial)[NCT05104268] | Phase 1/Phase 2 | 100 participants (Anticipated) | Interventional | 2021-11-30 | Not yet recruiting | ||
| A Phase 1/Phase 2 Study for the Prevention of Oral Mucositis (SPOM)[NCT05338398] | Phase 1/Phase 2 | 100 participants (Anticipated) | Interventional | 2022-04-15 | Enrolling by invitation | ||
| Phase I Study of Multiple Ascending Dose, to Investigate the Safety and Tolerability of the Use of Copaiba in Patients With Oral Cancer Submitted to Radiotherapy[NCT05308732] | Phase 1 | 36 participants (Anticipated) | Interventional | 2021-05-11 | Recruiting | ||
| Impacts of Oral Supplement With L-Glutamine on the Radiation-induced Toxicity and Nutritional Status of Head and Neck Cancer Patients Under Radiotherapy[NCT03015077] | 59 participants (Actual) | Interventional | 2014-07-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Pharmacokinetics of 5-FU - Cmax plasma levels (NCT01206465)
Timeframe: 22, 23, 45 & 46 hours during the 48 hour infusion
| Intervention | mg/m^2 (Mean) |
|---|---|
| 22 Hours | 1147 |
| 23 Hours | 1159 |
| 45 Hours | 1123 |
| 46 Hours | 1113 |
Plasma concentrations versus time (at all time points) (NCT01206465)
Timeframe: Pre-treatment, end of infusion, at 15, 30, and 60 min, and then at 2, 4, 6, 8, 12, 22, 23, 24, 45, and 46 hours for PDX.
| Intervention | ng/ml *hr (Mean) |
|---|---|
| 75 mg/m^2 | 12,818 |
| 94 mg/m^2 | 16300 |
| 118 mg/m^2 | 15680 |
| 148 mg/m^2 | 23570 |
| 185 mg/m^2 | 42121 |
Recommended dose of PDX given in combination with a fixed dose of 5-FU administered as a 48-hour infusion given every other weekMaximum tolerated dose will have been exceeded when 2 patients entered at a given dose level experience specified dose-limiting toxicities in the initial cycle (NCT01206465)
Timeframe: During the initial course (day 1 & 15 of a 4 week schedule)
| Intervention | mg per meter square (Number) |
|---|---|
| Treatment (Enzyme Inhibitor Therapy) | 148 |
Time to disease progression in all Participants (NCT01206465)
Timeframe: restaging imaging done after each two 4-week course until time of progression (longest time to progression = 588 days)
| Intervention | days (Median) |
|---|---|
| Treatment (Enzyme Inhibitor Therapy) | 112 |
Participants remained on study as long as they did not progress, and wished to continue on study (no limit on number of cycles) (NCT01206465)
Timeframe: "., From the time the subject signs the consent form and ending 4 weeks following the final chemotherapy, an average of 3 years"
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| gr 3-4 neutropenia | gr 3-4 thrombocytopenia | gr 3-4 anemia | gr 3-4 diarrhea | gr 3-4 mucositis | gr 3-4 dehydration | gr 3-4 fatigue | |
| Treatment (Enzyme Inhibitor Therapy) | 4 | 0 | 4 | 1 | 5 | 1 | 1 |
Number of Participants with Polymorphisms in Methylenetetrahydrofolate Reductase and Thymidylate Synthase (NCT01206465)
Timeframe: Prior to the first dose of protocol therapy
| Intervention | percentage of patients (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| SLC19A1 80G>A | gamma glutamyl hydrolase (GGH) 401C>T | gamma glutamyl hydrolase (GGH) 452C>T | folyl polyglutamate synthase (FPGS) rs10760502A>G | folyl polyglutamate synthase (FPGS) rs1544105C>T | methylene tetrahydrofolate reductase (MTHFR 677C>T | methylene tetrahydrofolate reductase MTHFR 1298A>C | thymidylate synthase 28-bp tandem repeats (2 or 3) | |
| Heterozygous | 40.7 | 37.0 | 11.1 | 4.0 | 55.6 | 25.9 | 33.3 | 48.2 |
| Homozygous Variant | 7.4 | 7.4 | 0 | 0 | 18.5 | 18.5 | 14.8 | 37.0 |
| Wild Type | 51.9 | 55.6 | 88.9 | 96.0 | 25.9 | 55.6 | 51.9 | 14.8 |
"Clinical exam included laryngoscopy in office or operating room.~Complete response rate includes complete response (CR) which is defined as 100% decrease in tumor size and it also includes near complete response (near CR) defined as 95-99% decrease in tumor size." (NCT00736944)
Timeframe: post-2 cycles of induction (approximately 42 days from start of treatment)
| Intervention | participants (Number) |
|---|---|
| Induction Chemo + RT + Cisplatin or Cetuximab | 16 |
"Clinical exam included laryngoscopy in office or operating room.~Partial response rate (PR) defined as 50% to 94% decrease in tumor size." (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) |
|---|---|
| Induction Chemo + RT + Cisplatin or Cetuximab | 14 |
Time from complete response to death from any cause, to disease progression or to last follow-up alive. (NCT00736944)
Timeframe: 10 years from completion of treatment
| Intervention | months (Mean) |
|---|---|
| Induction Chemo + RT + Cisplatin or Cetuximab | 93.529 |
Time from diagnosis to death or to last follow-up alive. (NCT00736944)
Timeframe: 10 years from completion of treatment
| Intervention | months (Mean) |
|---|---|
| Induction Chemo + RT + Cisplatin or Cetuximab | 83.960 |
Time from initiation of induction chemotherapy to death due to disease progression, to disease progression, or to last follow-up alive. (NCT00736944)
Timeframe: 10 years from completion of treatment
| Intervention | months (Mean) |
|---|---|
| Induction Chemo + RT + Cisplatin or Cetuximab | 38.675 |
(NCT00736944)
Timeframe: completion of the first 10 patients induction chemotherapy
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergic reaction/hypersensitivity | Other allergic reaction:cipro | Other allergic reaction:hives | Hypotension | INR | Fatigue | Alopecia | Chelitis | Dry skin | Rash | Rash:acneiform | Rash:penile (unconfirmed HSV) | Anorexia | Colitis | Constipation | Dehydration | Dental:teeth | Diarrhea | Hemorrhoids | Nausea | Taste alteration | Vomiting | Other:soft stools | Hemoglobin | Leukocytes (WBC) | Lymphopenia | Neutrophils (ANC) | Platelets | Hemmorrhage:nose | Alkaline phosphatase | SGPT (ALT) | Infection other:sinus infection | Edema:limb | Albumin, low | Calcium, low | Magnesium, low | Potassium, low | Potassium, high | Sodium, low | Phosphorus | Dizziness | Mood alteration:anger | Neuropathy:sensory (peripheral) | Vision-photophobia | Pain:thigh | Pain:tumor pain | Hiccoughs (hiccups) | Obstruction/stenosis of airway:trachea | Creatinine | GFR | Renal failure | Thrombosis/thrombus/embolism | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 1 | 1 | 1 | 1 | 1 | 10 | 5 | 1 | 1 | 1 | 7 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 9 | 1 | 1 | 1 | 8 | 8 | 8 | 8 | 2 | 1 | 3 | 2 | 1 | 2 | 1 | 5 | 4 | 3 | 2 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 1 |
"Clinical exam consisted of physical exam of neck in office.~Complete response rate includes complete response (CR) which is defined as 100% decrease in tumor size and near complete response (near CR) defined as 95-99% decrease in tumor size.~Partial response rate defined as 50% to 94% decrease in tumor size." (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | |
|---|---|---|
| Complete response | Partial response | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 11 | 7 |
"Clinical exam included laryngoscopy in office or operating room.~Clinical exam consisted of physical exam of neck in office.~Complete response rate includes complete response (CR) which is defined as 100% decrease in tumor size and it also includes near complete response (near CR) defined as 95-99% decrease in tumor size.~Partial response rate defined as 50% to 94% decrease in tumor size." (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days)
| Intervention | participants (Number) | |
|---|---|---|
| Overall complete response | Overall partial response | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 13 | 17 |
"Complete response rate defined as complete resolution of the metabolically active primary tumor.~Partial response rate defined as 20% or greater decrease in maximum SUV [SUV g/ml) = ROI activity (mCi/ml) / (injected dose (mCi/body weight(g))] from baseline. No unequivocal metabolic progression of non-target disease, and no unequivocal new lesions." (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | |
|---|---|---|
| Complete response | Partial response | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 9 | 14 |
"Complete response rate defined as complete resolution of the metabolically active primary tumor.~Partial response rate defined as 20% or greater decrease in maximum SUV [SUV g/ml) = ROI activity (mCi/ml) / (injected dose (mCi/body weight(g))] from baseline. No unequivocal metabolic progression of non-target disease, and no unequivocal new lesions." (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | |
|---|---|---|
| Complete response | Partial response | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 9 | 17 |
In the future, primary tumor site, nodal, and overall tumor response by visual categorical response (CR-x or PR-x = yes or no) will be compared with response based on CT scan (CR-x or PR-x = yes or no) using a test for difference in paired, binary values (e.g., McNemar's test). Median standardized uptake value of FDG measured by PET/CT will be compared among those with or without response (CR-x or PR-x) using nonparametric Wilcoxon-Mann-Whitney tests. At this point, we are releasing results based on comparing actual responses from visual categorical response, CT scan, and FDG-PET/CT scan after 2 cycles of induction. (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Complete Response | Partial Response | Stable Disease/Progressive Disease | |
| Clinical Examination | 61 | 39 | 0 |
| CT Scan | 30 | 48 | 22 |
| FDG-PET/CT | 36 | 56 | 8 |
In the future, primary tumor site, nodal, and overall tumor response by visual categorical response (CR-x or PR-x = yes or no) will be compared with response based on CT scan (CR-x or PR-x = yes or no) using a test for difference in paired, binary values (e.g., McNemar's test). Median standardized uptake value of FDG measured by PET/CT will be compared among those with or without response (CR-x or PR-x) using nonparametric Wilcoxon-Mann-Whitney tests. At this point, we are releasing results based on comparing actual responses from visual categorical response, CT scan, and FDG-PET/CT scan after 2 cycles of induction. (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Complete Response | Partial Response | Stable Disease/Progressive Disease | |
| Clinical Examination | 43 | 57 | 0 |
| CT Scan | 14 | 50 | 36 |
| FDG-PET/CT | 24 | 66 | 10 |
"In the future, primary tumor site, nodal, and OTR by VCR (CR-x or PR-x = Y or N) will be compared with response based on CT scan (CR-x or PR-x = Y or N) using a test for difference in paired, binary values. Median standardized uptake value of FDG measured by PET/CT will be compared among those with or without response (CR-x or PR-x) using nonparametric Wilcoxon-Mann-Whitney tests.~We are releasing results based on comparing actual responses from visual categorical response, CT scan, and FDG-PET/CT scan after 2 cycles." (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Complete Response | Partial Response | Stable Disease/Progressive Disease | |
| Clinical Examination | 53 | 47 | 0 |
| CT Scan | 33 | 41 | 26 |
| FDG-PET/CT | 32 | 61 | 7 |
SPARC expression = intensity of SPARC staining in tumor (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Negative staining | 1+ staining (weak) | 2+ staining (moderate) | 3+ staining (strong) | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 14 | 0 | 1 | 0 |
SPARC expression = intensity of SPARC staining in tumor (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Negative staining | 1+ staining (weak) | 2+ staining (moderate) | 3+ staining (strong) | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 6 | 2 | 4 | 1 |
SPARC expression = Proportion of tumor cells SPARC-positive in 10 high-power fields (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Negative staining | 1+ staining (0%-24%) | 2+ staining (25%-49%) | 3+ staining (50%-74%) | 4+ staining (75%-100%) | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 14 | 0 | 1 | 0 | 0 |
SPARC expression = Proportion of tumor cells SPARC-positive in 10 high-power fields (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Negative staining | 1+ staining (0%-24%) | 2+ staining (25%-49%) | 3+ staining (50%-74%) | 4+ staining (75%-100%) | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 6 | 4 | 1 | 2 | 0 |
"Complete response rate defined as complete resolution of the metabolically active primary tumor.~Partial response rate defined as 20% or greater decrease in maximum SUV [SUV g/ml) = ROI activity (mCi/ml) / (injected dose (mCi/body weight(g))] from baseline. No unequivocal metabolic progression of non-target disease, and no unequivocal new lesions." (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | |
|---|---|---|
| Overall complete response | Overall partial response | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 7 | 19 |
"Complete response rate per RECIST criteria is defined as disappearance of all target lesions.~Partial response rate per RECIST criteria is defined as at least a 30% decrease in the sum of the longest diameter of target lesions taking as reference the baseline sum longest diameter." (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | |
|---|---|---|
| Complete response | Partial response | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 7 | 12 |
"Complete response rate per RECIST criteria is defined as disappearance of all target lesions.~Partial response rate per RECIST criteria is defined as at least a 30% decrease in the sum of the longest diameter of target lesions taking as reference the baseline sum longest diameter." (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | |
|---|---|---|
| Complete response | Partial response | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 10 | 11 |
"Complete response rate per RECIST criteria is defined as disappearance of all target lesions.~Partial response rate per RECIST criteria is defined as at least a 30% decrease in the sum of the longest diameter of target lesions taking as reference the baseline sum longest diameter." (NCT00736944)
Timeframe: post-2 cycles of induction therapy (approximately 42 days from start of treatment)
| Intervention | participants (Number) | |
|---|---|---|
| Overall complete response | Overall partial response | |
| Induction Chemo + RT + Cisplatin or Cetuximab | 4 | 14 |
14 reviews available for fluorouracil and Mucositis
| Article | Year |
|---|---|
Chemotherapy-Induced Intestinal Microbiota Dysbiosis Impairs Mucosal Homeostasis by Modulating Toll-like Receptor Signaling Pathways.
Topics: Animals; Antineoplastic Agents; Apoptosis; Drug Therapy; Drug-Related Side Effects and Adverse React | 2021 |
Possible cytoprotective mechanisms of oxytocin against 5-fluorouracil-induced gastrointestinal mucositis.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Fluorouracil; Humans; Intestinal Mucosa; M | 2022 |
The Intestinal Redox System and Its Significance in Chemotherapy-Induced Intestinal Mucositis.
Topics: Antineoplastic Agents; Fluorouracil; Humans; Intestinal Mucosa; Intestines; Mucositis; Necrosis; Oxi | 2022 |
Experimental Chemotherapy-Induced Mucositis: A Scoping Review Guiding the Design of Suitable Preclinical Models.
Topics: Animals; Antineoplastic Agents; Fluorouracil; Humans; Irinotecan; Methotrexate; Mice; Mucositis; Rab | 2022 |
Experimental Chemotherapy-Induced Mucositis: A Scoping Review Guiding the Design of Suitable Preclinical Models.
Topics: Animals; Antineoplastic Agents; Fluorouracil; Humans; Irinotecan; Methotrexate; Mice; Mucositis; Rab | 2022 |
Experimental Chemotherapy-Induced Mucositis: A Scoping Review Guiding the Design of Suitable Preclinical Models.
Topics: Animals; Antineoplastic Agents; Fluorouracil; Humans; Irinotecan; Methotrexate; Mice; Mucositis; Rab | 2022 |
Experimental Chemotherapy-Induced Mucositis: A Scoping Review Guiding the Design of Suitable Preclinical Models.
Topics: Animals; Antineoplastic Agents; Fluorouracil; Humans; Irinotecan; Methotrexate; Mice; Mucositis; Rab | 2022 |
Impact of chemotherapy-induced enteric nervous system toxicity on gastrointestinal mucositis.
Topics: Animals; Antineoplastic Agents; Cisplatin; Enteric Nervous System; Fluorouracil; Gastrointestinal Di | 2020 |
Raltitrexed-based chemotherapy for advanced colorectal cancer.
Topics: Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Chemical and Drug Induce | 2014 |
Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cell Death; Colorectal Neoplas | 2014 |
Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cell Death; Colorectal Neoplas | 2014 |
Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cell Death; Colorectal Neoplas | 2014 |
Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cell Death; Colorectal Neoplas | 2014 |
Dark Agouti rat model of chemotherapy-induced mucositis: establishment and current state of the art.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluor | 2015 |
Irinotecan- and 5-fluorouracil-induced intestinal mucositis: insights into pathogenesis and therapeutic perspectives.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Cytokines; Fluorou | 2016 |
A review of complementary therapies for chemotherapy induced gastrointestinal mucositis.
Topics: Antimetabolites, Antineoplastic; Complementary Therapies; Fluorouracil; Gastrointestinal Diseases; H | 2017 |
Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Fluorouracil; Humans | 2011 |
Topical antineoplastic agents in the treatment of mucocutaneous diseases.
Topics: Administration, Topical; Aminoquinolines; Antineoplastic Agents; Diterpenes; Fluorouracil; Humans; I | 2011 |
Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy.
Topics: Antidotes; Antimetabolites, Antineoplastic; Biotransformation; Deoxyuracil Nucleotides; Diarrhea; Di | 2004 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
27 trials available for fluorouracil and Mucositis
| Article | Year |
|---|---|
Effect of cryotherapy in preventing mucositis associated with the use of 5-fluorouracil.
Topics: Antineoplastic Agents; Cryotherapy; Fluorouracil; Humans; Mucositis; Stomatitis | 2020 |
A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohor | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2014 |
A phase 1 clinical trial of sequential pralatrexate followed by a 48-hour infusion of 5-fluorouracil given every other week in adult patients with solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Aminopterin; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; | 2015 |
Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cohort Stud | 2009 |
Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2009 |
Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cycloph | 2010 |
Weekly 5-fluorouracil plus cisplatin for concurrent chemoradiotherapy in patients with locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2010 |
Phase II study of docetaxel, cisplatin, and 5-FU induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetax | 2010 |
Phase I study of TPF neoadjuvant chemotherapy followed by radical radiotherapy in advanced nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Fluorouracil; H | 2010 |
Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antimetabolites, Antineoplastic; An | 2010 |
Re-irradiation combined with capecitabine in locally recurrent squamous cell carcinoma of the head and neck. A prospective phase II trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Squamous Cell; Combined Modal | 2012 |
Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 2013 |
Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 2013 |
Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 2013 |
Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 2013 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Pegylated liposomal doxorubicin-based combination chemotherapy as salvage treatment in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; alpha-Fetoproteins; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2005 |
A phase II trial of gemcitabine and weekly high-dose 5-fluorouracil in a 48-hour continuous-infusion schedule in patients with advanced pancreatic carcinoma. A study of the Spanish Cooperative Group for Gastrointestinal Tumour Therapy (TTD).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; D | 2005 |
Chronomodulated chemotherapy with oxaliplatin, 5-FU and sodium folinate in metastatic gastrointestinal cancer patients: original analysis of non-hematological toxicity and patient characteristics in a pilot investigation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Chronotherapy; Diarrhe | 2006 |
Paclitaxel and leucovorin-modulated infusional 5-fluorouracil combination chemotherapy for metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Disease Progression; Female; | 2006 |
The effect of oral glutamine on 5-fluorouracil/leucovorin-induced mucositis/stomatitis assessed by intestinal permeability test.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chromi | 2007 |
Analysis of efficacy and toxicity of chemotherapy with cisplatin, 5-fluorouracil, methotrexate and leucovorin (PFML) and radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2007 |
Acceleration of hyperfractionated chemoradiation regimen for advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinoma, Squamous Cell; | 2007 |
Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celeco | 2007 |
[Concurrent chemoradiotherapy followed by adjuvant chemotherapy for stage III-IVa nasopharyngeal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Ci | 2007 |
Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group.
Topics: Antimetabolites, Antineoplastic; Diarrhea; Dihydrouracil Dehydrogenase (NADP); DNA Methylation; Fema | 2008 |
Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuva | 2008 |
Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2008 |
199 other studies available for fluorouracil and Mucositis
| Article | Year |
|---|---|
Wound healing process with different photobiomodulation therapy protocols to treat 5-FU-induced oral mucositis in hamsters.
Topics: Animals; Cricetinae; Fluorouracil; Low-Level Light Therapy; Mouth Mucosa; Mucositis; Stomatitis; Wou | 2021 |
2'-Fucosyllactose Ameliorates Chemotherapy-Induced Intestinal Mucositis by Protecting Intestinal Epithelial Cells Against Apoptosis.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Diarrhea; Fluorouracil; Goblet Cells; Mice; Muc | 2022 |
Thymol ameliorates 5-fluorouracil-induced intestinal mucositis: Evidence of down-regulatory effect on TGF-β/MAPK pathways through NF-κB.
Topics: Animals; Chymases; Fluorouracil; Intestinal Diseases; MAP Kinase Signaling System; Mucositis; NF-kap | 2022 |
Activation of G protein coupled estrogen receptor prevents chemotherapy-induced intestinal mucositis by inhibiting the DNA damage in crypt cell in an extracellular signal-regulated kinase 1- and 2- dependent manner.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line; Cell Proliferation; Cytoprotection; Disease Mo | 2021 |
TBHQ attenuates ferroptosis against 5-fluorouracil-induced intestinal epithelial cell injury and intestinal mucositis via activation of Nrf2.
Topics: Animals; Cell Death; Cell Line; Cytokines; Diarrhea; Disease Models, Animal; Epithelial Cells; Ferro | 2021 |
The protective effects of quercetin nano-emulsion on intestinal mucositis induced by 5-fluorouracil in mice.
Topics: Animals; Antioxidants; Catalase; Emulsions; Fluorouracil; Gene Expression; Hypoxia-Inducible Factor | 2021 |
Losartan improves intestinal mucositis induced by 5-fluorouracil in mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antimetabolites, Antineoplastic; Cytokines; Female | 2021 |
Oral administration of cystine and theanine attenuates 5-fluorouracil-induced intestinal mucositis and diarrhea by suppressing both glutathione level decrease and ROS production in the small intestine of mucositis mouse model.
Topics: Animals; Cystine; Diarrhea; Disease Models, Animal; Drug Therapy, Combination; Fluorouracil; Glutama | 2021 |
Chemotherapeutics Combined with Luminal Irritants: Effects on Small-Intestinal Mannitol Permeability and Villus Length in Rats.
Topics: Animals; Doxycycline; Ethanol; Fluorouracil; Injections, Intraperitoneal; Intestinal Mucosa; Irinote | 2022 |
Colorectal cancer chemotherapy: can sex-specific disparities impact on drug toxicities?
Topics: Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug-Related | 2022 |
Protective role of casuarinin from Melastoma malabathricum against a mouse model of 5-fluorouracil-induced intestinal mucositis: Impact on inflammation and gut microbiota dysbiosis.
Topics: Animals; Disease Models, Animal; Dysbiosis; Fluorouracil; Gastrointestinal Diseases; Gastrointestina | 2022 |
Three important short-chain fatty acids (SCFAs) attenuate the inflammatory response induced by 5-FU and maintain the integrity of intestinal mucosal tight junction.
Topics: Animals; Beclin-1; Caco-2 Cells; Fatty Acids, Volatile; Fluorouracil; Humans; Inflammation; Interleu | 2022 |
Protective effect of polysaccharides isolated from the seeds of Cuscuta chinensis Lam. on 5-fluorouracil-induced intestinal mucositis in mice.
Topics: Animals; Antimetabolites, Antineoplastic; bcl-2-Associated X Protein; Body Weight; Caspase 3; Cuscut | 2022 |
Akkermansia muciniphila and its outer membrane protein Amuc_1100 prophylactically attenuate 5-fluorouracil-induced intestinal mucositis.
Topics: Akkermansia; Animals; Fluorouracil; Intestinal Mucosa; Intestines; Membrane Proteins; Mice; Mice, In | 2022 |
Investigation of the protective effect of gel incorporating Eugenia jambolana leaf extract on 5-fluorouracil-induced oral mucositis: an animal study.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Fluorouracil; Gels; Mucositis; Plant Extracts; Rats | 2022 |
Taurine Treatment Alleviates Intestinal Mucositis Induced by 5-Fluorouracil in Mice.
Topics: Animals; Fluorouracil; Intestinal Mucosa; Intestines; Mice; Mucositis; NF-kappa B; Taurine | 2022 |
Protective Effect of
Topics: Antioxidants; Apocynaceae; Cytokines; Fluorouracil; Humans; Inflammation; Intestinal Mucosa; Latex; | 2023 |
Murine response to the opportunistic bacterium Pseudomonas aeruginosa infection in gut dysbiosis caused by 5-fluorouracil chemotherapy-induced mucositis.
Topics: Animals; Antineoplastic Agents; Bacteria; Dysbiosis; Fluorouracil; Intestinal Mucosa; Mice; Mice, In | 2022 |
Preparation and pharmaceutical properties of Hangeshashinto oral ointment and its safety and efficacy in Syrian hamsters with 5-fluorouracil-induced oral mucositis.
Topics: Animals; Cricetinae; Fluorouracil; Male; Mesocricetus; Mucositis; Ointments; Stomatitis | 2023 |
Evaluation of Probiotic Properties of Novel Brazilian Lactiplantibacillus plantarum Strains.
Topics: Animals; Anti-Bacterial Agents; Brazil; Caco-2 Cells; Fluorouracil; Humans; Lactobacillaceae; Lactob | 2023 |
Evaluation and validation of chemotherapy-specific diarrhoea and histopathology in rats.
Topics: Animals; Antineoplastic Agents; Atrophy; Body Weight; Diarrhea; Doxorubicin; Fluorouracil; Idarubici | 2022 |
Wumei pills attenuates 5-fluorouracil-induced intestinal mucositis through Toll-like receptor 4/myeloid differentiation factor 88/nuclear factor-κB pathway and microbiota regulation.
Topics: Animals; Antineoplastic Agents; Body Weight; Butyrates; Cadherins; Claudin-1; Diarrhea; Drugs, Chine | 2022 |
Study on Huangqi Bazhen Decoction on Relieving Chemotherapy Intestinal Mucositis in Capecitabine Gavage Mice.
Topics: Animals; Capecitabine; Fluorouracil; Intestinal Mucosa; Mice; Mucositis; Superoxide Dismutase; Tumor | 2022 |
The beneficial effects of
Topics: Animals; Colon; Fluorouracil; Interleukin-6; Intestinal Mucosa; Intestine, Small; Lacticaseibacillus | 2022 |
Moderate temperature reduction is sufficient for prevention of 5-fluorouracil-induced oral mucositis: an experimental in vivo study in rats.
Topics: Animals; Antineoplastic Agents; Fluorouracil; Interleukin-6; Male; Mucositis; Rats; Rats, Sprague-Da | 2023 |
Moderate temperature reduction is sufficient for prevention of 5-fluorouracil-induced oral mucositis: an experimental in vivo study in rats.
Topics: Animals; Antineoplastic Agents; Fluorouracil; Interleukin-6; Male; Mucositis; Rats; Rats, Sprague-Da | 2023 |
Moderate temperature reduction is sufficient for prevention of 5-fluorouracil-induced oral mucositis: an experimental in vivo study in rats.
Topics: Animals; Antineoplastic Agents; Fluorouracil; Interleukin-6; Male; Mucositis; Rats; Rats, Sprague-Da | 2023 |
Moderate temperature reduction is sufficient for prevention of 5-fluorouracil-induced oral mucositis: an experimental in vivo study in rats.
Topics: Animals; Antineoplastic Agents; Fluorouracil; Interleukin-6; Male; Mucositis; Rats; Rats, Sprague-Da | 2023 |
Association of Fructo-oligosaccharides and Arginine Improves Severity of Mucositis and Modulate the Intestinal Microbiota.
Topics: Animals; Arginine; Fluorouracil; Gastrointestinal Microbiome; Intestinal Mucosa; Intestines; Mice; M | 2023 |
Short-Chain Fatty Acids Attenuate 5-Fluorouracil-Induced THP-1 Cell Inflammation through Inhibiting NF-κB/NLRP3 Signaling via Glycerolphospholipid and Sphingolipid Metabolism.
Topics: Anti-Inflammatory Agents; Fatty Acids, Volatile; Fluorouracil; Humans; Inflammasomes; Inflammation; | 2023 |
Alleviative effects of glutamate against chemotherapeutic agent-induced intestinal mucositis.
Topics: Animals; Antimetabolites, Antineoplastic; Fluorouracil; Glutamic Acid; Intestinal Mucosa; Intestines | 2022 |
Characterization of a novel dual murine model of chemotherapy-induced oral and intestinal mucositis.
Topics: Animals; Antimetabolites, Antineoplastic; Diarrhea; Disease Models, Animal; Fluorouracil; Intestinal | 2023 |
Anakinra and dexamethasone treatment of idarubicin-induced mucositis and diarrhoea in rats.
Topics: Animals; Antineoplastic Agents; Dexamethasone; Diarrhea; Fluorouracil; Idarubicin; Interleukin 1 Rec | 2023 |
Berberine-Based Carbon Quantum Dots Improve Intestinal Barrier Injury and Alleviate Oxidative Stress in C57BL/6 Mice with 5-Fluorouracil-Induced Intestinal Mucositis by Enhancing Gut-Derived Short-Chain Fatty Acids Contents.
Topics: Animals; Berberine; Fatty Acids, Volatile; Fluorouracil; Intestinal Diseases; Intestinal Mucosa; Mic | 2023 |
Probiotic Supplementation Attenuates Chemotherapy-Induced Intestinal Mucositis in an Experimental Colorectal Cancer Liver Metastasis Rat Model.
Topics: Animals; Antineoplastic Agents; Colorectal Neoplasms; Diarrhea; Fluorouracil; Male; Mucositis; Probi | 2023 |
Polysaccharide Fraction from
Topics: Animals; Antimetabolites, Antineoplastic; Fluorouracil; Inflammation; Intestinal Mucosa; Mice; Mucos | 2023 |
Thymoquinone protects against 5-Fluorouracil-induced mucositis by NF-κβ and HIF-1 mechanisms in mice.
Topics: Animals; Antineoplastic Agents; Antioxidants; Fluorouracil; Mice; Mucositis; Oxidative Stress | 2023 |
Association of Age With Treatment-Related Adverse Events and Survival in Patients With Metastatic Colorectal Cancer.
Topics: Abdominal Pain; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Female; Fluorouracil; Human | 2023 |
Synergistic synbiotic containing fructooligosaccharides and Lactobacillus delbrueckii CIDCA 133 alleviates chemotherapy-induced intestinal mucositis in mice.
Topics: Animals; Antineoplastic Agents; Fluorouracil; Intestinal Mucosa; Lactobacillus delbrueckii; Mice; Mu | 2023 |
Mucoprotective effect of ellagic acid in 5 fluorouracil-induced intestinal mucositis model.
Topics: Animals; Antineoplastic Agents; Antioxidants; Cytokines; Ellagic Acid; Fluorouracil; Glutathione; In | 2023 |
Peficitinib ameliorates 5-fluorouracil-induced intestinal damage by inhibiting aging, inflammatory factors and oxidative stress.
Topics: Animals; Cellular Senescence; Colorectal Neoplasms; Fluorouracil; Humans; Intestinal Mucosa; Mice; M | 2023 |
Topics: Alpinia; Animals; Diarrhea; Dinoprostone; Fluorouracil; Gastrointestinal Microbiome; Mice; Mucositis | 2023 |
Effect of the Cannabinoid Agonist WIN 55,212-2 on Neuropathic and Visceral Pain Induced by a Non-Diarrheagenic Dose of the Antitumoral Drug 5-Fluorouracil in the Rat.
Topics: Animals; Benzoxazines; Cannabinoid Receptor Agonists; Cannabinoids; Diarrhea; Fluorouracil; Humans; | 2023 |
Lacticaseibacillus casei decrease long-chain fatty acids and most substances in an experimental model of intestinal mucositis.
Topics: Animals; Fatty Acids; Fluorouracil; Intestinal Mucosa; Lacticaseibacillus; Lacticaseibacillus casei; | 2023 |
Modulation of 5-fluorouracil activation of toll-like/MyD88/NF-κB/MAPK pathway by Saccharomyces boulardii CNCM I-745 probiotic.
Topics: Animals; Caco-2 Cells; Chemokine CXCL1; Cytokines; Fluorouracil; Humans; Ileum; Immunohistochemistry | 2020 |
Prebiotics Fructo-, Galacto-, and Mannan-Oligosaccharide Do Not Protect against 5-Fluorouracil-Induced Intestinal Mucositis in Rats.
Topics: Animals; Antimetabolites, Antineoplastic; Feces; Female; Fermentation; Fluorouracil; Intestinal Muco | 2019 |
Mucoprotective effects of Saikosaponin-A in 5-fluorouracil-induced intestinal mucositis in mice model.
Topics: Animals; Antimetabolites, Antineoplastic; Antioxidants; Apoptosis; Cytokines; Diarrhea; Disease Mode | 2019 |
Dipeptidyl-peptidase-4 (DPP-4) inhibitor ameliorates 5-flurouracil induced intestinal mucositis.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Body Weight; Diarrhea; Dipeptidyl Pe | 2019 |
Modulations of probiotics on gut microbiota in a 5-fluorouracil-induced mouse model of mucositis.
Topics: Animals; Antimetabolites, Antineoplastic; Dietary Supplements; Disease Models, Animal; Fluorouracil; | 2020 |
NOD-Like Receptor Family Pyrin Domain-Containing 3 Inflammasome Activation Exacerbates 5-Fluorouracil-Induced Small Intestinal Mucositis via Interleukin-1β Activation.
Topics: Animals; Caspase 1; Fluorouracil; Inflammasomes; Interleukin-1beta; Mice; Mice, Inbred C57BL; Mucosi | 2021 |
Patchouli oil ameliorates 5-fluorouracil-induced intestinal mucositis in rats via protecting intestinal barrier and regulating water transport.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cytokines; Diarrhea; Dose-Response Relationship | 2020 |
Patchouli alcohol attenuates 5-fluorouracil-induced intestinal mucositis via TLR2/MyD88/NF-kB pathway and regulation of microbiota.
Topics: Animals; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Fluorouracil; Gastrointe | 2020 |
Protective effect of Andrographolide on 5-Fu induced intestinal mucositis by regulating p38 MAPK signaling pathway.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; | 2020 |
Açaí (
Topics: Animals; Antioxidants; Euterpe; Fluorouracil; Jejunum; Mice; Mice, Inbred BALB C; Mucositis; Plant E | 2021 |
Cannabidiol on 5-FU-induced oral mucositis in mice.
Topics: Animals; Cannabidiol; Disease Models, Animal; Fluorouracil; Intestinal Mucosa; Mice; Mucositis; Stom | 2020 |
Dihydrotanshinone attenuates chemotherapy-induced intestinal mucositis and alters fecal microbiota in mice.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Bacteria; Colon; Diglycerides; Disease Mod | 2020 |
Role of Rutin in 5-Fluorouracil-Induced Intestinal Mucositis: Prevention of Histological Damage and Reduction of Inflammation and Oxidative Stress.
Topics: Animals; Fluorouracil; Inflammation; Intestinal Diseases; Male; Mice; Mucositis; Oxidative Stress; R | 2020 |
Effect of Topical 2% Eucalyptus Extract on 5-FU-Induced Oral Mucositis in Male Golden Hamsters.
Topics: Animals; Cricetinae; Eucalyptus; Fluorouracil; Male; Mesocricetus; Mouth Mucosa; Mucositis; Plant Ex | 2020 |
Evaluation of vitamin-producing and immunomodulatory lactic acid bacteria as a potential co-adjuvant for cancer therapy in a mouse model.
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents; Breast Neoplasms; Caco-2 Cells; Cell Line; C | 2021 |
Beneficial effect of oral administration of zinc sulfate on 5-fluorouracil-induced gastrointestinal mucositis in rats.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Disease Models, Animal; Female; Fluo | 2020 |
Prophylactic and therapeutic supplementation using fructo-oligosaccharide improves the intestinal homeostasis after mucositis induced by 5- fluorouracil.
Topics: Acetates; Animals; Bacteria; Bacterial Translocation; Butyrates; Disease Models, Animal; Fatty Acids | 2021 |
Effects of mild moxibustion on intestinal microbiome and NLRP3 inflammasome in rats with 5-fluorouracil-induced intestinal mucositis.
Topics: Animals; Fluorouracil; Gastrointestinal Microbiome; Inflammasomes; Intestinal Mucosa; Male; Moxibust | 2021 |
Neutrophil elastase inhibitor (MPH-966) improves intestinal mucosal damage and gut microbiota in a mouse model of 5-fluorouracil-induced intestinal mucositis.
Topics: Animals; Cell Line; Cytokines; Disease Models, Animal; Dysbiosis; Fluorouracil; Gastrointestinal Mic | 2021 |
Babao Dan Alleviates 5-Fluorouracil-Induced Intestinal Damage via Wnt/β-Catenin Pathway.
Topics: Animals; Antineoplastic Agents; beta Catenin; Diarrhea; Fluorouracil; Intestinal Mucosa; Male; Mice; | 2022 |
Oyster polysaccharides ameliorate intestinal mucositis and improve metabolism in 5-fluorouracil-treated S180 tumour-bearing mice.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Butyric Acid; Cell Line, Tumor; DNA | 2021 |
Anti-inflammatory effects of Radix Aucklandiae herbal preparation ameliorate intestinal mucositis induced by 5-fluorouracil in mice.
Topics: Animals; Anti-Inflammatory Agents; Asteraceae; Body Weight; Cytokines; Diarrhea; Disease Models, Ani | 2021 |
Se@Albumin nanoparticles ameliorate intestinal mucositis caused by cisplatin via gut microbiota-targeted regulation.
Topics: Albumins; Animals; Cisplatin; Fluorouracil; Gastrointestinal Microbiome; Mice; Mucositis; Nanopartic | 2021 |
Oral Administration of Melatonin or Succinyl Melatonin Niosome Gel Benefits 5-FU-Induced Small Intestinal Mucositis Treatment in Mice.
Topics: Administration, Oral; Animals; Fluorouracil; Interleukin-1beta; Intestinal Mucosa; Intestine, Small; | 2021 |
Bioinspired silk fibroin nano-delivery systems protect against 5-FU induced gastrointestinal mucositis in a mouse model and display antitumor effects on HT-29 colorectal cancer cells
Topics: Colorectal Neoplasms; Fibroins; Fluorouracil; HT29 Cells; Humans; Mucositis | 2021 |
Antarctic Strain of Rhodotorula mucilaginosa UFMGCB 18,377 Attenuates Mucositis Induced by 5-Fluorouracil in Mice.
Topics: Animals; Antarctic Regions; Fluorouracil; Humans; Intestinal Mucosa; Mice; Mucositis; Rhodotorula | 2022 |
Amelioration of 5-fluorouracil-induced intestinal mucositis by Streptococcus thermophilus ST4 in a mouse model.
Topics: Animals; Body Weight; Disease Models, Animal; Eating; Fluorouracil; Intestinal Mucosa; Male; Mice; M | 2021 |
RNA-seq and
Topics: Animals; Cell Line; Curcumin; Disease Models, Animal; Epithelial Cells; Fluorouracil; Gene Expressio | 2021 |
Puerarin Ameliorates 5-Fluorouracil-Induced Intestinal Mucositis in Mice by Inhibiting JAKs.
Topics: Animals; Antimetabolites, Antineoplastic; Caco-2 Cells; Dose-Response Relationship, Drug; Fluorourac | 2021 |
Evaluating the mucoprotective effects of glycyrrhizic acid-loaded polymeric nanoparticles in a murine model of 5-fluorouracil-induced intestinal mucositis via suppression of inflammatory mediators and oxidative stress.
Topics: Animals; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Antioxidants; Drug Carriers; Flu | 2021 |
Apoptosis, Dysbiosis and Expression of Inflammatory Cytokines are Sequential Events in the Development of 5-Fluorouracil-Induced Intestinal Mucositis in Mice.
Topics: Animals; Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Apoptosis; Cell Proliferation; Cyto | 2017 |
Mulberry leaf extract fermented with Lactobacillus acidophilus A4 ameliorates 5-fluorouracil-induced intestinal mucositis in rats.
Topics: Acetamides; Animals; Cytokines; Disease Models, Animal; Fermentation; Fluorouracil; Intestinal Mucos | 2017 |
Lafutidine, a histamine H2 receptor antagonist with mucosal protective properties, attenuates 5-fluorouracil-induced intestinal mucositis in mice through activation of extrinsic primary afferent neurons.
Topics: Acetamides; Animals; Antimetabolites, Antineoplastic; Diarrhea; Famotidine; Fluorouracil; Histamine | 2017 |
Probiotic Bifidobacterium bifidum G9-1 attenuates 5-fluorouracil-induced intestinal mucositis in mice via suppression of dysbiosis-related secondary inflammatory responses.
Topics: Animals; Apoptosis; Bifidobacterium bifidum; Body Weight; Diarrhea; Dysbiosis; Fluorouracil; Inflamm | 2017 |
Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protoco | 2017 |
Oral Administration of Polaprezinc Attenuates Fluorouracil-induced Intestinal Mucositis in a Mouse Model.
Topics: Animals; Anti-Ulcer Agents; Antimetabolites, Antineoplastic; Carnosine; Cell Proliferation; Colorect | 2017 |
A correlation study of fluorouracil pharmacodynamics with clinical efficacy and toxicity.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Chemotherapy, Adjuvant; Female; Fluo | 2018 |
Bifidobacterium Infantis Ameliorates Chemotherapy-Induced Intestinal Mucositis Via Regulating T Cell Immunity in Colorectal Cancer Rats.
Topics: Animals; Antineoplastic Agents; Bifidobacterium longum subspecies infantis; Cell Line; Colorectal Ne | 2017 |
5-Fluorouracil induces inflammation and oxidative stress in the major salivary glands affecting salivary flow and saliva composition.
Topics: Animals; Antineoplastic Agents; Cell Death; Cell Proliferation; Cricetinae; Fluorouracil; Mucositis; | 2017 |
Rebamipide suppresses 5-fluorouracil-induced cell death via the activation of Akt/mTOR pathway and regulates the expression of Bcl-2 family proteins.
Topics: Alanine; Animals; Antimetabolites; Antioxidants; Cell Death; Cell Survival; Fluorouracil; Gene Expre | 2018 |
Alteration of Gut Microbiota and Inflammatory Cytokine/Chemokine Profiles in 5-Fluorouracil Induced Intestinal Mucositis.
Topics: Animals; Antigens, CD; Bacteria; Body Weight; Cadherins; Cell Adhesion Molecules; Chemokines; Colon; | 2017 |
Oral microbiota reduce wound healing capacity of epithelial monolayers, irrespective of the presence of 5-fluorouracil.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bacterial Load; Cell Culture Tech | 2018 |
Oral administration of Simbioflora® (synbiotic) attenuates intestinal damage in a mouse model of 5-fluorouracil-induced mucositis.
Topics: Administration, Oral; Animals; Bifidobacterium animalis; Body Weight; Fatty Acids, Volatile; Feces; | 2018 |
Carboxymethyl pachyman (CMP) reduces intestinal mucositis and regulates the intestinal microflora in 5-fluorouracil-treated CT26 tumour-bearing mice.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Drugs, Chinese Herbal; Fluorour | 2018 |
A Judgement Bias Test to Assess Affective State and Potential Therapeutics in a Rat Model of Chemotherapy-Induced Mucositis.
Topics: Affect; Analgesics, Opioid; Animals; Antineoplastic Agents; Buprenorphine; Disease Models, Animal; D | 2018 |
Endogenous glucagon-like peptide- 1 and 2 are essential for regeneration after acute intestinal injury in mice.
Topics: Animals; Drug Synergism; Exenatide; Female; Fluorouracil; Glucagon-Like Peptide 1; Glucagon-Like Pep | 2018 |
Conjugated linoleic acid prevents damage caused by intestinal mucositis induced by 5-fluorouracil in an experimental model.
Topics: Animals; Bacterial Translocation; Body Weight; Chemokines; Disease Models, Animal; Feeding Behavior; | 2018 |
Ellagitannins from Pomegranate Ameliorates 5-Fluorouracil-Induced Intestinal Mucositis in Rats while Enhancing Its Chemotoxicity against HT-29 Colorectal Cancer Cells through Intrinsic Apoptosis Induction.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Antioxid | 2018 |
Folate-producing lactic acid bacteria reduce inflammation in mice with induced intestinal mucositis.
Topics: Animals; Caco-2 Cells; Cytokines; Diarrhea; Fluorouracil; Folic Acid; Humans; Inflammation; Intestin | 2018 |
Protective effect of the riboflavin-overproducing strain Lactobacillus plantarum CRL2130 on intestinal mucositis in mice.
Topics: Animals; Antineoplastic Agents; Caco-2 Cells; Cell Culture Techniques; Disease Models, Animal; Femal | 2018 |
Assessment of dose-response relationship of 5-fluorouracil to murine intestinal injury.
Topics: Amine Oxidase (Copper-Containing); Animals; Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associ | 2018 |
SCID/NOD mice model for 5-FU induced intestinal mucositis: Safety and effects of probiotics as therapy.
Topics: Animals; Cytokines; Disease Models, Animal; Fluorouracil; Intestinal Mucosa; Male; Mice; Mice, Inbre | 2019 |
Spilanthol, the Principal Alkylamide from Acmella oleracea, Attenuates 5-Fluorouracil-Induced Intestinal Mucositis in Mice.
Topics: Animals; Asteraceae; Fluorouracil; Intestinal Diseases; Jejunum; Male; Mice; Mucositis; Polyunsatura | 2019 |
Gut microbiome modulation during treatment of mucositis with the dairy bacterium Lactococcus lactis and recombinant strain secreting human antimicrobial PAP.
Topics: Animals; Anti-Infective Agents; Biodiversity; Feces; Female; Fluorouracil; Gastrointestinal Microbio | 2018 |
Effects of simvastatin on 5-fluorouracil-induced gastrointestinal mucositis in rats.
Topics: Animals; Anti-Inflammatory Agents; Biomarkers; Disease Models, Animal; Fluorouracil; Interleukin-1be | 2018 |
The protective effects of Aquilariae Lignum Resinatum extract on 5-Fuorouracil-induced intestinal mucositis in mice.
Topics: Animals; Antimetabolites, Antineoplastic; Diarrhea; Fluorouracil; Intestinal Diseases; Male; Medicin | 2019 |
Diadzein ameliorates 5-fluorouracil-induced intestinal mucositis by suppressing oxidative stress and inflammatory mediators in rodents.
Topics: Animals; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Antioxidants; Cytokines; Fluorou | 2019 |
5-Fluorouracil Induces Enteric Neuron Death and Glial Activation During Intestinal Mucositis via a S100B-RAGE-NFκB-Dependent Pathway.
Topics: Animals; Cell Death; Cytokines; Down-Regulation; Enteric Nervous System; Fluorouracil; Glial Fibrill | 2019 |
Role of oral flora in chemotherapy-induced oral mucositis in vivo.
Topics: Animals; Antineoplastic Agents; Cytokines; Fluorouracil; Mice; Mouth; Mucositis | 2019 |
Treatment with selenium-enriched Saccharomyces cerevisiae UFMG A-905 partially ameliorates mucositis induced by 5-fluorouracil in mice.
Topics: Animals; Antimetabolites, Antineoplastic; Antioxidants; Disease Models, Animal; Female; Fluorouracil | 2019 |
Hyposalivation due to chemotherapy exacerbates oral ulcerative mucositis and delays its healing.
Topics: Animals; Antineoplastic Agents; Cisplatin; Fluorouracil; Mucositis; Rats; Salivary Glands; Sublingua | 2019 |
Effects of laser irradiation at different wavelengths (660, 810, 980, and 1,064 nm) on mucositis in an animal model of wound healing.
Topics: Animals; Cell Proliferation; Disease Models, Animal; Fibroblast Growth Factor 2; Fibroblasts; Fluoro | 2014 |
Clinical outcome and patterns of recurrence of head and neck squamous cell carcinoma with a limited field of postoperative radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe | 2013 |
Increased expression of 5-HT3 and NK 1 receptors in 5-fluorouracil-induced mucositis in mouse jejunum.
Topics: Animals; Autocrine Communication; Disease Models, Animal; Fluorouracil; Jejunal Diseases; Macrophage | 2013 |
Safety and efficacy of modified FOLFOX6 plus high-dose bevacizumab in second-line or later treatment of patients with metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2013 |
Emu oil expedites small intestinal repair following 5-fluorouracil-induced mucositis in rats.
Topics: Animals; Cytokines; Energy Metabolism; Female; Fluorouracil; Intestine, Small; Jejunum; Mucositis; O | 2013 |
New roles of serotonin and tachykinins in intestinal mucositis?
Topics: Animals; Fluorouracil; Jejunal Diseases; Male; Mucositis; Receptors, Neurokinin-1; Receptors, Seroto | 2013 |
A DPYD variant (Y186C) specific to individuals of African descent in a patient with life-threatening 5-FU toxic effects: potential for an individualized medicine approach.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Colonic N | 2014 |
Grape seed extract dose-responsively decreases disease severity in a rat model of mucositis; concomitantly enhancing chemotherapeutic effectiveness in colon cancer cells.
Topics: Administration, Oral; Animals; Antioxidants; Caco-2 Cells; Cell Proliferation; Cell Survival; Female | 2014 |
Sodium glucose cotransporter 1 ligand BLF501 as a novel tool for management of gastrointestinal mucositis.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Disease Models, Animal; Doxorub | 2014 |
IL-1Ra selectively protects intestinal crypt epithelial cells, but not tumor cells, from chemotoxicity via p53-mediated upregulation of p21(WAF1) and p27(KIP1.).
Topics: Animals; Antimetabolites, Antineoplastic; Camptothecin; Cell Line; Cell Line, Tumor; Colon; Cyclin-D | 2014 |
Pretreatment with Saccharomyces boulardii does not prevent the experimental mucositis in Swiss mice.
Topics: Animals; Antimetabolites, Antineoplastic; Feeding Behavior; Fluorouracil; Intestinal Mucosa; Mice; M | 2014 |
Aprepitant, a NK-1R antagonist could be employed for cytotoxic therapy induced alimentary tract mucosal inflammation.
Topics: Animals; Fluorouracil; Jejunal Diseases; Male; Mucositis; Receptors, Neurokinin-1; Receptors, Seroto | 2014 |
Activation of p38-MAPK by CXCL4/CXCR3 axis contributes to p53-dependent intestinal apoptosis initiated by 5-fluorouracil.
Topics: Animals; Antibodies, Neutralizing; Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Pr | 2014 |
Chemotherapy mediates intestinal injury via p53/p53 upregulated modulator of apoptosis (PUMA) signaling pathway.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Cell Proliferati | 2014 |
Positive effects of oral β-glucan on mucositis and leukopenia in colorectal cancer patients receiving adjuvant FOLFOX-4 combination chemotherapy.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; b | 2014 |
Exogenous IL-1Ra attenuates intestinal mucositis induced by oxaliplatin and 5-fluorouracil through suppression of p53-dependent apoptosis.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; | 2015 |
Human uridine phosphorylase-1 inhibitors: a new approach to ameliorate 5-fluorouracil-induced intestinal mucositis.
Topics: Animals; Antimetabolites, Antineoplastic; Enzyme Inhibitors; Female; Fluorouracil; Humans; Intestina | 2014 |
The assessment of general well-being using spontaneous burrowing behaviour in a short-term model of chemotherapy-induced mucositis in the rat.
Topics: Animal Welfare; Animals; Disease Models, Animal; Drug Therapy; Fluorouracil; Inflammation; Injection | 2015 |
Tachykinin Peptide, substance p, and its receptor have a significant role in tissue reactions induced by cytotoxic therapy.
Topics: Animals; Fluorouracil; Jejunal Diseases; Male; Mucositis; Receptors, Neurokinin-1; Receptors, Seroto | 2014 |
Bifidobacterium infantis has a beneficial effect on 5-fluorouracil-induced intestinal mucositis in rats.
Topics: Animals; Bifidobacterium; Biomarkers; Body Weight; Fluorouracil; Immunohistochemistry; Intestinal Mu | 2015 |
The chemokine CXCL9 exacerbates chemotherapy-induced acute intestinal damage through inhibition of mucosal restitution.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line; Cell Proliferation; Chemokine CXCL9; Disease Mo | 2015 |
Saireito (TJ-114), a Japanese traditional herbal medicine, reduces 5-fluorouracil-induced intestinal mucositis in mice by inhibiting cytokine-mediated apoptosis in intestinal crypt cells.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Body Weight; Caspase 3; Cytokines; Drugs, Chine | 2015 |
Regulatory role of Lactobacillus acidophilus on inflammation and gastric dysmotility in intestinal mucositis induced by 5-fluorouracil in mice.
Topics: Animals; Antimetabolites, Antineoplastic; Cytokines; Fluorouracil; Gastric Emptying; Gastrointestina | 2015 |
Pretreatment With L-Citrulline Positively Affects the Mucosal Architecture and Permeability of the Small Intestine in a Murine Mucositis Model.
Topics: Animals; Citrulline; Dietary Supplements; Disease Models, Animal; Fluorouracil; Intestinal Mucosa; M | 2016 |
Taurine ameliorates 5-flourouracil-induced intestinal mucositis, hepatorenal and reproductive organ damage in Wistar rats: A biochemical and histological study.
Topics: Animals; Dose-Response Relationship, Drug; Fluorouracil; Intestinal Diseases; Intestines; Kidney; Li | 2016 |
Rebamipide attenuates 5-Fluorouracil-induced small intestinal mucositis in a mouse model.
Topics: Alanine; Animals; Anti-Ulcer Agents; Antimetabolites, Antineoplastic; Apoptosis; Disease Models, Ani | 2015 |
L-arginine pretreatment reduces intestinal mucositis as induced by 5-FU in mice.
Topics: Animals; Antimetabolites, Antineoplastic; Arginine; Fluorouracil; Intestinal Mucosa; Male; Mice; Muc | 2015 |
Alanyl-glutamine attenuates 5-fluorouracil-induced intestinal mucositis in apolipoprotein E-deficient mice.
Topics: Animals; Antimetabolites, Antineoplastic; Apolipoproteins E; Apoptosis; Body Weight; Dipeptides; Fem | 2015 |
Elemental diet moderates 5-fluorouracil-induced gastrointestinal mucositis through mucus barrier alteration.
Topics: Animals; Antineoplastic Agents; Fluorouracil; Food, Formulated; Gastrointestinal Tract; Male; Mucosi | 2015 |
Dietary supplementation with omega-3 fatty acid attenuates 5-fluorouracil induced mucositis in mice.
Topics: Animals; Apoptosis; Dietary Supplements; Escherichia coli; Fatty Acids, Omega-3; Fluorouracil; Ileum | 2015 |
Effects of acute chemotherapy-induced mucositis on spontaneous behaviour and the grimace scale in laboratory rats.
Topics: Animal Welfare; Animals; Facial Expression; Fluorouracil; Injections, Intraperitoneal; Male; Mucosit | 2016 |
Long Survival and Severe Toxicity Under 5-Fluorouracil-Based Therapy in a Patient With Colorectal Cancer Who Harbors a Germline Codon-Stop Mutation in TYMS.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Diarrhea; Fluorouracil; Gene Frequency; Genet | 2015 |
Oral Nucleotides Only Minimally Improve 5-Fluorouracil-Induced Mucositis in Rats.
Topics: Animals; Female; Fluorouracil; Intestinal Mucosa; Intestine, Small; Mucositis; Nucleotides; Organ Si | 2015 |
Amelioration of Chemotherapy-Induced Intestinal Mucositis by Orally Administered Probiotics in a Mouse Model.
Topics: Administration, Oral; Animals; Bifidobacterium; Cytokines; Diarrhea; Disease Models, Animal; Fluorou | 2015 |
Evaluation of the Risk of Grade 3 Oral and Pharyngeal Dysphagia Using Atlas-Based Method and Multivariate Analyses of Individual Patient Dose Distributions.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Computer Graphics; De | 2015 |
A new animal model of intestinal mucositis induced by the combination of irinotecan and 5-fluorouracil in mice.
Topics: Animals; Antineoplastic Agents; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Drug Admin | 2016 |
Protective effect of Bu-Zhong-Yi-Qi decoction, the water extract of Chinese traditional herbal medicine, on 5-fluorouracil-induced intestinal mucositis in mice.
Topics: Animals; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Apoptosis; Cytokines; Drugs, Chi | 2016 |
Protective effect and potential mechanisms of Wei-Chang-An pill on high-dose 5-fluorouracil-induced intestinal mucositis in mice.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Biomarkers; Cell Proliferation; Chromatogra | 2016 |
Administration of probiotic mixture DM#1 ameliorated 5-fluorouracil-induced intestinal mucositis and dysbiosis in rats.
Topics: Animals; Cytokines; Dysbiosis; Fluorouracil; Gastrointestinal Microbiome; Ileum; Inflammation; Inter | 2017 |
Emu Oil Combined with Lyprinol™ Reduces Small Intestinal Damage in a Rat Model of Chemotherapy-Induced Mucositis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Biomarkers; Dasyp | 2016 |
Potential Benefits of Oral Cryotherapy for Chemotherapy-Induced Mucositis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cryotherapy; Female; Fluorouracil; Humans; Ic | 2016 |
Effect of Conjugated Linoleic Acid-enriched Butter After 24 hours of Intestinal Mucositis Induction.
Topics: Animals; Body Weight; Butter; Chemokines; Cytokines; Fluorouracil; Food, Fortified; Immunoglobulin A | 2017 |
Alleviation of 5-fluorouracil-induced intestinal mucositis in rats by vitamin E via targeting oxidative stress and inflammatory markers.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Biomarkers; Cyclooxygenase 2; Fluorouracil; Inflamm | 2016 |
May cannabinoids prevent the development of chemotherapy-induced diarrhea and intestinal mucositis? Experimental study in the rat.
Topics: Animals; Antineoplastic Agents; Cannabinoids; Diarrhea; Fluorouracil; Gastrointestinal Motility; Int | 2017 |
Early-Onset 5-Fluorouracil Toxicity in a Patient Negative for Dihydropyrimidine Dehydrogenase Mutations: The Clinical Course of Reversal with Uridine Triacetate.
Topics: Acetates; Aged; Antidotes; Antimetabolites, Antineoplastic; Anus Neoplasms; Dihydrouracil Dehydrogen | 2016 |
Rifaximin modulates 5-fluorouracil-induced gastrointestinal mucositis in rats.
Topics: Animals; Antimetabolites, Antineoplastic; Fluorouracil; Intestinal Mucosa; Mucositis; Rats; Rats, Wi | 2016 |
Oral Administration of Surface-Deacetylated Chitin Nanofibers and Chitosan Inhibit 5-Fluorouracil-Induced Intestinal Mucositis in Mice.
Topics: Acetylation; Administration, Oral; Animals; Apoptosis; Caspase 3; Chitin; Chitosan; Female; Fluorour | 2017 |
Clinical Outcomes of Hypopharyngeal Cancer Receiving Definitive Radiotherapy with Concurrent Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Deglutition Diso | 2017 |
Secretion of biologically active pancreatitis-associated protein I (PAP) by genetically modified dairy Lactococcus lactis NZ9000 in the prevention of intestinal mucositis.
Topics: Animals; Antibiosis; Antigens, Neoplasm; Biomarkers, Tumor; Disease Models, Animal; Enterococcus fae | 2017 |
Changes in the mucus barrier of the rat during 5-fluorouracil-induced gastrointestinal mucositis.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Fluorouracil; Gastrointestinal Disea | 2008 |
Lactobacillus fermentum BR11 and fructo-oligosaccharide partially reduce jejunal inflammation in a model of intestinal mucositis in rats.
Topics: Animals; Body Weight; Female; Fluorouracil; Jejunum; Limosilactobacillus fermentum; Mucositis; Oligo | 2008 |
Gastrointestinal microflora and mucins may play a critical role in the development of 5-Fluorouracil-induced gastrointestinal mucositis.
Topics: Animals; Antimetabolites, Antineoplastic; Bacteria; Colony Count, Microbial; Electrolytes; Female; F | 2009 |
The herbal extract, Iberogast, improves jejunal integrity in rats with 5-Fluorouracil (5-FU)-induced mucositis.
Topics: Animals; Antimetabolites, Antineoplastic; Breath Tests; Female; Fluorouracil; Jejunum; Mucositis; Or | 2009 |
Grape seed extract protects IEC-6 cells from chemotherapy-induced cytotoxicity and improves parameters of small intestinal mucositis in rats with experimentally-induced mucositis.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line; Cell Survival; Female; Fluorouracil; Humans; In | 2009 |
Effects of Streptococcus thermophilus TH-4 on intestinal mucositis induced by the chemotherapeutic agent, 5-Fluorouracil (5-FU).
Topics: Animals; Body Weight; Female; Fluorouracil; Injections, Intraperitoneal; Intestinal Mucosa; Jejunum; | 2009 |
Weekly low-dose docetaxel-based chemoradiotherapy for locally advanced oropharyngeal or hypopharyngeal carcinoma: a retrospective, single-institution study.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined | 2010 |
Radiotherapy and concomitant intra-arterial docetaxel combined with systemic 5-fluorouracil and cisplatin for oropharyngeal cancer: a preliminary report--improvement of locoregional control of oropharyngeal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2009 |
Minocycline attenuates 5-fluorouracil-induced small intestinal mucositis in mouse model.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Apoptosis; Cell P | 2009 |
Altered glucose metabolism during chemoradiation for head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Cispl | 2009 |
Efficacy of CR3294, a new benzamidine derivative, in the prevention of 5-fluorouracil-induced gastrointestinal mucositis and diarrhea in mice.
Topics: Amidines; Animals; Antimetabolites, Antineoplastic; Cytokines; Diarrhea; Dose-Response Relationship, | 2010 |
Orally administered emu oil decreases acute inflammation and alters selected small intestinal parameters in a rat model of mucositis.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Dromaiidae; Female; Fluorouracil; Ileum; In | 2010 |
Enteral feeding during chemoradiotherapy for advanced head-and-neck cancer: a single-institution experience using a reactive approach.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Squa | 2011 |
Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cros | 2010 |
Interleukin-1 receptor antagonist reduced apoptosis and attenuated intestinal mucositis in a 5-fluorouracil chemotherapy model in mice.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Benzimidazoles; Diarrhea; Disease Models, Anima | 2011 |
Protective effects of glycoglycerolipids extracted from spinach on 5-fluorouracil induced intestinal mucosal injury.
Topics: Alkaline Phosphatase; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Caco-2 Cells; | 2010 |
Interleukin-10 and -12 predict chemotherapy-associated toxicity in esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisp | 2010 |
Interleukin 1 receptor antagonist reduces lethality and intestinal toxicity of 5-fluorouracil in a mouse mucositis model.
Topics: Animals; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Body Weight; Diarrhea; Disease M | 2010 |
Role of platelet-activating factor in the pathogenesis of 5-fluorouracil-induced intestinal mucositis in mice.
Topics: Animals; Antimetabolites, Antineoplastic; Cytokines; Duodenum; Fluorouracil; Ginkgolides; Intestinal | 2011 |
Probiotic factors partially improve parameters of 5-fluorouracil-induced intestinal mucositis in rats.
Topics: Animals; Enzyme Activation; Female; Fluorouracil; Intestinal Mucosa; Intestine, Small; Mucins; Mucos | 2011 |
Non-invasive detection of a palifermin-mediated adaptive response following chemotherapy-induced damage to the distal small intestine of rats.
Topics: Adaptation, Physiological; Animals; Antimetabolites, Antineoplastic; Breath Tests; Female; Fibroblas | 2011 |
Interleukin 1 receptor antagonist reduces lethality and intestinal toxicity of 5-Fluorouracil in a mouse mucositis model.
Topics: Animals; Body Weight; Diarrhea; Disease Models, Animal; Drug Interactions; Female; Fluorouracil; Gen | 2011 |
CXCL9 attenuated chemotherapy-induced intestinal mucositis by inhibiting proliferation and reducing apoptosis.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Proliferation; Chemokine CXCL9; Diarrhea; | 2011 |
Comparison of the efficacy and toxicity of two dose levels of cisplatin/5-fluorouracil as the chemoradiotherapy regimen for the treatment of locally advanced squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2011 |
[Comparison of the toxicities and efficacies of the combination chemotherapy regimens in advanced gastric cancer patients who achieved complete response after chemotherapy].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Ci | 2011 |
Potential role of the NADPH oxidase NOX1 in the pathogenesis of 5-fluorouracil-induced intestinal mucositis in mice.
Topics: Animals; Antimetabolites, Antineoplastic; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase | 2012 |
5-Fluorouracil induced intestinal mucositis via nuclear factor-κB activation by transcriptomic analysis and in vivo bioluminescence imaging.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Enzyme Activation | 2012 |
[Role of pharmacokinetic monitoring of serum fluorouracil concentration in patients with local advanced and metastatic colorectal cancer and further improving efficacy of fluorouracil-based chemotherapy].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2012 |
Apolipoprotein E COG 133 mimetic peptide improves 5-fluorouracil-induced intestinal mucositis.
Topics: Animals; Apolipoproteins E; Apoptosis; Biomimetic Materials; Cell Movement; Cell Proliferation; Cell | 2012 |
Probiotic factors partially prevent changes to caspases 3 and 7 activation and transepithelial electrical resistance in a model of 5-fluorouracil-induced epithelial cell damage.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Caspase 3; Caspase 7; Cells, Cultured; Electric | 2012 |
Oral supplementation of butyrate reduces mucositis and intestinal permeability associated with 5-Fluorouracil administration.
Topics: Administration, Oral; Animals; Butyrates; Female; Fluorouracil; Intestinal Mucosa; Intestines; Mice; | 2012 |
Exogenous glucagon-like peptide-2 (GLP-2) prevents chemotherapy-induced mucositis in rat small intestine.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Proliferation; Female; Fluorouracil; Glucagon-Like Pe | 2012 |
Relationship between antimetabolite toxicity and pharmacogenetics in Turkish cancer patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Alleles; Antimetabolites, Antineop | 2012 |
Effects of Streptococcus thermophilus TH-4 on intestinal mucositis induced by the chemotherapeutic agent 5-Fluorouracil (5-FU).
Topics: Animals; Antineoplastic Agents; Body Weight; Female; Fluorouracil; Intestinal Mucosa; Mucositis; Pro | 2009 |
5-HT₃ receptor antagonists ameliorate 5-fluorouracil-induced intestinal mucositis by suppression of apoptosis in murine intestinal crypt cells.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Benzimidazoles; | 2013 |
Glucagon-like peptide-1 as a treatment for chemotherapy-induced mucositis.
Topics: Animals; Antimetabolites, Antineoplastic; Female; Fluorouracil; Glucagon-Like Peptide 1; Glucagon-Li | 2013 |
Inflammatory intestinal damage induced by 5-fluorouracil requires IL-4.
Topics: Animals; Antimetabolites, Antineoplastic; Duodenum; Fluorouracil; Interleukin-1beta; Interleukin-4; | 2013 |
[Relationship of serum level of dihydropyrimidine dehydrogenase and serum concentration of 5-fluorouracil to treatment response and adverse events in colorectal cancer patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diarrhea; Dihydroura | 2005 |
Panmucositis and chemosensitisation associated with betel quid chewing during dose-dense adjuvant breast cancer chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Areca; Breast Neoplasms; Chemotherapy, Adjuvant; Cyc | 2006 |
[Correlative analysis between serum dihydropyrimidine dehydrogenase, activity, concentration of 5-fluorouracil and adverse events in the treatment of advanced gastric cancer patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Dihydrouracil Dehydrogenase ( | 2006 |
Chemotherapy-induced mucositis: focusing on diarrhea.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Budesonide; Camptothecin; Dehydration; Diar | 2007 |
Lyprinol only partially improves indicators of small intestinal integrity in a rat model of 5-fluorouracil-induced mucositis.
Topics: Animals; Antimetabolites, Antineoplastic; Breath Tests; Disease Models, Animal; Dose-Response Relati | 2008 |
Effect of Eriobotrya japonica seed extract on 5-fluorouracil-induced mucositis in hamsters.
Topics: Animals; Antimetabolites, Antineoplastic; Chromatography, High Pressure Liquid; Cricetinae; Eriobotr | 2008 |
Predicting fluorouracil toxicity: can we finally do it?
Topics: Antimetabolites, Antineoplastic; Diarrhea; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Genetic | 2008 |
Role of palifermin in fluorouracil-based therapy for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fibroblast Growth Factor 7; Fl | 2008 |
Gastrointestinal dysmotility in 5-fluorouracil-induced intestinal mucositis outlasts inflammatory process resolution.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carbachol; Fluorouracil; Gastric Emptying; Gast | 2008 |
Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered?
Topics: Animals; Antineoplastic Agents; Camptothecin; Colon; Female; Fluorouracil; Immunohistochemistry; Int | 2009 |
Effects of acid antisecretory drugs on mucus barrier of the rat against 5-fluorouracil-induced gastrointestinal mucositis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetamides; Animals; Anti-Ulcer Agents; Antimetabolites, An | 2008 |